Document:

Exhibit 10.1

 

Collaboration and License Agreement

  REDACTED

Certain identified
information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would
likely cause competitive harm if publicly disclosed.

 

 

 

COLLABORATION AND LICENSE AGREEMENT

 

 

 

dated

 

19 DECEMBER, 2019

 

by

 

CUREVAC
AG

(“CureVac”)

 

and

 

GENMAB
B.V.

(“Genmab”)

 

    1

     

    

 

Table of Contents

 

	1.	DEFINITIONS	5
	2.	LICENSES; EXCLUSIVITY	29
	3.	REPLACEMENT TARGET; RESERVED
    TARGETS; OPTIONED TARGETS	35
	4.	LNP TECHNOLOGY	37
	5.	RESEARCH AND DEVELOPMENT
    COLLABORATION	40
	6.	MANUFACTURING AND COMMERCIALIZATION	46
	7.	CUREVAC’S OPT-IN AND
    CO-PROMOTION RIGHTS	49
	8.	CO-PROMOTION IN LIEU OF
    AN OPT-IN	54
	9.	GOVERNANCE	56
	10.	CONSIDERATION	63
	11.	INTELLECTUAL PROPERTY	70
	12.	ENFORCEMENT AND DEFENSE	76
	13.	CONFIDENTIALITY	81
	14.	INDEMNIFICATION AND REPRESENTATIONS
    AND WARRANTIES	85
	15.	TERM AND TERMINATION	90
	16.	CONSEQUENCES OF TERMINATION	91
	17.	GENERAL PROVISIONS	94

 

    2

     

    

 

Exhibits

 

	Exhibit 1.13	Patent Rights licensed to BioNTech
	 	 
	Exhibit 1.54	CureVac Know How
	 	 
	Exhibit 1.59	CureVac Patent Rights
	 	 
	Exhibit 1.77	First Program Antibody
	 	 
	Exhibit 1.90	Genmab Know-How
	 	 
	Exhibit 1.111	LNP Technology
	 	 
	Exhibit 1.144	Other Technologies
	 	 
	Exhibit 3.2.2	Templates for clearance of proposed Research Program
    Antibody and Research Program Antibody Combination
	 	 
	Exhibit 5.1.1	First Program Research Plan
	 	 
	Exhibit 5.11	Approved Subcontractors
	 	 
	Exhibit 6.2	Summary of key terms of the Early Clinical Supply Agreement
	 	 
	Exhibit 10.6.2	Examples of calculations of royalties
	 	 
	Exhibit 11.3	List of non-limiting examples of ownership of different
    types of potential Inventions
	 	 
	Exhibit 13.6	Draft Press Release
	 	 
	Exhibit 14.4	Disclosure Letter

 

    3

     

    

 

COLLABORATION AND LICENSE AGREEMENT

 

between 

 

CUREVAC AG

 

And

 

GENMAB B.V.

 

 

This COLLABORATION AND LICENSE AGREEMENT
(“Agreement”) is effective as of the 19th of December, 2019 (“Effective Date”)
and is entered into by and between:

 

CUREVAC
AG, a German corporation, having a place of business at Paul-Ehrlich-Strasse 15, 72076 Tübingen, Germany

 

on the one side;

 

and

 

GENMAB
B.V., KvK No. 3016 9902, a Dutch corporation, having a place of business at Uppsalalaan 15, 3584 CM Utrecht, the Netherlands

 

on the other side.

 

INTRODUCTION

 

		A.	WHEREAS, CureVac is a biotechnology
                                         company that is a pioneer and technology leader in messenger ribonucleic acid (“mRNA”)
                                         based therapeutic approaches and especially discovers, designs and optimizes first-in-class
                                         mRNA therapies for, inter alia, the treatment of oncological diseases with unmet
                                         medical need.

 

		B.	WHEREAS, Genmab is a pharmaceutical
                                         company and has expertise and intellectual property relating to the identification, design
                                         and optimization of recombinant antibodies and validated proprietary antibody technologies,
                                         including the DuoBody® platform, HexaBody® and HexaBody®
                                         related platforms and other antibody-engineering platforms for, inter alia,
                                         the generation of bispecific antibodies and antibodies with enhanced effector functions.

 

		C.	WHEREAS, the Parties wish to collaborate
                                         in (i) the further development of one mRNA- encoded antibody designed to express Genmab’s
                                         proprietary [*****] and (ii) the generation of preclinical data packages for up to four
                                         (4) other Product candidates from which a maximum of three (3) could be selected for
                                         further development and commercialization by Genmab; all such products incorporating
                                         (a) CureVac’s mRNA technology; (b) monoclonal, bispecific and/or multispecific
                                         antibodies (or combination of antibodies) proprietary to Genmab; and (c) a selected lipid
                                         nanoparticle (LNP) delivery technology.

 

    4

     

    

 

		D.	WHEREAS, CureVac wishes to grant to
                                         Genmab an exclusive license to the product referenced under (C)(i); and exclusive options
                                         for exclusive licenses to the products referenced under (C)(ii) above; provided that
                                         CureVac wishes to retain certain opt-in rights for up to one (1) of the products referenced
                                         under (C)(ii) that is a Cocktail Product (as defined below).

 

NOW THEREFORE, in consideration of the
foregoing premises and the following mutual covenants and other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the Parties agree as follows:

 

		1.	DEFINITIONS.

 

For purposes of this Agreement,
the following capitalized terms shall have the following meanings, whether used in the singular or plural:

 

		1.1	“Acuitas
                                         License” shall mean licenses available to CureVac at the Effective Date under
                                         the Development and Option Agreement made between Curevac and Acuitas Therapeutics Inc.
                                         dated April 29, 2016 and amended as of December 1, 2016 relating to LNP Technology owned
                                         by Acuitas.

 

		1.2	“Affiliate”
                                         shall mean any corporation or other entity that controls, is controlled by, or is under
                                         common control with a Party. A corporation or other entity will be regarded as under
                                         the control of another corporation or entity if the latter corporation or entity owns
                                         or directly or indirectly controls fifty percent (50%) or more of the voting stock or
                                         other ownership interest of the former corporation or other entity, or if the latter
                                         corporation or entity possesses, directly or indirectly, the power to direct or cause
                                         the direction of the management and policies of the former corporation or other entity
                                         or the power to elect or appoint more than fifty percent (50%) of the members of the
                                         governing body of the former corporation or other entity, provided, however, that
                                         regarding CureVac, Affiliate shall not include Mr. Dietmar Hopp, dievini Hopp BioTech
                                         holding GmbH & Co.KG and/or any other companies controlled by Mr. Dietmar Hopp and/or
                                         dievini Hopp BioTech holding GmbH & Co.KG that are not subsidiaries of CureVac. For
                                         avoidance of doubt, the term “Affiliate” shall include CureVac’s subsidiary
                                         company currently called CureVac Real Estate GmbH.

 

		1.3	“Agreement”
                                         shall have the meaning set forth in the Preamble.

 

		1.4	“Alliance
                                         Manager” shall have the meaning set forth in Section 9.1.1.

 

    5

     

    

 

		1.5	“Antibody”
                                         shall mean a molecule, defined by its amino acid sequence, including an engineered molecule
                                         that comprises one (1) or more immunoglobulin variable domains or functional parts of
                                         such domains. [*****] shall
                                         be considered one and the same Antibody; provided, however, that any such [*****].
                                         For clarity, an “Antibody” can be a [*****]. The maximum number
                                         of Targets that a single Antibody can bind to is [*****]. For purposes of this Agreement,
                                         and unless otherwise set forth herein, Antibody shall include an Antibody Combination,
                                         as applicable.

 

		1.6	“Antibody
                                         Combination” shall mean a combination of [*****] Antibodies and so binding
                                         to a maximum of [*****] distinct Targets.

 

		1.7	“Applicable
                                         Laws” shall mean all applicable provisions of all national, supranational regional,
                                         state and local, laws, treaties, statutes, rules, regulations, directives, administrative
                                         codes, ordinances, decrees, orders, decisions, guidance documents, injunctions, awards,
                                         judgments, and permits of or from any court, arbitrator, stock exchange, regulatory authority
                                         or governmental authority having jurisdiction over or related to the subject item.

 

		1.8	“Arcturus
                                         License” shall mean licenses available to CureVac at the Effective Date under
                                         the Development and Option Agreement made between Curevac and Arcturus Therapeutics Inc.
                                         dated January 1, 2018 and amended as of May 3, 2018, as of September 28, 2018 and as
                                         of July 24, 2019 relating to LNP Technology owned by Arcturus.

 

		1.9	“Assigning
                                         Party” shall have the meaning set forth in Section 7.8.2.

 

		1.10	“Assigned
                                         Invention” shall have the meaning set forth in Section 11.4.

 

		1.11	“Background
                                         Technology” shall mean the CureVac Background Technology and/or Genmab Background
                                         Technology, as applicable.

 

		1.12	“Breaching
                                         Party” shall have the meaning set forth in Section 15.4.

 

		1.13	“BioNTech
                                         License” shall mean the non-exclusive license made between CureVac and BioNTech
                                         AG dated [*****] granting BioNTech certain non-exclusive rights under [*****] listed
                                         in Exhibit 1.13. For the purposes of this Agreement, the term “BioNTech
                                         License” shall not include any amendments made to the non-exclusive license agreement
                                         between CureVac and BioNTech AG after the Effective Date.

 

		1.14	“BLA”
                                         shall mean (i) a Biologic License Application or New Drug Application submitted and filed
                                         with the FDA (or successor regulatory agency) necessary for approval of a drug or biologic
                                         in connection with the commercial sale or use of such drug or biologic in conformance
                                         with Applicable Laws and regulations in the United States or (ii) the equivalent application
                                         submitted to another Regulatory Agency including a Marketing Authorization Application
                                         (“MAA”).

 

    6

     

    

 

		1.15	“Business
                                         Day” shall mean any day other than Saturday, Sunday, or any day that banks
                                         are authorized or required to be closed in Tübingen, Germany or Utrecht, the Netherlands.

 

		1.16	“Calendar
                                         Quarter” shall mean each successive period of three (3) months ending on March
                                         31, June 30, September 30 and December 31 of each Calendar Year; provided, that the first
                                         Calendar Quarter under this Agreement will be the period beginning on the Effective Date
                                         and ending on the end of the Calendar Quarter in which the Effective Date is encompassed
                                         and the last Calendar Quarter of the Term will be the period beginning on January 1,
                                         April 1, July 1 or October 1, as applicable, and ending on the effective date of expiration
                                         or termination of this Agreement.

 

		1.17	“Calendar
                                         Year” shall mean each successive period of twelve (12) months commencing on
                                         January 1 and ending on December 31; provided, however, that the first Calendar
                                         Year under this Agreement will be the period beginning on the Effective Date and ending
                                         on the end of the Calendar Year in which the Effective Date is encompassed and the last
                                         Calendar Year of the Term will be the period beginning on January 1 and ending on the
                                         effective date of expiration or termination of this Agreement.

 

		1.18	“CDO”
                                         shall mean Chief Development Officer (or equivalent C-level manager) of each Party.

 

		1.19	“CDR”
                                         shall mean complementarity-determining regions.

 

		1.20	“Change
                                         of Control” shall mean, with respect to CureVac, (i) the sale or disposition
                                         to a Third Party of all or substantially all of the assets of CureVac to which the subject
                                         matter of this Agreement relates (including as part of the sale or disposition to a Third
                                         Party of all or substantially all of the assets of CureVac); (ii) the acquisition by
                                         a single Third Party, or two (2) or more Third Parties acting in concert, of beneficial
                                         ownership of fifty percent (50%) or more of the shares in CureVac; or (iii) the acquisition,
                                         merger or consolidation of CureVac with or into another Person, other than, in the case
                                         of this definition, an acquisition or a merger or consolidation of CureVac in which the
                                         holders of shares of voting capital stock of CureVac, immediately prior to such acquisition,
                                         merger or consolidation will beneficially own, directly or indirectly, at least fifty
                                         percent (50%) of the shares of voting capital stock of the acquiring Third Party or the
                                         surviving entity in such acquisition, merger or consolidation, as the case may be, immediately
                                         after such acquisition, merger or consolidation.

 

		1.21	“Clinical
                                         Phase I Study” shall mean a clinical study of a product as further defined
                                         in 21 CFR §312.21(a) or the non-United States equivalent thereof. A Clinical Phase
                                         I Study is a clinical study in humans, the primary objective of which is to determine
                                         preliminary safety in healthy volunteers or patients. Such clinical study may also have
                                         secondary objectives, including tolerability, pharmacological activity or pharmacokinetics
                                         and preliminary efficacy parameters and may therefore be regarded as a phase I/II clinical
                                         trial. For the purposes of this Agreement, (i) the term Clinical Phase I Study shall
                                         also cover such phase I/II clinical trial; and (ii) at the point in such study when the
                                         cohort is expanded beyond the original phase I/II design so that the study becomes prospectively
                                         designed to generate sufficient data (if successful) to commence a Pivotal Study, a Clinical
                                         Phase II Study shall be deemed to have commenced.

 

    7

     

    

 

		1.22	“Clinical
                                         Phase II Study” shall mean a clinical study in humans of the safety, dose ranging
                                         and efficacy of a product, which is prospectively designed to generate sufficient data
                                         (if successful) to commence Pivotal/Clinical Phase III Studies, as further defined in
                                         21 CFR §312.21(b) or (or the non-United States equivalent thereof).

 

		1.23	“Clinical
                                         Phase III Study” shall mean a controlled, and usually multicenter, clinical
                                         study in humans of the efficacy and safety of a product, which is prospectively designed
                                         to demonstrate statistically whether such product is effective and safe for use in humans
                                         in the indication being investigated in a manner sufficient to submit a BLA to obtain
                                         Regulatory Approval to market such product, as further defined in 21 CFR §312.21(c)
                                         (or the non-United States equivalent thereof).

 

		1.24	“Clinical
                                         Studies” shall mean all Clinical Phase I Studies, Clinical Phase II Studies
                                         and Clinical Phase III Studies, including Pivotal Studies.

 

		1.25	“CMC
                                         Development” shall mean all research and development activities conducted in
                                         respect of the Manufacture of Products, including chemistry, manufacturing and control
                                         (CMC), creation of master and working cell banks, test method development and stability
                                         testing, process development, manufacturing scale-up, qualification and validation, quality
                                         assurance and quality control processes and techniques.

 

		1.26	“CMO”
                                         shall mean a contract manufacturing organization.

 

		1.27	“Cocktail
                                         Product” shall mean a Product that is designed to express a Program Antibody
                                         Combination.

 

		1.28	“CoGs”
                                         shall mean the total cost of Manufacture of a unit of Product and shall include Direct
                                         Cost, Indirect Cost and Pass-Through Cost as defined below:

 

		1.28.1	“Direct
                                         Costs” within CoGs shall include:

 

		(i)	direct
                                         labor costs, based on the actual hours consumed by manufacturing and facility personnel
                                         charged at an average hourly wage rate which is designed to approximate actual cost for
                                         each employee’s position; and

 

		(ii)	direct
                                         labor fringe benefit costs, including, without limitation, compensation expense (other
                                         than wages included in direct labor cost in paragraph (i), payroll taxes and benefits
                                         allocated based on a proportionate percentage of direct labor costs charged to the manufacture
                                         of the Product to total actual plant-wide labor costs.

 

    8

     

    

 

		1.28.2	“Indirect
                                         Costs” within CoGs shall include:

 

		(i)	facility
                                         and occupancy cost including, without limitation, rent, site insurance, depreciation,
                                         electricity and water charges, other services, waste removal, such cost to be allocated
                                         pro-rata to (i) the percent time-utilization of the manufacturing line in the Calendar
                                         Year out of the total time the manufacturing line is potentially capable of being utilized
                                         (including idle time); and (ii) the percent occupancy represented by the manufacturing
                                         line to the total plant;

 

		(ii)	the
                                         cost of plant support services, which includes quality control, process sciences, quality
                                         assurance and validation services and being labor, payroll taxes and fringe benefit costs,
                                         allocated to the cost of supplies based on the proportion of actual labor hours consumed
                                         in relation to the Manufacture of the supplies to total actual labor hours consumed on
                                         all of the Products being Manufactured in the plant; and

 

		(iii)	the
                                         cost of allocable overhead, being an amount added to an item of cost to reflect central
                                         or other overhead costs incurred by a Party or for its account including overhead costs
                                         attributable to the operation by it of its information systems, payroll, purchasing,
                                         supervisory and other internal groups being such costs normally allocated by such Party
                                         to its departments or project groups based on space occupied or headcount or other activity-based
                                         method consistently applied. Allocable overhead shall not include costs for general corporate
                                         activities including, by way of example only, investor relations, business development,
                                         legal affairs, human resources and finance, and any other activities not supporting activities
                                         conducted under this Agreement.

 

		1.28.3	“Pass-Through
                                         Costs” within CoGs shall include the actual invoiced amounts paid by a Party
                                         to a CMO, excluding recoverable taxes such as VAT, and cost of materials and supplies
                                         for Manufacturing Product, based on actual costs including any applicable freight, taxes,
                                         duties, customs or import fees, less any discounts or free goods.

 

		1.29	“Collaboration
                                         Committee” shall have the meaning set forth in Section 9.8.

 

		1.30	“Collaboration
                                         Target” shall mean a Target in relation to which the Parties have agreed to
                                         seek to Develop a Product under this Agreement. For purposes of this Agreement, and unless
                                         otherwise set forth herein, Collaboration Target shall include Collaboration Target Combinations,
                                         the First Collaboration Target, the Replacement Target, the Reserved Targets, and the
                                         Optioned Targets, as applicable.

 

		1.31	“Collaboration
                                         Target Combination” shall mean a Target Combination in relation to which the
                                         Parties have agreed to seek to Develop a Product under this Agreement. For purposes of
                                         this Agreement, and unless otherwise set forth herein, Collaboration Target Combination
                                         shall include Reserved Target Combinations, and Optioned Target Combinations, as applicable.

 

		1.32	“Combination
                                         Product” shall mean:

 

		(i)	a
                                         single pharmaceutical formulation containing as its active pharmaceutical ingredients
                                         both the active ingredients licensed hereunder and one or more other therapeutically
                                         or prophylactically active pharmaceutical ingredients;

 

    9

     

    

 

		(ii)	any
                                         combination therapy comprised of the Product and one or more other therapeutically or
                                         prophylactically active products, that is (i) priced and sold in a single package containing
                                         such multiple products; or (ii) packaged separately but sold together for a single price;
                                         or

 

		(iii)	a
                                         product comprised of a Product and a companion or complementary diagnostic, priced and
                                         sold in a single package containing such multiple products or packaged separately but
                                         sold together for a single price;

 

in each case, including all
dosage forms, formulations, presentations, line extensions, and package configurations.

 

		1.33	“Commercialization”
                                         shall mean any and all activities directed to the preparation for sale of, offering for
                                         sale of, or sale of a Product, including activities related to marketing, promoting,
                                         distributing, importing and exporting such Products, interacting with Regulatory Agencies
                                         regarding any of the foregoing and medical affairs functions. For the avoidance of doubt,
                                         “Commercialization” shall not include the Manufacture of Products. When used
                                         as a verb, to “Commercialize” and “Commercializing”
                                         shall mean to engage in Commercialization, and “Commercialized” has
                                         a correlative meaning.

 

		1.34	“Commercialization
                                         Agreement” shall mean the meaning set forth in Section 7.7.

 

		1.35	“Commercially
                                         Reasonable Efforts” shall mean, with respect to a Party, those efforts, expertise
                                         and resources commensurate with efforts, expertise and resources commonly used in the
                                         biotechnology industry by a company of comparable size in connection with the development,
                                         manufacture and/or commercialization of a comparable pharmaceutical product which is
                                         of similar market potential at a similar stage of development or commercialization in
                                         light of issues of safety and efficacy, product profile, the competitiveness of the marketplace,
                                         the proprietary position of the compound or product, the regulatory structure involved,
                                         the profitability of the applicable products, product reimbursement, and other relevant
                                         factors such as technical, legal, scientific, or medical factors. For purposes of clarity,
                                         Commercially Reasonable Efforts will be determined on a country-by-country basis within
                                         the Territory, and it is anticipated that the level of effort may be different for different
                                         countries and may change over time, reflecting changes in the status of such product
                                         and the country(ies) involved.

 

		1.36	“Confidential
                                         Information” shall mean all Know-How, Development Data or other information
                                         of a Party whether or not marked confidential or proprietary, including:

 

		(i)	all
                                         communications between the Parties or information of whatever kind whether recorded or
                                         not and, if recorded, in whatever medium, relating to or arising out of this Agreement,
                                         whether disclosed prior to or after entering into this Agreement; and

 

		(ii)	all
                                         copies and excerpts of the communications, information, notes, reports and documents
                                         in whatever form referred to in paragraph (i) of this definition.

 

    10

     

    

 

 

For purposes of the confidentiality
obligations set forth herein, (a) Genmab Know-How, Genmab Materials and Genmab Inventions shall be deemed Confidential Information
of Genmab; and CureVac Know-How, CureVac Materials and CureVac Inventions (to the extent not incorporated in any Genmab Inventions)
shall be deemed Confidential Information of CureVac; (b) Confidential Information jointly owned by the Parties shall be deemed
Confidential Information of both Parties; and (c) the terms and conditions of this Agreement shall be deemed Confidential Information
of both Parties (and both Parties shall be deemed the Receiving Party with respect thereto). “Confidential Information”
also includes all information exchanged between the Parties pursuant to the Confidentiality Agreements and Material Transfer Agreement.
Without limiting the foregoing, all Know-How and Development Data generated under this Agreement that is specific to a Genmab
Invention, Genmab Other Invention, Collaboration Target, Collaboration Target Combination, Program Antibody, Program Antibody
Combination, an mRNA construct expressing a Program Antibody or Program Antibody Combination, and/or Product shall be deemed the
Confidential Information of Genmab. All Know-How and CMC Development data generated under this Agreement that is specific to any
CureVac Invention or CureVac Other Invention shall, to the extent such CureVac Invention or CureVac Other Invention is not incorporated
in any Genmab Invention, be considered Confidential Information of CureVac.

 

		1.37	“Confidentiality
                                         Agreements” shall mean Confidentiality Agreement No. 1 and Confidentiality
                                         Agreement No. 2.

 

		1.38	“Confidentiality
                                         Agreement No. 1” shall mean that certain Mutual Confidentiality and Nondisclosure
                                         Agreement entered into between the Parties as of October 10, 2016.

 

		1.39	“Confidentiality
                                         Agreement No. 2” shall mean that certain Mutual Confidentiality and Nondisclosure
                                         Agreement entered into between the Parties as of 12 April 2018.

 

		1.40	“Control”
                                         shall mean, with respect to any material, information or intellectual property right,
                                         that a Party (i) owns such material, information or intellectual property right; or (ii)
                                         has a license to or right to use or grant access to such material, information or intellectual
                                         property right, in each case of (i) or (ii), without violating the terms of any agreement
                                         or other arrangement with a Third Party.

 

		1.41	“Co-Promote”
                                         shall mean, with respect to the Co-Promotion Territory, to promote a Product through
                                         Genmab’s and CureVac’s respective sales forces under a single trademark in
                                         such Co-Promotion Territory. “Co-Promotion” shall have a correlative
                                         meaning.

 

		1.42	“Co-Promotion
                                         Agreement” shall have the meaning as set forth in Section 8.2.

 

		1.43	“Co-Promotion
                                         Committee” shall have the meaning set forth in Section 8.2(i).

 

		1.44	“Co-Promotion
                                         Product” shall have the meaning set forth in Section 8.1.

 

		1.45	“Co-Promotion
                                         Territory” shall have the meaning as set forth in Section 8.1.

 

    11

     

    

 

		1.46	“Co-Promotion
                                         Territory Commercialization Plan” shall have the meaning as set forth in Section
                                         8.2(iii).

 

		1.47	“Cover”
                                         shall mean, with respect to a claim of a Patent Right, that such claim would be infringed,
                                         absent a license, by the Development, Manufacture or Commercialization of a Product.

 

		1.48	“CRO”
                                         shall mean a contract research organization.

 

		1.49	“CureVac
                                         Alliance Manager” shall have the meaning set forth in Section 9.1.1.

 

		1.50	“CureVac
                                         Background Technology” shall have the meaning set forth in Section 11.1.

 

		1.51	“CureVac
                                         Co-Promotion Option” shall have the meaning set forth in Section 8.1.

 

		1.52	“CureVac
                                         Indemnified Parties” shall have the meaning set forth in Section 14.1.

 

		1.53	“CureVac
                                         Invention” shall have the meaning set forth in Section 11.3.2.

 

		1.54	“CureVac
                                         Know-How” shall mean all Know-How within the CureVac Background Technology
                                         and all Know-How, including Know-How comprised in the CureVac Manufacturing Technology,
                                         Controlled by CureVac or its Affiliates arising or generated during the Research Period
                                         in connection with the performance of activities under this Agreement, in including performance
                                         of activities under the R&D Plans (to be determined on a Collaboration Target-by-Collaboration
                                         Target basis) that is required for the Parties to Develop the Programs and/or to Develop,
                                         Manufacture and Commercialize Products under this Agreement, provided, however,
                                         that CureVac Know-How does not include (i) Know-How included in the LNP Technology; (ii)
                                         Know-How included in CVCMs; (iii) Know-How included in the Other Technologies; and (iv)
                                         Know-How that may be Controlled by CureVac in the future as a result of a Change of Control;
                                         i.e., that was Developed by a Third Party prior to such Change of Control, or by CureVac
                                         after the Change of Control, and is fully or partly based on technology Controlled by
                                         a Third Party prior to such Change of Control. CureVac Know-How shall also include Know-How
                                         related to CureVac Inventions and other Know-How generated by CureVac under a Program.
                                         The CureVac Know-How as so defined existing at the Effective Date is further described
                                         in Exhibit 1.54.

 

		1.55	“CureVac
                                         Manufacturing Technology” shall mean Patent Rights and Know-How Controlled
                                         by CureVac or its Affiliates (including CureVac Real Estate GmbH even if it does not
                                         remain an Affiliate) related to CMC Development and/or the Manufacture of Products actually
                                         used in the CMC Development and/or Manufacture of a Product by or on behalf of CureVac
                                         and/or its Affiliates during the Development and/or Manufacture of such Product under
                                         an R&D Plan during the Research Period. For the avoidance of doubt, such CureVac
                                         Manufacturing Technology shall be licensed to Genmab for all subsequent Products under
                                         this Agreement no matter whether CureVac or its Affiliates (or their approved subcontractor
                                         or approved CMO) Manufactures the particular Product.

 

    12

     

    

 

		1.56	“CureVac
                                         Materials” shall mean any compounds, assays or other materials that are disclosed
                                         or otherwise made available by or on behalf of CureVac and/or its Affiliate(s) to Genmab
                                         hereunder for the purposes of this Agreement, including the compounds, assays, negative
                                         and positive mRNA control constructs (excluding, for clarity, any Product) and other
                                         materials set forth on Exhibit 5.1.1, and progeny, modifications or derivatives
                                         thereof that do not include use of Genmab Materials.

 

		1.57	“CureVac
                                         Other Invention” shall have the meaning set forth in Section 11.3.3.

 

		1.58	“CureVac
                                         Other Invention Patent Right” shall have the meaning set forth in Section 11.7.4

 

		1.59	“CureVac
                                         Patent Right(s)” shall mean (i) all Patent Rights within the CureVac Background
                                         Technology Controlled by CureVac or its Affiliates as of the Effective Date; and (ii)
                                         all CureVac Program Patent Rights, CureVac Other Invention Patent Rights and CureVac’s
                                         interest in Joint Patent Rights that (in case of each of (i) and (ii)) are required for
                                         the Development of the Programs and/or for the Development, Manufacture and Commercialization
                                         of Products (including Product candidates under the research license) under the Agreement;
                                         and (iii) all Patent Rights within the CureVac Manufacturing Technology to the extent
                                         not within (i) or (ii); and (iv) any New Patent Rights that Genmab notifies CureVac it
                                         desires to include pursuant to Section 2.9. provided, however, that CureVac Patent
                                         Rights do not include (i) Patent Rights included in the LNP Technology or the Patent
                                         Rights referred to in Section 1.63 (Definition of CVCM); (ii) Patent Rights included
                                         in the Other Technologies; and (iii) Patent Rights that may be Controlled by CureVac
                                         in the future as a result of a Change of Control; i.e., that were Developed by a Third
                                         Party prior to such Change of Control. The CureVac Patent Rights as of the Effective
                                         Date are listed in Exhibit 1.59. For avoidance of doubt, the CureVac Patent Rights
                                         shall include any future Patent Rights Controlled by CureVac or its Affiliates that claim
                                         priority from any of the patents and patent applications listed in Exhibit 1.59.

 

		1.60	“CureVac
                                         Program Patent Right” shall mean a Program Patent Right owned by CureVac, as
                                         set forth in Section 11.3 below, that Covers a CureVac Invention.

 

		1.61	“CureVac
                                         Project Leader” shall have the meaning set forth in Section 9.1.2.

 

		1.62	“CureVac
                                         Technology” shall mean CureVac Patent Rights, CureVac Inventions, CureVac Other
                                         Inventions, CureVac Know-How, CureVac Manufacturing Technology (to the extent not within
                                         the foregoing) and Third Party IP that is deemed to be CureVac Technology pursuant to
                                         Section 2.8.

 

		1.63	“CVCM”
                                         shall mean CureVac’s next generation mRNA delivery vehicle, also referred to as
                                         CureVac Carrier MoleculeTM, which is disclosed in CureVac’s patent families
                                         [*****], that is appropriate for formulation of an mRNA construct.

 

    13

     

    

 

		1.64	“Development”
                                         shall mean all research, non-clinical, and clinical testing and drug development activities
                                         conducted in respect of the Collaboration Targets, Program Antibodies and Products, including
                                         those necessary or reasonably useful or otherwise requested or required by a Regulatory
                                         Authority as a condition or in support of obtaining or maintaining Regulatory Approvals
                                         and to successfully Develop, Manufacture and Commercialize the Products for use in the
                                         Field. “Development” shall include CMC Development, delivery system
                                         development, non-clinical testing, mechanism studies, toxicology, pharmacokinetics, clinical
                                         studies, regulatory affairs activities, statistical analysis and report writing, submission
                                         of documents, market research, pharmacoeconomic studies, and epidemiological/real world
                                         data studies. Development shall mean both (a) non-clinical and clinical Development;
                                         and (b) CMC Development. “Develop” and “Developed”
                                         have a correlative meaning.

 

		1.65	“Development
                                         Data” shall mean (i) reports of non-clinical studies and Clinical Studies,
                                         (ii) CMC Development data; and (iii) all other documentation containing or embodying
                                         any non- clinical or clinical data relating to the Collaboration Targets, Program Antibodies
                                         and the Products or the use of the Products in the Field, such data in each case (i),
                                         (ii) and (iii) required for the Development and Commercialization of the Products, including
                                         but not limited to, registration dossiers.

 

		1.66	“Disclosing
                                         Party” shall have the meaning set forth in Section 13.1

 

		1.67	“Disclosure
                                         Letter” shall have the meaning set forth in Section 14.4.

 

		1.68	“Early
                                         Clinical Supply Agreement” shall the meaning set forth in Section 6.1.

 

		1.69	“Effective
                                         Date” shall have the meaning set forth in the Preamble.

 

		1.70	“FDA”
                                         shall have the meaning set forth in the definition of Regulatory Agency.

 

		1.71	“Field”
                                         shall mean any and all uses for the prophylaxis or treatment of human conditions and
                                         diseases.

 

		1.72	“Financial
                                         Partner” shall have the meaning set forth in Section 13.4.1(vi) below.

 

		1.73	“First
                                         Collaboration Program” shall mean the Program addressing the First Collaboration
                                         Target and First Program Antibody, as described in the First Program Research Plan.

 

		1.74	“First
                                         Collaboration Target” shall mean the target named [*****]. For purposes of
                                         this Agreement, and unless otherwise set forth herein, First Collaboration Target shall
                                         include the Replacement Target, as applicable.

 

		1.75	“First
                                         Commercial Sale” shall mean, on a Product-by-Product and country-by-country
                                         basis, the first sale by Genmab or its Affiliates or Sublicensees or subcontractors to,
                                         such as but not limited to, a Third Party wholesaler, pharmacy, outpatient clinic, inpatient
                                         clinic, hospital, or dispensing physician in a given country after necessary Regulatory
                                         Approval has been granted with respect to such Product in such country. For avoidance
                                         of doubt, any sale of a Product by Genmab to an Affiliate or Sublicensee or subcontractor
                                         is not a First Commercial Sale.

 

    14

     

    

 

		1.76	“First
                                         Composition of Matter Patent Rights” shall mean, Product-by-Product, all Patent
                                         Rights within the first “composition of matter” Genmab Program Patent Rights
                                         (i.e. Genmab Program Patent Rights where the earliest priority date is the same) that
                                         Cover and claim the specific composition of matter of the particular Product. For clarity,
                                         such first “composition of matter” Genmab Program Patent Rights may not be
                                         the first to be filed Patent Rights Covering the particular Product if such first to
                                         be filed Patent Rights do not also claim the specific composition of matter of such Product.

 

		1.77	“First
                                         Program Antibody” shall mean Genmab’s proprietary [*****] as described
                                         in detail in Exhibit 1.77, that binds to the First Collaboration Target.

 

		1.78	“First
                                         Program Research Plan” shall have the meaning set forth in Section 5.1.1, such
                                         First Program Research Plan as of the Effective Date being attached hereto as Exhibit
                                         5.1.1.

 

		1.79	“FTE”
                                         shall mean, with respect to a person, the equivalent of the work of one (1) employee
                                         full time for one (1) year (consisting of at least [*****] working hours per year (with
                                         no further reductions for vacations and holidays)). Overtime, and work on weekends, holidays
                                         and the like will not be counted with any multiplier (e.g., time-and-a-half or double
                                         time) toward the number of hours that are used to calculate the FTE contribution. The
                                         portion of a FTE billable by CureVac or Genmab for one (1) individual during a given
                                         accounting period shall be determined by dividing the number of hours worked by said
                                         individual on the work to be conducted under the Agreement during such accounting period
                                         and the number of FTE hours applicable for such accounting period based on [*****] working
                                         hours per calendar year. For clarity, no individual person can ever constitute more than
                                         a single FTE.

 

		1.80	“FTE
                                         Rate” shall mean, for the period commencing on the Effective Date until such
                                         time as the Parties mutually agree otherwise, an annual rate of [*****]. The FTE Rate
                                         shall include all fully loaded costs, including costs of salaries, benefits, supplies,
                                         other employee costs, consumables, overhead and supporting general and administration
                                         allocations. In the event of Opt-In by CureVac, the Parties will renegotiate and agree
                                         in good faith on a new FTE Rate which should be reflective of the stage of development
                                         and market conform.

 

		1.81	“FTO
                                         License” shall have the meaning set forth in Section 10.6.4.

 

		1.82	“Force
                                         Majeure” shall have the meaning set forth in Section 17.2.

 

		1.83	“Generally
                                         Applicable Patent Right” shall mean a claim of a Genmab Program Patent Right
                                         Covering (i) a [*****] (“Target Class Inventions”); (ii)
                                         an Antibody or Antibody Combination functionally defined in such claim as [*****] and (iii) a [*****] provided, however,
                                         that for each of (i), (ii) and (iii), where the Invention is made, conceived and/or
                                         reduced to practice after the Research Period, such claim shall only be considered a
                                         Generally Applicable Patent Right if [*****] with respect to such claim. For avoidance
                                         of doubt, the term Generally Applicable Patent Right shall not include any claim where
                                         the Program Antibody or Program Antibody Combination is functionally defined as binding
                                         to a Collaboration Target or Collaboration Target Combination or even more specifically,
                                         such as e.g. where the Program Antibody or Program Antibody Combination is functionally
                                         defined as binding to an epitope on a Collaboration Target or epitopes on the Collaboration
                                         Targets included in the Collaboration Target Combination or where the Program Antibody
                                         or Program Antibody Combination is defined by sequences.

 

    15

     

    

 

		1.84	“Generic
                                         Product” shall mean, with respect to a particular Product in a particular country
                                         in the Territory, any pharmaceutical product (other than the Product) that (i) contains
                                         the same active ingredient(s) (including biosimilar or bioequivalent biologic API) in
                                         a comparable quality and quantity as such Product, irrespective of its pharmaceutical
                                         form, and is approved for the same indication as such Product, as applicable, and (ii)
                                         is approved for sale in the country pursuant to a regulatory approval process governing
                                         the approval of generic, interchangeable, biosimilar or bioequivalent biologic products,
                                         with the Product being the reference product.

 

		1.85	“Generic
                                         Therapeutic Concept” shall mean an Invention consisting of a new approach to
                                         therapy or treatment that has general applicability beyond use of such approach in relation
                                         to the Collaboration Target or specific Collaboration Target Combination (i.e. the Optioned
                                         Target Combination) that is targeted by a Program Antibody or Program Antibody Combination,
                                         as applicable. By way of non-limiting examples, a Generic Therapeutic Concept would include
                                         (i) an Invention consisting of combining [*****] different Antibodies targeting [*****]
                                         different pathways such as an anti-apoptotic pathway, an anti-proliferative pathway and
                                         an anti- metastatic pathway to obtain a certain therapeutic effect; and (ii) an Invention
                                         relating to a [*****]. The term Generic
                                         Therapeutic Concept shall not comprise Target Class Inventions. Further, the term Generic
                                         Therapeutic Concept shall not comprise the therapeutic or treatment approach to the extent
                                         that such approach applies to a Collaboration Target or specific Collaboration Target
                                         Combination.

 

		1.86	“Genmab
                                         Alliance Manager” shall have the meaning set forth in Section 9.1.1.

 

		1.87	“Genmab
                                         Background Technology” shall have the meaning as set forth in Section 11.1.

 

		1.88	“Genmab
                                         Indemnified Parties” shall have the meaning set forth in Section 14.2.

 

		1.89	“Genmab
                                         Invention” shall have the meaning set forth in Section 11.3.1.

 

    16

     

    

 

		1.90	“Genmab
                                         Know-How” shall mean all Know-How Controlled by Genmab or its Affiliates as
                                         of the Effective Date or thereafter during the Term that (a) is necessary for CureVac
                                         to perform the obligations and other activities pursuant to this Agreement, or (b) is
                                         used by or on behalf of Genmab its Affiliates or Sub-licensees to Develop, Manufacture
                                         and Commercialize Products under this Agreement. Genmab Know-How shall include (i) Know-How
                                         comprised in the Genmab Background Technology; (ii) Know-How related to Genmab Inventions;
                                         and (iv) other Know-How generated by Genmab under a Program. Notwithstanding the foregoing,
                                         if any Third Party becomes an Affiliate of Genmab after the Effective Date, Genmab Know-How
                                         will exclude any Know-How that is Controlled by such Third Party before such Third Party
                                         became Genmab’s Affiliate. The Genmab Know-How as so defined existing at the Effective
                                         Date is further described in Exhibit 1.90.

 

		1.91	“Genmab
                                         Materials” shall mean any compounds, assays or other materials, including sequences
                                         and recombinant proteins, that are disclosed or otherwise made available by or on behalf
                                         of Genmab and/or its Affiliate(s) to CureVac hereunder for the purposes of this Agreement,
                                         including materials set forth on Exhibit 5.1.1, and progeny, modifications or
                                         derivatives thereof that do not include use of CureVac Materials.

 

		1.92	“Genmab
                                         Other Invention” shall have the meaning set forth in Section 11.3.3.

 

		1.93	“Genmab
                                         Other Invention Patent Right” shall have the meaning set forth in Section 11.7.5.

 

		1.94	“Genmab
                                         Patent Right(s)” shall mean all Patent Rights Controlled by Genmab or its Affiliates
                                         as of the Effective Date or thereafter during the Term that (a) is necessary for CureVac
                                         to perform the obligations and other activities pursuant to this Agreement, or (b) [*****] Genmab its Affiliates or Sub-licensees to Develop, Manufacture
                                         and Commercialize Products under this Agreement. Genmab Patent Rights shall include Patent
                                         Rights comprised in the Genmab Background Technology, Genmab Program Patent Rights, Genmab
                                         Other Invention Patent Rights and Genmab’s interest in Joint Patent Rights.

 

		1.95	“Genmab
                                         Program Patent Right” shall mean a Program Patent Right owned by Genmab, as
                                         set forth in Section 11.3 below, that Covers a Genmab Invention.

 

		1.96	“Genmab
                                         Project Leader” shall have the meaning set forth in Section 9.1.2.

 

		1.97	“Genmab
                                         Technology” shall mean any and all Genmab Patent Rights, Genmab Inventions
                                         and Genmab Know-How.

 

		1.98	“GxP”
                                         shall mean the good practice regulations in the pharmaceutical industry with respect
                                         to distribution, manufacturing, clinical and laboratory practices (GDP, GMP, GCP and
                                         GLP).

 

		1.99	“IND”
                                         shall mean an investigational new drug application filed with, and accepted by, the FDA
                                         prior to beginning clinical trials in humans in the USA, or any comparable application
                                         to and acceptance by the Regulatory Authority of a country or group of countries other
                                         than the USA thereto including the European Medicines Authority (“EMA”)
                                         prior to beginning clinical trials in humans in that country or in that group of countries.

 

		1.100	“Indication”
                                         shall mean, with respect to a particular Product, the use of such Product for treating
                                         a separate and distinct disease or medical condition.

 

    17

     

    

 

		1.101	“Invention”
                                         shall mean an invention or discovery, whether or not patentable, discovered, made, conceived
                                         and/or first reduced to practice during the Term by or on behalf of CureVac or Genmab
                                         or Affiliates of CureVac or Genmab, alone or jointly with each other and/or any Third
                                         Party, which arise from the performance of activities under this Agreement, including
                                         performance of activities under the R&D Plans, or under the Material Transfer and
                                         Technology Evaluation Agreement.

 

		1.102	“IP
                                         Sub-committee” shall mean the sub-committee to be established pursuant to Section
                                         9.6.

 

		1.103	“Joint
                                         Commercialization Committee”, and “JCC” shall have the meaning
                                         set forth in Section 7.7(i).

 

		1.104	“Joint
                                         Development and Manufacturing Agreement” shall have the meaning set forth in
                                         Section 7.6.

 

		1.105	“Joint
                                         Invention” shall have the meaning set forth in Section 11.3.3.

 

		1.106	“Joint
                                         Patent Rights” shall have the meaning set forth in Section10.8.1

 

		1.107	“Joint
                                         Research Committee”, and “JRC” shall have the meaning set
                                         forth in Section 9.2.

 

		1.108	“Joint
                                         Steering Committee”, and “JSC” shall have the meaning set
                                         forth in Section 7.2.

 

		1.109	“Know-How”
                                         shall mean all technical, scientific and other information, inventions, discoveries,
                                         trade secrets, knowledge, technology, means, methods, processes, practices, formulae,
                                         instructions, skills, techniques, procedures, expressed ideas, technical assistance,
                                         designs, drawings, assembly procedures, computer programs, apparatuses, specifications,
                                         Development Data, results, non-clinical, clinical, safety, process and Manufacturing
                                         and quality control data and information (including trial designs and protocols), registration
                                         dossiers, in each case, solely to the extent confidential and proprietary and in written,
                                         electronic or any other form now known or hereafter Developed.

 

		1.110	“LNP”
                                         shall mean a lipid nanoparticle system comprised of individual lipid components at specific
                                         ratios, which are manufactured in such a manner to encapsulate and deliver mRNA into
                                         a target cell.

 

		1.111	“LNP
                                         Technology” shall mean Patent Rights and Know-How covering an LNP system (i.e.
                                         a lipid nanoparticle system which is used to formulate and deliver mRNA), as further
                                         defined in Exhibit 1.111 hereto.

 

		1.112	“LNP
                                         Technology License Documentation Package” shall have the meaning set forth
                                         in Section 4.2 below.

 

		1.113	“Major
                                         Markets Countries” shall mean [*****].

 

    18

     

    

 

		1.114	“Manufacture”
                                         shall mean all manufacturing operations (including for mRNA, lipids and drug product
                                         as well as formulation, fill and finish, packaging and labelling) for Products, including
                                         all activities related to the preparation and use of master and working cell banks, making,
                                         production, processing, purifying, formulating, filling, and finishing, of the Product,
                                         or any intermediate thereof, pre-clinical, clinical and commercial production, product,
                                         stability testing, quality assurance, and quality control. “Manufacturing”
                                         has a correlative meaning.

 

		1.115	“Materials”
                                         shall mean CureVac Materials and Genmab Materials.

 

		1.116	“Material
                                         Transfer and Technology Evaluation Agreement” shall mean that certain Material
                                         Transfer and Technology Evaluation Agreement entered into between the Parties as of April
                                         12, 2017.

 

		1.117	“mRNA”
                                         shall have the meaning set forth in the Introduction.

 

		1.118	“MSA”
                                         shall have the meaning set forth in Section 6.4.2 below.

 

		1.119	“Negotiation
                                         Period” shall have the meaning as set forth in Section 7.8.2.

 

		1.120	“Net
                                         Sales” shall mean, with respect to each Product, the gross amount invoiced
                                         for sales of such Product by or on behalf of Genmab and its Affiliates and Sublicensees
                                         to unrelated Third Parties (i.e., excluding Sublicensees), less the following deductions
                                         [*****]:

 

		a.	[*****]

 

		b.	[*****]

 

		c.	[*****]

 

    19

     

    

 

		d.	[*****]

 

		e.	[*****]

 

		f.	[*****] and

 

		g.	[*****]

 

[*****].

 

Disposition of Product for,
or use of the Product in, clinical trials or other scientific testing, as free samples, or under compassionate use, patient assistance,
or test marketing programs or other similar programs or studies where a Product is supplied without charge shall not result in
any Net Sales, however if Genmab or any of its Affiliates or Sublicensees charges for such Product, the amount billed will be
included in the calculation of Net Sales, but for the sake of clarity such disposition or use of the Product shall never constitute
a First Commercial Sale.

 

In the event a Product is sold
as a Combination Product, Net Sales of the Combination Product will be calculated, on a [*****] as follows:

 

		(i)	[*****].

 

    20

     

    

 

		(ii)	[*****].

 

		(iii)	[*****].

 

		(iv)	[*****].

 

		(v)	[*****].

 

		1.121	“New
                                         Patent Right” shall have the meaning set forth in Section 2.9.

 

		1.122	“Non-Assigning
                                         Party” shall have the meaning set forth in Section 7.8.2.

 

		1.123	“Non-Breaching
                                         Party” shall have the meaning set forth in Section 15.4.

 

		1.124	“Non-Terminating
                                         Party” shall have the meaning set forth in Section 7.9.

 

		1.125	“Opt-In”
                                         shall have the meaning set forth in Section 7.1.

 

		1.126	“Opt-In
                                         Data Package” shall have the meaning set forth in Section 7.1.

 

		1.127	“Opt-In
                                         Product” shall have the meaning set forth in Section 7.1.

 

		1.128	“Opt-In
                                         Product Assignment” shall have the meaning set forth in Section 7.8.2.

 

		1.129	“Opt-In
                                         Program” shall mean a Program (for a [*****]) for which CureVac has exercised
                                         its right to Opt-In.

 

    21

     

    

 

		1.130	“Opt-In
                                         R&D Plan” shall have the meaning set forth in Section 7.2.

 

		1.131	“Opt-In
                                         Target” shall have the meaning set forth in Section 7.1.

 

		1.132	“Opt-In
                                         Termination Notice” shall have the meaning set forth in Section 7.9.

 

		1.133	“Option
                                         Exercise” shall have the meaning set forth in Section 3.4.

 

		1.134	“Option
                                         Exercise Fee” shall have the meaning set forth in Section 10.2.

 

		1.135	“Option
                                         Period” shall have the meaning set forth in Section 3.4 below.

 

		1.136	“Optioned
                                         Target” shall mean a Reserved Target for which Genmab has exercised its option
                                         under Section 3.4 below. For purposes of this Agreement, and unless otherwise set forth
                                         herein, Optioned Target shall include an Optioned Target Combination, as applicable.

 

		1.137	“Optioned
                                         Target Combination” shall have the meaning set forth in Section 3.4.

 

		1.138	“Other
                                         Pre-IND Program” shall mean a Program envisaged in Section 5.2.3 directed against
                                         an Optioned Target and including an Other Program Antibody (for clarity, excluding the
                                         First Collaboration Program) and LNP Technology.

 

		1.139	“Other
                                         Pre-IND Program Research Plan” shall have the meaning set forth in Section
                                         5.2.3 below.

 

		1.140	“Other
                                         Program Antibody” shall mean a Program Antibody (i) that binds to an Optioned
                                         Target, or to an Optioned Target Combination; and (ii) that Genmab has elected to use
                                         and is to be used in an Other Pre-IND Program as described in Section 5.2.3. To the extent
                                         applicable, and unless otherwise set forth, Other Program Antibody shall include Other
                                         Program Antibody Combinations.

 

		1.141	“Other
                                         Program Antibody Combination” shall mean a Program Antibody Combination that
                                         (i)binds to an Optioned Target, or to an Optioned Target Combination; and (ii) Genmab
                                         has elected to use and is to be used in an Other Pre-IND Program as described in Section
                                         5.2.3.

 

		1.142	“Other
                                         Invention” shall have the meaning set forth in Section 11.3.3.

 

		1.143	“Other
                                         Invention Patent Right” shall mean a CureVac Other Invention Patent Right or
                                         Genmab Other Invention Patent Right, as applicable.

 

		1.144	“Other
                                         Technologies” shall mean the technologies licensed to CureVac (i) by GeneArt
                                         AG under a license agreement dated [*****] concerning [*****]; (ii) by TriLink Biotechnologies
                                         LLC under a license Agreement dated [*****], [*****]. The respective Patent Rights are
                                         listed in Exhibit 1.144.

 

    22

     

    

 

		1.145	“Parties”
                                         shall mean CureVac and Genmab.

 

		1.146	“Party”
                                         shall mean CureVac or Genmab.

 

		1.147	“Patent
                                         Rights” shall mean any and all patents and patent applications, including provisional
                                         and non-provisional applications, reissues, extensions, substitutions, confirmations,
                                         re-registrations, re-examinations, re-validations, patents of addition, supplementary
                                         protection certificates or the equivalents thereof, continuations, continuations-in-part
                                         and divisionals thereof and all foreign counterparts, and the like of any of the foregoing.

 

		1.148	“Patent
                                         Term Extensions” shall have the meaning set forth in Section 10.9.

 

		1.149	“Person”
                                         shall mean an individual, firm, company, corporation, association, trust, estate, state
                                         or agency of a state, government or government department or agency, municipal or local
                                         authority and any other entity, whether or not incorporated and whether or not having
                                         a separate legal personality.

 

		1.150	“Pivotal
                                         Study” shall mean a Clinical Study of Product in human patients intended to
                                         provide evidence for drug marketing approval. Clinical Phase III Studies are typically
                                         Pivotal Studies, and in exceptional cases a Clinical Phase II Study may become a Pivotal
                                         Study, and may require additional confirmatory studies post approval.

 

		1.151	“Product”
                                         shall mean any product that contains one or more mRNA construct(s) that is designed to
                                         express a Program Antibody or a Program Antibody Combination, and formulated with [*****]. Product includes both a [*****] or a [*****]. For
                                         clarification, a Product may consist of several mRNA constructs that together express
                                         a Program Antibody or Program Antibody Combination.

 

		1.152	“Product
                                         Development Plan(s)” shall mean the development plans to be prepared upon Product
                                         Selection under any Program for the further Development of a Product, as set forth in
                                         Section 5.3.

 

		1.153	“Product
                                         Selection” shall have the meaning set forth in Section 5.3.

 

		1.154	“Product
                                         Selection Notice” shall have the meaning set forth in Section 5.3.

 

		1.155	“Product
                                         Development Program” shall mean a program for the further Development of a
                                         Product pursuant to a Product Development Plan.

 

		1.156	“Program”
                                         shall mean, on a Collaboration Target-by-Collaboration Target basis, any and all Development,
                                         Manufacturing and Commercialization activities conducted under R&D Plans. Programs
                                         shall include the First Collaboration Program. Save in respect of the First Collaboration
                                         Program, the sequence of a Program shall be (i) Research Program; then (ii) Other Pre-IND
                                         Program; then (iii) Product Development Program.

 

		1.157	“Program
                                         Antibody” shall mean a [*****] that [*****] and that Genmab has elected to use in a Program and which has been
                                         finally cleared under Section 3.2.2. To the extent applicable, and unless otherwise set
                                         forth, [*****].

 

    23

     

    

 

		1.158	“Program
                                         Antibody Combination” shall mean an Antibody Combination that Genmab has elected
                                         to use in a Program and which has been finally cleared under Section 3.2.2.

 

		1.159	“Program
                                         Breach” shall have the meaning set forth in Section 15.4.

 

		1.160	“Program
                                         Patent Rights” shall mean Patent Rights Covering Inventions.

 

		1.161	“Project
                                         Leaders” shall have the meaning set forth in Section 9.1.2 below.

 

		1.162	“R&D
                                         Plan(s)” shall mean the research and development plans to be prepared under
                                         this Agreement and shall include the First Program Research Plan in Exhibit 5.1.1,
                                         the Reserved Target Research Plans, the Other Pre-IND Program Research Plans, the Opt-In
                                         R&D Plan, and the Product Development Plans.

 

		1.163	“Receiving
                                         Party” shall have the meaning set forth in Section 13.1.

 

		1.164	“Regulatory
                                         Agency” shall mean any one of the following: United States Food and Drug Administration
                                         (“FDA”) or any successor agency; or any counterparts thereof in jurisdictions
                                         outside of the U.S.

 

		1.165	“Regulatory
                                         Approval” shall mean any and all approvals (including supplements, amendments,
                                         pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations
                                         or authorizations (including marketing and labeling authorizations) of any national,
                                         supra-national (e.g., the European Commission or the Council of the European Union),
                                         regional, state or local Regulatory Agency, department, bureau, commission, council or
                                         other governmental entity, that are necessary for the development, registration, manufacture
                                         (including formulation), distribution, use, sale, import or export of a Product in a
                                         given jurisdiction.

 

		1.166	“Regulatory
                                         Exclusivity” shall mean any exclusive marketing rights or data exclusivity
                                         rights conferred by any Regulatory Agency with respect to a Product, other than Patent
                                         Rights.

 

		1.167	“Relevant
                                         Infringement” shall have the meaning set forth in Section 11.1.

 

		1.168	“Replacement
                                         Target” shall have the meaning set forth in Section 3.1.

 

		1.169	“Replacement
                                         Target Exclusivity Period” shall have the meaning set forth in Section 2.1.2.

 

    24

     

    

 

		1.170	“Replacement
                                         Target Antibody” shall mean a single Antibody directed at a Replacement Target.

 

		1.171	“Research
                                         Completion Deadline” shall have the meaning set forth in Section 5.2.1.

 

		1.172	“Research
                                         Period” shall mean, on a Target-by-Target basis, the period during which research
                                         and Development activities under this Agreement are being conducted (i) under the First
                                         Program Research Plan (whether in relation to the First Program Antibody or in relation
                                         to a Replacement Target Antibody); and (ii) the Reserved Target Research Plans (to be
                                         determined on a Research Target-by-Research Target basis); and/or (iii) the Other Pre-IND
                                         Program Research Plans (to be determined on an Optioned Target -by- Optioned Target basis).

 

		1.173	“Research
                                         Program” shall mean a program of research relating to a Reserved Target, a
                                         Research Program Antibody and LNP Technology.

 

		1.174	“Research
                                         Program Antibody” shall mean a Program Antibody (i) that [*****] as applicable; and (ii) that Genmab has elected
                                         to use and is to be used in a Reserved Target Research Plan as described in Section 5.2.1.

 

		1.175	“Research
                                         Program Antibody Combination” shall mean a Program Antibody Combination that
                                         [*****].

 

		1.176	“Reservation
                                         Fee” shall have the meaning set forth in Section 3.3 below.

 

		1.177	“Reservation
                                         Period” shall have the meaning set forth in Section 3.2.1 below.

 

		1.178	“Reserved
                                         Target” shall have the meaning set forth in Section 3.2.1 below. For purposes
                                         of this Agreement, and unless otherwise set forth herein, Reserved Target shall include
                                         a Reserved Target Combination, as applicable.

 

		1.179	“Reserved
                                         Target Combination” shall have the meaning set forth in section 3.2.1 below.

 

		1.180	“Reserved
                                         Target Data Package” shall have the meaning set forth in Section 5.2.2.

 

		1.181	“Reserved
                                         Target Research Plan” shall have the meaning set forth in Section 5.2.1 below.

 

		1.182	“Roche
                                         License” shall mean the non-exclusive license made between CureVac and F.Hoffmann-La
                                         Roche Ltd dated [*****] granting Roche [*****]. For the purposes of this Agreement, the
                                         term Roche License shall not include any amendments made to the non- exclusive license
                                         agreement between CureVac and Roche after the Effective Date.

 

		1.183	“Royalty
                                         Product Patent Rights” shall mean, on a Product-by-Product basis the First
                                         Composition of Matter Patent Rights. For the avoidance of doubt, the term Royalty Product
                                         Patent Rights shall not include any later filed Patent Rights not claiming priority from
                                         or comprised in the First Composition of Matter Patent Rights, such as later filed Patent
                                         Rights that relate to other aspects of the Product (e.g., Patent Rights relating to formulation,
                                         processes, uses or other applications of the Product).

 

    25

     

    

 

		1.184	“Royalty
                                         Term” shall have the meaning set forth in Section 10.6.3.

 

		1.185	“Single
                                         Antibody Product” shall mean a Product that is designed to express one Program
                                         Antibody. Single Antibody Product includes the First Program Antibody and the Replacement
                                         Target Antibody.

 

		1.186	“Sub-Committee”
                                         shall have the meaning set forth in Section 9.4 below.

 

		1.187	“Sublicensee”
                                         shall mean any Third Party licensee (aside from Genmab’s Affiliates and any Third
                                         Party contractors used by Genmab in the Development, Manufacture or Commercialization
                                         of the Products on Genmab’s behalf), which obtains rights to the CureVac Technology
                                         or LNP Technology under a license granted by Genmab, its Affiliates or another such Third
                                         Party that was sublicensed such rights by Genmab, its Affiliates or another Sublicensee.

 

		1.188	“Successful
                                         GLP Tox” shall mean the earlier of (i) the date where a formal decision by
                                         Genmab’s relevant project board or equivalent to file for IND submission is communicated
                                         to CureVac, whether or not the JRC has received data confirming that the success criteria
                                         as defined in the R&D Plan for the formal toxicology studies required for such IND
                                         submission have been fulfilled; or (ii) [*****] after the JRC has received data confirming
                                         that the success criteria as defined in the R&D Plan for the formal toxicology studies
                                         required for such IND submission have been fulfilled.

 

		1.189	“Switching
                                         Costs” shall mean those incremental additional payments to be made by CureVac
                                         to a provider of LNP Technology other than under the Acuitas License or Arcturus License
                                         resulting from the decision by Genmab to switch from the First Collaboration Target to
                                         a Replacement Target, including payment of additional license or reservation fees and/or
                                         increased royalties because a new license of LNP Technology is required other than the
                                         Arcturus License or Acuitas License. For clarity, the term “Switching Costs”
                                         shall only comprise the delta between what CureVac would have had to pay to Arcturus
                                         under the Arcturus License or to Acuitas under the Acuitas License for an LNP Technology
                                         license relating to the First Collaboration Target and what CureVac will have to pay
                                         to a provider of LNP Technology other than under the Acuitas License or Arcturus License
                                         for an LNP Technology license relating to the Replacement Target. The Switching Costs
                                         shall be determined from time to time when any payment relating to the Replacement Target
                                         is due under such LNP Technology license other than Acuitas License or Arcturus License
                                         by comparing the actual total payments made or due under such other LNP Technology license
                                         with the payments that would have been made by or due from CureVac under the Arcturus
                                         License or Acuitas License with respect to the given Product. Whether the Arcturus License
                                         or Acuitas License will be used as reference point when making such calculations of the
                                         then current total Switching Costs will depend on which of the two LNP Technologies that
                                         were used for Product based on the First Program Antibody.

 

    26

     

    

 

		1.190	“Target”
                                         shall mean a distinct single antigen defined by its unique UniProt/SwissProt number.
                                         For purposes of this Agreement, and unless otherwise set forth herein, Target shall include
                                         a Target Combination, as applicable.

 

		1.191	“Target
                                         List” and “Target List Rep” shall have the meanings set
                                         forth in Section 3.2.2.

 

		1.192	“Target
                                         Combination” shall mean a combination of up to [*****] distinct antigens per
                                         Product, as defined by their unique UniProt/SwissProt numbers.

 

		1.193	“Target
                                         Subset” shall mean any individual Targets or subcombinations thereof within
                                         an Optioned Target Combination which does not contain the specific combination of Targets
                                         constituting an Optioned Target Combination targeted by an Other Program Antibody or
                                         Other Program Antibody Combination (e.g., if Genmab has exercised an Optioned Target
                                         Combination consisting of “a+b+c”, then any individual Target or other subcombination
                                         of Targets within the Optioned Target Combination of “a+b+c”, i.e. the combinations
                                         of “a+b”, “b+c” or “a+c” or the individual Targets
                                         “a” or “b” or “c”), would each constitute a Target
                                         Subset.

 

		1.194	“Term”
                                         shall have the meaning set forth in Section 15.1.

 

		1.195	“Terminating
                                         Party” shall have the meaning set forth in Section 7.9.

 

		1.196	“Territory”
                                         shall mean the world.

 

		1.197	“Third
                                         Party” shall mean any Person, other than CureVac or Genmab and their respective
                                         Affiliates.

 

		1.198	“Third
                                         Party IP” shall have the meaning set forth in Section 2.8.

 

		1.199	“Valid
                                         Claim” shall mean either (i) a claim of an issued and unexpired patent within
                                         (A) CureVac Patent Rights, excluding any claim within the CureVac Program Patent Rights,
                                         CureVac Other Invention Patent Rights or Joint Patent Rights Covering a Product where
                                         such CureVac Program Patent Right(s), CureVac Other Invention Patent Right(s) or Joint
                                         Patent Right(s) has a later priority date than any Royalty Product Patent Right Covering
                                         such Product; (B) Patent Rights within LNP Technology Controlled by CureVac and licensed
                                         by CureVac to Genmab under or in connection with this Agreement; or (C) Royalty Product
                                         Patent Rights, and, in each case of (A), (B) and (C), which has not been revoked or held
                                         permanently unenforceable, unpatentable or invalid by a decision of a court or other
                                         governmental agency of competent jurisdiction, unappealable or unappealed within the
                                         time allowed for appeal, and which has not been found or admitted to be abandoned, disclaimed,
                                         denied, invalid or unenforceable through re-examination, reissue or disclaimer or otherwise;
                                         or (ii) a claim of a pending patent application within the CureVac Patent Rights, (excluding
                                         any claim within the CureVac Program Patent Rights, CureVac Other Invention Patent Rights
                                         or Joint Patent Rights Covering a Product where such CureVac Program Patent Right(s),
                                         CureVac Other Invention Patent Rights or Joint Patent Right(s) has a later priority date
                                         than any Royalty Product Patent Right Covering such Product), Patent Rights within LNP
                                         Technology Controlled by CureVac and licensed by CureVac to Genmab under or in connection
                                         with this Agreement, or Royalty Product Patent Rights, which claim has not been cancelled,
                                         withdrawn, abandoned or finally disallowed, and which claim has been prosecuted in good
                                         faith and not been pending for more than [*****] from the date of its earliest priority
                                         date. For avoidance of doubt, the term “Valid Claim” shall not include any
                                         claim of Third Party IP that has been deemed part of CureVac Technology pursuant to Section
                                         2.8.

 

    27

     

    

 

		1.200	Interpretation

 

In this Agreement, unless the context
otherwise requires, a reference to:

 

		(i)	a
                                         paragraph, section, exhibit or schedule is a reference to a paragraph, section, exhibit
                                         or schedule to this Agreement;

 

		(ii)	any
                                         document includes a reference to that document (and, where applicable, any of its provisions)
                                         as amended, novated, supplemented or replaced from time to time;

 

		(iii)	a
                                         statute or other law includes regulations and other instruments under it and consolidations,
                                         amendments, re-enactments or replacements of any of them;

 

		(iv)	the
                                         singular includes the plural and vice versa, except as it regards the definitions of
                                         Party and Parties;

 

		(v)	one
                                         gender includes the other;

 

		(vi)	“written”
                                         and “in writing” include any means of reproducing words, figures or symbols
                                         in a tangible and visible form, including acknowledged email or facsimile;

 

		(vii)	a
                                         month or year is a reference to a calendar month or Calendar Year, as the case may be;

 

		(viii)	“include”,
                                         “includes” and “including” means including without limitation,
                                         or like expression unless otherwise specified, and “for example”, “e.g.”,
                                         “such as” and similar words or phrases are descriptive, not limiting; and

 

		(ix)	the
                                         official text of this Agreement and any Exhibits shall be in English, and any notices
                                         given or accounts or statements for communication between the Parties will be in English
                                         and in the event of any dispute concerning the construction or interpretation of this
                                         Agreement, reference shall be made only to this Agreement as written in English and not
                                         to any other translation into any other language.

  

    28

     

    

 

		2.	LICENSES;
                                         EXCLUSIVITY.

 

		2.1	License
                                         Grants to Genmab.

 

		2.1.1	First
                                         Collaboration Target License. With respect to the First Collaboration Target and
                                         the First Program Antibody, subject to the terms and conditions of the Agreement, and
                                         for the Term, CureVac hereby grants to Genmab, and Genmab hereby accepts, an exclusive
                                         (subject to Section 2.1.6) license under the CureVac Technology to Develop, Manufacture
                                         and Commercialize a Single Antibody Product in the Field and in the Territory. This license
                                         shall automatically terminate upon final clearance by CureVac of a Replacement Target
                                         and related Program Antibody nominated by Genmab in accordance with Section 3.2.2 below.
                                         For clarity, the grant of a license under this Section 2.1.1 to [*****],
                                         unless otherwise specified in this Agreement.

 

		2.1.2	Replacement
                                         Target License. With respect to a Replacement Target nominated by Genmab and cleared
                                         by CureVac under the provisions of Section 3.2.2, as of the final clearance of such Replacement
                                         Target and related Program Antibody(-ies), and subject to the terms and conditions of
                                         this Agreement, and for a term starting upon clearance of the Replacement Target and
                                         ending at the earlier of (i) [*****], or (ii) [*****] after clearance of the respective Replacement Target
                                         (“Replacement Target Exclusivity Period”), CureVac hereby grants to
                                         Genmab, and Genmab accepts, an exclusive (subject to Section 2.1.6) license under the
                                         CureVac Technology to Develop, Manufacture and Commercialize a Single Antibody Product
                                         in the Field in the Territory. For clarity, the grant of a license under this Section
                                         2.1.2 to Manufacture shall not require CureVac to transfer any Know-How comprised in
                                         the CureVac Manufacturing Technology, unless otherwise specified in this Agreement.

 

		2.1.3	Reserved
                                         Target License. With respect to a Reserved Target, subject to the terms and conditions
                                         of this Agreement, and for a period of [*****] after the Effective Date, CureVac hereby
                                         grants to Genmab, and Genmab hereby accepts an exclusive (subject to Section 2.1.6) license
                                         under the CureVac Technology to conduct or have conducted research and pre-clinical Development
                                         on Antibody-based Products in the Field and in the Territory, such research and pre-clinical
                                         Development to enable Genmab to make a decision as to whether it wants to advance the
                                         Reserved Target to an Optioned Target. If the Reserved Target is a Reserved Target Combination,
                                         the exclusivity under this Section 2.1.3 shall apply to all combinations, including subsets
                                         of combinations within the respective Reserved Target Combination, but does not apply
                                         to individual Targets within such Reserved Target Combination. For illustration purposes,
                                         if the Reserved Target Combination was a+b+c, the exclusivity would also apply to the
                                         combination of a+b, b+c and a+c, but not to a, b or c individually.

 

		2.1.4	Optioned
                                         Target License. With respect to any Optioned Target, subject to an Option Exercise
                                         under Section 3.4 below, and subject to the terms and conditions of this Agreement, and
                                         for a term starting upon Option Exercise and ending at the earlier of (i) [*****]; or (ii) [*****]
                                         after the Option Exercise (“Optioned Target Exclusivity Period”),
                                         CureVac hereby grants to Genmab, and Genmab hereby accepts an exclusive (subject to Section
                                         2.1.6) license under the CureVac Technology to Develop, Manufacture and Commercialize
                                         Single Antibody Products or Cocktail Products, as applicable. If the Optioned Target
                                         is an Optioned Target Combination, the exclusivity under this Section 2.1.4 applies to
                                         the specific combination within the respective Optioned Target Combination, and neither
                                         applies to any other combinations, nor to individual Targets within such Optioned Target
                                         Combination. The grant of a license under this Section 2.1.4 to Manufacture shall not
                                         require CureVac to transfer any Know-How comprised in the CureVac Manufacturing Technology,
                                         unless otherwise specified in this Agreement.

 

    29

     

    

 

		2.1.5	Other
                                         Product Licenses. With respect to any Product (and related Program Antibodies and
                                         Program Antibody Combinations) generated during Replacement Target Exclusivity Period,
                                         Reservation Period or Optioned Target Exclusivity Period, subject to the terms and conditions
                                         of this Agreement, and for the Term, CureVac hereby grants to Genmab, and Genmab hereby
                                         accepts, an exclusive (subject to Section 2.1.6) license under the CureVac Technology
                                         to Develop, Manufacture and Commercialize such Products in the Field and in the Territory.
                                         For clarity, the grant of a license under this Section 2.1.5 to [*****].

 

		2.1.6	BioNTech
                                         License and Roche License. Notwithstanding the above, until [*****] the licenses
                                         under the CureVac Technology granted to Genmab pursuant to this Section 2.1 shall be
                                         non-exclusive with respect to rights under Patent Rights [*****] listed in Exhibit
                                         1.13 to the extent the non-exclusive license granted by CureVac to BioNTech AG is
                                         overlapping with the license granted to Genmab under said Patent Rights. Further, until
                                         [*****] the licenses under the CureVac Technology granted to Genmab pursuant to this
                                         Section 2.1 shall be non-exclusive with respect to rights under [*****] to the extent
                                         the non-exclusive license granted by CureVac to F.Hoffmann-La Roche Ltd is overlapping
                                         with the licenses granted to Genmab under [*****]”.

 

		2.1.7	Other
                                         Technologies Licenses. The rights granted under this Section 2.1 (2.1.1, 2.1.2, 2.1.3,
                                         2.1.4, and 2.1.5) include (i) an extension of CureVac’s rights to Genmab, its Affiliates,
                                         subcontractors and permitted Sublicensees as “Direct Collaboration Partner”
                                         or “Indirect Collaboration Partner” under the Patent Rights identified by
                                         the patent family identifier CV-P- Geneart in Exhibit 1.144; and (ii) a non-exclusive
                                         sublicense of CureVac to Genmab, under the Patent Rights identified by the patent family
                                         identifier [*****] in Exhibit 1.144.

 

		2.2	Sublicenses.
                                         Subject to the terms and conditions of this Agreement, Genmab shall have the right
                                         to sublicense any and all rights licensed to Genmab under Section 2.1 to its Affiliates.
                                         With respect to any and all rights licensed to Genmab under Section 2.1, and subject
                                         to the terms and conditions of this Agreement, Genmab shall have the right to sublicense
                                         to any Third Party (with the right to sublicense in multiple tiers) [*****] only upon
                                         CureVac’s prior written consent which CureVac may grant or withhold in its sole
                                         discretion. [*****], Genmab shall have the right to sublicense any and all rights licensed
                                         to Genmab under Sections 2.1.1 (First Collaboration Target) or 2.1.2 (Replacement Target),
                                         Section 2.1.5 (other Product license) and Section 2.1.7 (Other Technologies License)
                                         to any Third Party (with the right to sublicense in multiple tiers) upon CureVac’s
                                         prior written consent which shall not be unreasonably withheld; and such consent is only
                                         required if such Third Party is either a direct competitor of CureVac within the field
                                         of the development of mRNA-based products (such as, but not limited to, [*****] and/or
                                         is residing in [*****] at the time when Genmab wishes to grant such sublicense.
                                         After [*****] Genmab shall have the right
                                         to sublicense any and all rights licensed to Genmab under Sections 2.1.1 or 2.1.2 Section
                                         2.1.5 and Section 2.1.7 (Other Technologies License) without CureVac’s prior written
                                         consent. Any sublicense by Genmab to a Third Party shall be in writing and consistent
                                         with and subject to the terms of this Agreement, and shall include an obligation for
                                         each such Sublicensee to comply with the applicable obligations of Genmab set forth in
                                         this Agreement. Genmab will provide CureVac with written notice of any [*****].

 

    30

     

    

 

		2.3	License
                                         Grants to CureVac. Subject to the terms and conditions of the Agreement, Genmab hereby
                                         grants to CureVac, and CureVac hereby accepts, a non-exclusive, royalty-free license
                                         under the Genmab Technology to perform CureVac’s obligations under the Agreement
                                         with respect to the research and Development of Products on behalf of Genmab.

 

		2.4	Exclusivity.

 

		2.4.1	Genmab.
                                         Except for the exercise of rights hereunder with respect to Products, neither Genmab,
                                         its Affiliates nor its Sublicensees holding exclusive rights to the CureVac Technology
                                         in the Field and in the Territory, shall develop or commercialize an mRNA-based [*****]
                                         Antibody (including a [*****] Antibody) product or a
                                         [*****] Antibody that is based on [*****] as described in Exhibit 1.77.

 

		2.4.2	CureVac
                                         on the First Collaboration Target. During the term of this Agreement, CureVac, itself
                                         or through its Affiliates, shall not, directly or indirectly, offer any rights to a Third
                                         Party under the LNP Technology for the First Collaboration Target or conduct or participate
                                         in the research, development, manufacture, use, offer for sale, or other exploitation
                                         of any mRNA-based product that is designed to express a Single Antibody (including monoclonal,
                                         bispecific or multispecific Antibody) product that is directed at the First Collaboration
                                         Target or any recombinant single Antibody (including monoclonal, bispecific or multispecific
                                         Antibody) product directed at the First Collaboration Target. Notwithstanding the above,
                                         if Genmab replaces the First Collaboration Target with a Replacement Target pursuant
                                         to Section 3.1, then CureVac shall be released from its exclusivity obligations set out
                                         above in this Section 2.4.2 as of the date of such replacement and instead Section 2.4.3
                                         shall apply with respect to the Replacement Target.

 

		2.4.3	CureVac
                                         on the Replacement Target. CureVac, itself or through its Affiliates, shall not,
                                         directly or indirectly, offer any rights to a Third Party under the CureVac Technology
                                         or LNP Technology for the Replacement Target or conduct or participate in the research,
                                         development, manufacture, use, offer for sale, or other exploitation of any recombinant
                                         or mRNA-based Antibody product directed at the Replacement Target until the earlier of
                                         (i) [*****]; and (ii) [*****] after final clearance of the Replacement Target under Section
                                         3.2.2.

 

    31

     

    

 

		2.4.4	CureVac
                                         on Reserved Targets and Reserved Target Combinations; Optioned Targets and Optioned Target
                                         Combinations; Opt-In Target. Once a Target or Target Combination, as applicable,
                                         becomes a Reserved Target or Reserved Target Combination, CureVac, itself or through
                                         its Affiliates, shall not directly or indirectly, offer any rights to a third party under
                                         the CureVac Technology or LNP Technology for such Reserved Target or Reserved Target
                                         Combination or conduct or participate in the research, development, manufacture, use,
                                         offer for sale, or other exploitation of any mRNA-based product that is designed to express
                                         an Antibody or Antibody Combination that is directed at such Reserved Target or Reserved
                                         Target Combination, or any recombinant Antibody product or Antibody Combination product
                                         directed at such Reserved Target or Reserved Target Combination. The non-compete obligations
                                         under this Section 2.4.4 shall continue until expiry of the Reservation Period for such
                                         Reserved Target or Reserved Target Combination, as applicable, unless Genmab exercises
                                         an Option with respect to a Reserved Target or Reserved Target Combination, as applicable,
                                         in which case the non-compete obligations with respect to such Target or Target Combination
                                         (then an Optioned Target or Optioned Target Combination) shall remain in effect until
                                         the end of the Optioned Target Exclusivity Period. CureVac retains its rights to conduct
                                         or participate in the research, development, manufacture, use, offer for sale, or other
                                         exploitation of mRNA or recombinant based products directed at single Targets of a Reserved
                                         Target Combination during the Reservation Period, but not for combinations of individual
                                         Targets within a Reserved Target Combination (e.g., a combination of a+b where the Reserved
                                         Target Combination consists of a+b+c). After the Reservation Period, the non-compete
                                         obligations under this Section 2.4.4 automatically expire with respect to any Target
                                         Combinations within the Reserved Target Combination that is not the Optioned Target Combination
                                         (e.g., if Genmab exercises an option for the combination a+b+c, then CureVac will get
                                         the rights back to work on e.g.; “a+b” or “a+b+c+d”); and after
                                         the Optioned Target Exclusivity Period, the non-compete obligations under this Section
                                         2.4.4 automatically expire with respect to any Optioned Target and Optioned Target Combination
                                         that is not addressed by an Other Program Antibody. Notwithstanding anything to the contrary
                                         above, in the event of an Opt-In by CureVac under Section 7.1 and until the earlier of
                                         (i) an assignment by CureVac under Section 7.8 or (ii) CureVac’s termination of
                                         its [*****] collaboration of the Opt-In Program pursuant to Section 7.9, CureVac, itself
                                         or through its Affiliates, shall not, directly or indirectly, offer any rights to a Third
                                         Party under the CureVac Technology or LNP Technology for the Opt-In Target, or conduct
                                         or participate in the research, development, manufacture, use, offer for sale, or other
                                         exploitation of any mRNA-based product that is designed to express an Antibody product
                                         that is directed at the Opt-In Target or any recombinant Antibody product directed at
                                         the Opt-In Target. For avoidance of doubt, in the event of assignment by CureVac under
                                         Section 7.8 the exclusivity obligation set out above shall continue to apply with respect
                                         to the Third Party assignee.

 

		2.5	Trademarks.
                                         Genmab will be free to use and to register in any trademark office in the Territory
                                         any trademark for use with a Product in its sole discretion; provided, however,
                                         nothing herein shall grant Genmab any right to use any trademark Controlled by CureVac
                                         and/or its Affiliates. Genmab will own all right, title and interest in and to any such
                                         trademark it selects in its own name during and after the Term.

 

		2.6	Know-How
                                         Transfer; Availability of Employees. As and when required in relation to an R&D
                                         Plan (and from time to time during the Term if new Know-How comes to be Controlled by
                                         CureVac) or as soon as reasonably practicable upon Genmab’s request, CureVac shall
                                         disclose and/or deliver to Genmab copies of all Development Data and information in CureVac’s
                                         possession relating to the CureVac Know-How which is reasonably required for Genmab’s
                                         research and Development activity in accordance with the respective R&D Plan (including
                                         for regulatory purposes), with the exception, however, of all Know-How comprised in the
                                         CureVac Manufacturing Technology which shall be made available to Genmab or its designee
                                         as set forth in Sections 6.5 and/or pursuant to Tech Transfer Plan, the Early Clinical
                                         Supply Agreement and/or the MSA. [*****].
                                         The technology transfer to be undertaken under Sections 2.6 and 6.5 shall be overseen
                                         by the Joint Research Committee.

 

    32

     

    

 

		2.7	No
                                         Implied License. Nothing in this Agreement shall be deemed to constitute the grant
                                         of any license or other right to either Party in respect of any technology of the other
                                         Party, except as expressly set forth herein, and no license rights shall be created hereunder
                                         by implication, estoppel or otherwise. Neither Party shall represent to any Third Party
                                         that it enjoys, possesses, or exercises any proprietary or property right or otherwise
                                         has any other right, title or interest in the technology of the other Party except for
                                         such rights as are expressly set forth herein. Any rights of a Party not expressly granted
                                         to the other Party under the provisions of this Agreement shall be retained by such Party.

 

		2.8	Third
                                         Party Intellectual Property – CureVac Activities. If, during the Term, CureVac
                                         obtains a sub-licensable license to any Patent Rights or Know-How Controlled by a Third
                                         Party that is necessary or useful to Develop, Manufacture, Commercialize or otherwise
                                         exploit Products in the Field in the Territory (“Third Party IP”),
                                         then CureVac shall notify Genmab of the rights that CureVac has obtained with respect
                                         such Third Party IP (including details of the financial and commercial terms and other
                                         obligations that would be placed on Genmab as a sublicensee) promptly after obtaining
                                         such rights or, if reasonably possible before obtaining such rights and only in the circumstances
                                         that the license relates solely to a Product, allow Genmab to provide input to the draft
                                         terms to be taken into good faith consideration by CureVac. Genmab shall notify CureVac
                                         within [*****] after receipt of such notice whether Genmab desires to include such Third
                                         Party IP under the licenses granted to Genmab by CureVac pursuant to Section 2.1. If
                                         Genmab notifies CureVac that it desires to include Third Party IP under the license granted
                                         to Genmab by CureVac pursuant to Section 2.1, then (a) such Third Party IP is and shall
                                         be automatically included in the definition of CureVac Technology and in the licenses
                                         under Section 2.1, and (b) as a sublicensee of CureVac Genmab will meet all obligations
                                         of CureVac that are applicable to Genmab’s activities as a sub-licensee and have
                                         been disclosed by CureVac to Genmab; and (c) to the extent necessary CureVac will grant
                                         to Genmab a formal sublicense, and (d) subject to the below in this Section 2.8, [*****]. For avoidance of doubt, in the
                                         event that CureVac uses the Third Party IP for its own products or other Third Party
                                         products, [*****]. The proportionate
                                         amount shall be judged at the time of any payment by CureVac under the license, and shall
                                         be calculated by reference to the number of Products under Development by Genmab at that
                                         time in comparison to the number of products under research or development by CureVac
                                         or any licensee of CureVac and, if applicable, the number of available product slots
                                         (license options). For illustration purposes only, if Genmab then had one Product under
                                         Development, and CureVac and its licensees had five products under research or development
                                         and four available product slots (license options), the proportionate amount would be
                                         [*****] Genmab shall make such [*****] within [*****] after receipt of an invoice
                                         therefor from CureVac. For the avoidance of doubt, the obligations of [*****]
                                         amounts payable by CureVac to a Third Party as set forth in this Section 2.8 apply solely
                                         with respect to licenses under Third Party IP that are entered into by CureVac after
                                         the Effective Date. CureVac shall be solely responsible for any amounts payable with
                                         respect to licenses to Third Party IP entered into by CureVac (or an Affiliate to CureVac)
                                         prior to the Effective Date and forming part of CureVac Background Technology or Other
                                         Technologies. Notwithstanding anything to the contrary above, to the extent the Patent
                                         Rights comprised in the Third Party IP sublicensed hereunder to Genmab were granted Patent
                                         Rights as of the Effective Date and are referenced in the Disclosure Letter, then Genmab
                                         shall have the right to deduct one hundred per cent (100%) of the amounts [*****]
                                         to CureVac under this Section 2.8 from milestone payments due to CureVac under Section
                                         10.5 and/or from royalties due to CureVac under Section 10.6 subject always to the provisions
                                         of Section 10.6.9. If Genmab decides that it does not wish to take a sublicense to such
                                         Third Party IP from CureVac it shall not be treated as part of CureVac Technology. If
                                         Genmab subsequently takes a license to such Third Party IP to which CureVac holds a license
                                         and where CureVac has previously offered an equivalent sublicense, [*****]. For avoidance of doubt, with respect to sublicenses from
                                         CureVac to Third Party IP not referenced in the Disclosure Letter or Third Party Patent
                                         Rights referenced in the Disclosure Letter that are not granted as of the Effective Date,
                                         then to the extent that such sublicenses qualify as FTO Licenses, Genmab shall have the
                                         right to deduct [*****] made to CureVac in accordance with the
                                         provisions set out in Section 10.6.6 (Other Third Party Payments) and subject always
                                         to the provisions of Section 10.6.9.

 

    33

     

    

 

		2.9	CureVac
                                         New Patent Rights. CureVac shall notify Genmab of any Patent Right and related Know-How
                                         Controlled by CureVac that (a) Cover an invention made by CureVac during the Term outside
                                         the scope of this Agreement and are unrelated to CVCM or LNP technology, and, for clarity,
                                         that are not in-licensed from a Third Party, and (b) are necessary or reasonably useful
                                         to Develop, Manufacture, Commercialize or otherwise exploit Products in the Field in
                                         the Territory (each, a “New Patent Right”). For avoidance of doubt
                                         this does not include Patent Rights and related Know-How Covering manufacturing processes
                                         outside the scope of CureVac Manufacturing Technology. Genmab shall notify CureVac within
                                         [*****] after receipt of such notice whether Genmab desires to include such New Patent
                                         Right under the licenses granted to Genmab by CureVac pursuant to Section 2.1. If Genmab
                                         notifies CureVac that Genmab desires to include such New Patent Right under the licenses
                                         granted to Genmab by CureVac pursuant to Section 2.1, then such New Patent Right is and
                                         shall be automatically included in the definitions of the CureVac Patent Rights and shall
                                         be considered within 1.199 (i) (Valid Claim) regardless of the priority date of the New
                                         Patent Right and shall be included in the licenses granted to Genmab by CureVac pursuant
                                         to Section 2.1.

 

    34

     

    

 

 

		3.	REPLACEMENT
                                         TARGET; RESERVED TARGETS; OPTIONED TARGETS.

 

		3.1	Replacement
                                         of the First Collaboration Target. If the pre-clinical Program with respect to the
                                         First Collaboration Target does not meet the success criteria set forth in the First
                                         Program Research Plan attached hereto as Exhibit 5.1.1 (as may be modified by
                                         JRC), Genmab has the [*****] right, [*****] after the Effective Date, to
                                         seek to replace the First Collaboration Target by another Target (“Replacement
                                         Target”). Genmab shall nominate a Replacement Target by written notice to CureVac,
                                         and CureVac will then operate the clearance procedures, in accordance with Section 3.2.2.
                                         If CureVac gives written notice to Genmab that the Replacement Target is cleared and,
                                         upon written notice by Genmab that it wishes to replace the First Collaboration Target
                                         by such Replacement Target, the Replacement Target will replace the First Collaboration
                                         Target for purposes of this Agreement. Upon replacement, the Parties through the JRC
                                         will amend the First Program Research Plan as required to address any differences between
                                         the Replacement Target and the First Collaboration Target, as well as the changes in
                                         timeline resulting from the change of Target.

 

		3.2	Target
                                         Reservation.

 

		3.2.1	Reserved
                                         Targets and Reservation Period. During a period starting on the first anniversary
                                         of the Effective Date and ending [*****] after the Effective Date, Genmab shall have
                                         the right to exclusively reserve up to four (4) Targets or Target Combinations, in order
                                         to enable Genmab, to exercise up to three (3) options, to Develop, Manufacture and Commercialize
                                         Products against the Targets or Target Combinations, as applicable, for which the option
                                         is exercised, in addition to the Products against the First Collaboration Target or Replacement
                                         Target, as applicable. A Target or Target Combination shall become a “Reserved
                                         Target” or a “Reserved Target Combination” as applicable,
                                         upon (i) [*****], and (ii) [*****]. Such Reserved Target shall remain a Reserved Target until [*****] or such period as extended in accordance with Section 5.2.2 below
                                         (“Reservation Period”). If Genmab notifies CureVac that it does not
                                         wish to exercise an option with respect to a Reserved Target, latest upon expiry of the
                                         Reservation Period, the respective Target shall cease to be a Reserved Target; and upon
                                         exercise of three (3) options, any fourth (4th) Reserved Target shall cease to be such
                                         a Reserved Target.

 

		3.2.2	Clearance
                                         of Targets. CureVac shall appoint a representative of CureVac (“Target List
                                         Rep”) who is a legal counsel in the legal department or IP department of CureVac
                                         or employed with an external law firm, to keep a list of all Targets and Target Combinations
                                         that are the subject of or related to any ongoing evaluation or research project of CureVac
                                         and/or in collaboration with or under option or license to any Third Party (“Target
                                         List”). CureVac shall provide to Genmab contact details of the Target List
                                         Rep. If Genmab wishes to reserve a Target or Target Combination, Genmab shall in writing
                                         request CureVac to perform a Target or Target Combination clearance. Clearance will be
                                         conducted in accordance with the following process: First, Genmab shall inform the Target
                                         List Rep in writing that Genmab wishes to conduct a Target or Target Combination clearance.
                                         Second, within [*****] from receipt of such information from Genmab the Target List Rep
                                         updates the Target List and confirms to Genmab that the Target List is updated. Third,
                                         Genmab shall set out details of the Target or Target Combination to the Target List Rep
                                         and within [*****] the Target List Rep shall indicate to Genmab whether the Target or
                                         Target Combination is available. If the Target or Target Combination, as applicable,
                                         is available and Genmab wishes to go ahead, Genmab shall then submit to CureVac the full
                                         sequences of the proposed Research Program Antibody(-ies) as specified in the clearance
                                         templates in Exhibit 3.2.2, as applicable. Unless Genmab informs CureVac that
                                         it will independently secure rights to an appropriate LNP Technology, CureVac shall within
                                         a further [*****] review and investigate whether LNP Technology for a Product based on
                                         the Target or Target Combination and proposed Research Program Antibody(-ies) is potentially
                                         available through CureVac. In connection with such review and investigation, CureVac
                                         shall be authorized to provide the full sequences of the proposed Research Program Antibody(-ies)
                                         to the in-house legal or IP counsel of the potential LNP Technology provider or an external
                                         legal or IP representative handling any gatekeeping clearance procedures that it operates,
                                         provided that the LNP Technology provider and, if applicable, its external legal or IP
                                         representative is subject to confidentiality obligations at least as stringent as the
                                         confidentiality obligations on the Parties set forth herein as well as an obligation
                                         not to disclose the sequence to any Third Party. If CureVac determines that LNP Technology
                                         for a Product based on the Target or Target Combination and proposed Research Program
                                         Antibody(-ies) is available through CureVac, it shall give notice to Genmab hereof. If
                                         CureVac cannot identify any such LNP Technology the JRC shall consider the position to
                                         recommend a way forward. The Reserved Target or Reserved Target Combination, as applicable,
                                         shall be deemed finally cleared for purposes of this Agreement, if CureVac informs Genmab
                                         that the LNP Technology is available for the respective Product(s) and related Program
                                         Antibody/Program Antibody Combination, or if Genmab waives CureVac’s obligations
                                         to support Genmab with respect to the LNP Technology under this Agreement.

 

    35

     

    

 

		3.2.3	Costs.
                                         Subject to CureVac’s Opt-in Right and except as otherwise stated in this Agreement,
                                         all Development costs under any Program relating to Reserved Targets shall be borne by
                                         Genmab.

 

		3.3	Reservation
                                         Fee. Within [*****] after a Target or Target Combinations becomes a Reserved Target
                                         or Reserved Target Combination, as applicable, in accordance with Section 3.2.1, Genmab
                                         shall pay to CureVac a reservation fee of US Dollars [*****] per Reserved Target or Reserved
                                         Target Combination, as applicable, (“Reservation Fee”), provided,
                                         however, that in the event the Reservation Fee has not been paid within [*****] after
                                         the date that the Target or Target Combination became a Reserved Target or Reserved Target
                                         Combination, as applicable, pursuant to Section 3.2.1, such Target or Target Combination
                                         shall no longer be reserved for purpose of this Agreement. The Reservation Fee shall
                                         be creditable against the Option Exercise Fee for the respective Reserved Target or Reserved
                                         Target Combination, in the event Genmab advances such Reserved Target or Reserved Target
                                         Combination to an Optioned Target or Optioned Target.

 

		3.4	Exclusive
                                         Option. As of the Effective Date and in consideration for the respective Option Exercise
                                         Fee as set forth in Section 10.2, CureVac hereby grants to Genmab, and Genmab hereby
                                         accepts, three (3) exclusive options for the shorter of (i) a term of [*****] after the
                                         Effective Date; or (ii) on a Reserved Target-by-Reserved Target basis, the Reservation
                                         Period (“Option Period”), to obtain exclusive licenses to Reserved
                                         Targets, as set forth in Section 2.1.3 above. Genmab may exercise the option under this
                                         Section 3.4 on a Reserved Target-by-Reserved Target basis by way of written notice to
                                         CureVac during the Option Period (“Option Exercise”). As of the date
                                         of the Option Exercise, and provided the Option Exercise Fee has been timely paid in
                                         accordance with Section 10.2 below, the Reserved Target or Reserved Target Combination
                                         shall become an “Optioned Target” or “Optioned Target Combination”,
                                         as applicable. For clarity, in order to protect Genmab’s exclusive option, during
                                         the Option Period the exclusivity obligations set out in Section 2.4 shall apply.

 

    36

     

    

 

		4.	LNP
                                         TECHNOLOGY.

 

		4.1	First
                                         Program Antibody. CureVac will at its own cost secure the rights to the LNP Technology
                                         required for Genmab to Develop, Manufacture and Commercialize a Single Antibody Product
                                         identified under the First Program Research Plan (whether in relation to the First Collaboration
                                         Target or a Replacement Target) with the exception of any Switching Costs which will
                                         be borne by Genmab and/or CureVac pursuant to the mechanism set forth below in this Section
                                         4.1. The rights may be exclusive or non-exclusive, and may be under the Arcturus License,
                                         the Acuitas License or utilizing any other suitable LNP Technology of a Third Party other
                                         than Arcturus or Acuitas. CureVac shall hold the license required and, if CureVac decides
                                         to source other suitable LNP Technology, shall be responsible for (i) investigating the
                                         availability of such other suitable LNP Technology and in connection with such investigation,
                                         upon Genmab’s prior written approval (not to be unreasonably withheld), CureVac
                                         shall be authorized to provide the full sequences of the First Program Antibody or Replacement
                                         Target Antibody to the in-house legal or IP counsel of the potential LNP Technology provider
                                         or an external legal or IP representative handling any gatekeeping clearance procedures
                                         that it operates on behalf of said provider, provided that the LNP Technology provider
                                         and, if applicable, its external legal or IP representative is subject to confidentiality
                                         obligations at least as stringent as the confidentiality obligations on the Parties set
                                         forth herein and, in addition, an obligation not to share the sequences with any Third
                                         Party; and (ii) negotiating and agreeing the terms for the license under the LNP Technology
                                         for the conduct of the First Collaboration Program for the First Collaboration Target
                                         and, if applicable and subject to the below in this Section 4.1 and in Section 4.2, the
                                         Replacement Target. Prior to CureVac deciding on the use of a particular LNP Technology
                                         for the First Collaboration Target that is not the LNP Technology licensed under the
                                         Arcturus License or the Acuitas License, Genmab shall have the right to review and consider
                                         all terms relevant to Genmab for such LNP Technology license, including any relevant
                                         agreements with any Third Party provider for such LNP Technology, relevant Patent Rights,
                                         and FTO reports (if any). If CureVac decides to source other suitable LNP Technology
                                         and Genmab, having considered the terms available from the provider of the LNP Technology,
                                         suggests certain amendments to such terms, CureVac will use Commercially Reasonable Efforts
                                         to obtain such amendments, but if CureVac cannot obtain such amendments, CureVac shall
                                         be entitled to proceed with such LNP Technology license for the First Collaboration Target
                                         without such amendments. For avoidance of doubt, CureVac shall not enter into any LNP
                                         Technology license other than the Acuitas License or Arcturus License for the Replacement
                                         Target without Genmab’s prior written consent. In the event that the First Program
                                         Research Plan is amended to include a Replacement Target, the procedure for selection
                                         of a suitable LNP Technology set out in Section 4.2 below shall apply. CureVac shall
                                         obtain the LNP Technology license in relation to the Single Antibody Product identified
                                         under the First Program Research Plan and grant to Genmab a sublicense in the form required
                                         by the license to CureVac from the LNP Technology provider. If an LNP Technology license
                                         other than Acuitas License or Arcturus License is chosen with respect to the Replacement
                                         Target and Genmab is granted a sublicense pursuant to the procedure set out in Section
                                         4.2, [*****] any applicable Switching Costs within
                                         [*****] of the date of CureVac invoice therefor, provided, however, that if the
                                         Switching Costs at a given time exceed [*****] of the total costs for such LNP Technology
                                         license, then [*****] the then current total costs for such LNP Technology license for
                                         the Replacement Target pursuant to the principles applicable to Reserved Targets and
                                         Optioned Targets set out in Section 4.3 below. Upon Genmab’s reasonable request
                                         at any time following the Effective Date, CureVac shall provide to a representative of
                                         Genmab’s legal department (and on the basis that such legal department representative
                                         may share such copies with other representatives of Genmab’s legal department as
                                         reasonably necessary and may also summarize the contents for other Genmab stakeholders
                                         who need to know the relevant information) accurate, current and unredacted copies of
                                         (i) the Acuitas License, including any future amendments thereto and (ii) the Arcturus
                                         License, including any future amendments thereto.

 

    37

     

    

 

		4.2	Selection
                                         of LNP Technology for Replacement Target Antibody and Other Program Antibodies. Genmab
                                         shall not have the right to source the LNP Technology to be used in the First Program
                                         Research Plan for the First Collaboration Target (including any Replacement Target).
                                         Genmab may request CureVac in writing to source LNP Technology itself for use in a Reserved
                                         Target Research Plan. Subject to the below in this Section 4.2, such request shall be
                                         made by Genmab prior to submitting to CureVac the full sequences of the Research Program
                                         Antibody(ies) under Section 3.2.2. For avoidance of doubt, in such eventuality CureVac
                                         shall have no responsibility to source such LNP Technology. Absent such a notice from
                                         Genmab CureVac shall use Commercially Reasonable Efforts to ensure the availability of
                                         license rights to an LNP Technology which is suitable for the Development, Manufacture
                                         and Commercialization of Products Research Program Antibody(ies) in accordance with this
                                         Agreement. Such rights may be non-exclusive. As part of the clearance procedures under
                                         Section 3.2.2 (including as a result of the provisions of Section 3.1 in relation to
                                         a Replacement Target) CureVac will present a proposal to Genmab identifying the LNP Technology
                                         CureVac suggests is used and is available for in-licensing, considering Genmab’s
                                         preference for either an exclusive or non-exclusive license to the LNP Technology. As
                                         part of this process CureVac shall evaluate LNP Technologies it has been working with
                                         in the past with respect to both their suitability and availability for the respective
                                         Replacement Target Antibody or Research Program Antibody(ies). Genmab and CureVac shall
                                         consider together the options for LNP Technology to be used at the JRC, including if
                                         a new license is required, whether CureVac should hold the license and sub-license to
                                         Genmab (with the exception of a license for Product related to the Replacement Target
                                         where CureVac shall hold the license and sublicense to Genmab), or whether each Party
                                         should hold whatever licenses it requires. CureVac shall be responsible for negotiating
                                         and agreeing the terms for the license under the LNP Technology for the conduct of the
                                         Development of Products based on the Replacement Target Antibody or Research Program
                                         Antibody(ies) and the Commercialization of Products arising therefrom. In the case of
                                         the Replacement Target Antibody or the Research Program Antibody(ies) prior to finalizing
                                         any such new license for a particular LNP Technology to be used in relation to a First
                                         Collaboration Program (for the Replacement Target) or a Research Program, Genmab shall
                                         have the right to review the terms and conditions of a license of the respective LNP
                                         Technology, including the license agreement with a Third Party, whether an exclusive
                                         and non-exclusive is available, the financial terms (identifying the separate fees for
                                         an exclusive and non-exclusive license), the Patent Rights under the LNP Technology,
                                         FTO reports (if any), and other documentation the JRC may consider relevant for the selection
                                         of an LNP Technology (“LNP Technology License Documentation Package”).
                                         For clarity, CureVac will not guarantee that a suitable LNP Technology will be available
                                         for any Program except the First Collaboration Program based on the First Program Antibody.
                                         Within [*****] of receipt by Genmab of a complete LNP Technology License Documentation
                                         Package under Section 5.2.2, Genmab shall indicate by written notice to CureVac (i) whether
                                         or not Genmab agrees to take sub-license rights to the LNP Technology on the terms specified
                                         in the LNP Technology License Documentation Package; and, if it so agrees (ii) whether
                                         the license rights should be non- exclusive or exclusive, if both such options are available.
                                         If Genmab agrees to take sub-license rights, CureVac shall obtain the license and grant
                                         to Genmab the sublicense in the form required by the license to CureVac from the LNP
                                         Technology provider as specified in the LNP Technology License Documentation Package
                                         and approved in advance by Genmab. If Genmab does not agree to take sub-license rights
                                         to the LNP Technology on the terms specified in the LNP Technology License Documentation
                                         Package, then with the exception of LNP Technology being licensed in relation to Product
                                         based on the Replacement Target, Genmab shall have the right to source LNP Technology
                                         itself.

 

    38

     

    

 

		4.3	LNP
                                         Technology License Fees. Subject to the provisions of Section 4.1 concerning Switching
                                         Costs the license fees under any LNP Technology for use in relation to the first Product
                                         directed against the First Collaboration Target or Replacement Target, as applicable,
                                         are included in the license fees under this Agreement and CureVac shall thus be solely
                                         responsible for all and any payments related to the LNP Technology for use in relation
                                         to such first Product. With respect to Reserved Targets and Optioned Targets, and save
                                         where Genmab seeks to source the LNP Technology license directly from the provider (in
                                         which case Genmab shall be responsible for [*****] of all license fees), all license
                                         fees to be paid for the rights to the respective LNP Technologies to the Third Party
                                         licensor of the respective LNP Technologies (whether signature fees, annual fees, milestone
                                         payments or royalties) shall be [*****] shared by Genmab and CureVac to the extent that
                                         such payments relate only to a license of rights for the Development, Manufacturing or
                                         Commercialization of a Research Program Antibody and any subsequent Other Program Antibody
                                         and/or the related Product. If the license fees (for example an upfront or signature
                                         fee) cover license rights to several potential products but will be used for a Product,
                                         [*****]. The [*****] amount shall
                                         be judged at the time of any payment by CureVac under the license, and shall be calculated
                                         by reference to (i) the [*****] at that time;
                                         and (ii) in comparison to the number of products under research or development by CureVac
                                         or any licensee of CureVac at that time and/or, if applicable, product slots (license
                                         options) capable of use by CureVac. For illustration purposes only, [*****]. Notwithstanding the above, if Genmab in its sole discretion elects that the
                                         Parties should obtain an exclusive license although a non-exclusive license was available
                                         at the same time, [*****] provided, however,
                                         that if the Parties agree that an exclusive license to LNP Technology is to be obtained
                                         for any Opt-In Product the full costs for such exclusive license shall be [*****]. In cases where CureVac is the licensee under the LNP Technology license,
                                         CureVac shall invoice Genmab for Genmab’s share of the license fees to a licensor
                                         of LNP Technology as and when such fees fall due. If Genmab is the licensee, it shall
                                         invoice CureVac for its share of license fees as and when such fees fall due. For clarity,
                                         if CureVac obtains the license to the LNP Technology, and grants a sublicense to Genmab,
                                         the [*****] of all license fees for a non-exclusive license shall be a pass through license
                                         fee, without any mark-up for the benefit of CureVac. For further clarity, if Genmab waives
                                         CureVac’s obligation to support Genmab with respect to the LNP Technology under
                                         this Agreement, CureVac shall have no obligation to share in the license fees payable
                                         to a licensor of LNP Technology.

 

    39

     

    

 

		5.	RESEARCH
                                         AND DEVELOPMENT COLLABORATION.

 

		5.1	First
                                         Collaboration Target, and First Program Antibody.

 

		5.1.1	Research
                                         Collaboration on the First Collaboration Target. The Parties shall jointly collaborate
                                         on the preclinical Development of the First Collaboration Target and First Program Antibody
                                         with the objective to identify and take a Product to IND stage (“First Collaboration
                                         Program”). The initial preclinical Development plan is attached hereto as Exhibit
                                         5.1.1. It contains an outline of the activities to be performed by each Party, a
                                         budget for the research activities calculated by reference to the FTE Rate, success criteria,
                                         a target product profile and a high level Development plan up to IND for a Single Antibody
                                         Product, and may be amended from time to time by the JRC subject to the mechanisms in
                                         Section 9.5.1 (“First Program Research Plan”). CureVac will on a quarterly
                                         basis, within [*****] days after receipt of an invoice from Genmab, refund Genmab [*****]
                                         of the actual Development costs of Genmab [*****] as set forth in the then current First Program Research Plan by more
                                         than [*****] and subject always to the mechanisms in Section 8.5.1, provided, however
                                         that in the event Genmab replaces the First Collaboration Target by a Replacement
                                         Target, and the JRC amends the First Program Research Plan accordingly, [*****].

 

		5.1.2	Information
                                         Exchange. Following completion by CureVac and Genmab of the activities assigned to
                                         them in the First Program Research Plan, each Party shall provide the JRC with a data
                                         package containing all Development Data and other information necessary for Genmab to
                                         decide whether it will continue the Development of any Product identified in the First
                                         Program Research Plan by filing an IND and conducting Clinical Studies. The content of
                                         the data package, as well as criteria for evaluation and selection of a candidate for
                                         Product Selection, shall be determined by the JRC and is expected to include, inter alia,
                                         (i) in vivo PK and efficacy data, i.e., toxicology and any animal data; and (ii)
                                         CMC Development data. In addition, CureVac shall provide the LNP Technology License Documentation
                                         Package for the First Collaboration Program.

 

    40

     

    

 

		5.2	Research
                                         and Development of Reserved Targets and Other Program Antibodies.

 

		5.2.1	Reserved
                                         Target Research Plan. Once any Target or Target Combination, as applicable, has been
                                         finally cleared by CureVac under Section 3.2.2, Genmab shall, with CureVac providing
                                         adequate input and support, as soon as practicable, and in any event within [*****] under Section 3.2.2, provide a research plan to the JRC for discussion,
                                         which sets forth the contemplated nonclinical Development activities to be carried out
                                         by each Party during the Reservation Period to identify a Product such that Genmab may
                                         wish to undertake Option Exercise, and a budget for activities to be performed by CureVac
                                         calculated by reference to the FTE Rate, and including a preliminary target product profile
                                         (TPP) for such a Product based on the full antibody sequences of the proposed Research
                                         Program Antibody(-ies) and selected LNP Technology (“Reserved Target Research
                                         Plan”). The Reserved Target Research Plan shall include an overview of the
                                         studies and key data sets which should be included in the Reserved Target Data Package.
                                         The date for completion of the Reserved Target Research Plan shall be set to [*****]
                                         after the date of the JRC’s or CDOs’, as applicable, approval of the Reserved
                                         Target Research Plan if it relates to a Single Antibody Product, and [*****] after the
                                         date of the JRC’s or CDOs’, as applicable, approval of the Reserved Target
                                         Research Plan if it relates to a Cocktail Product (“Research Completion Deadline”)
                                         unless the Parties mutually agree to a different completion date. The Reserved Target
                                         Research Plan shall not include any IND-enabling or GxP Development activities. The Reserved
                                         Target Research Plan shall be discussed in the JRC and the JRC shall seek to approve
                                         the Reserved Target Research Plan within [*****] after final clearance of the Reserved
                                         Target or Reserved Target Combination in accordance with the clearance procedure set
                                         out in Section 3.2.2 above. At the expiry of such [*****] if the JRC has not approved
                                         the Reserved Target Research Plan, any remaining unresolved items regarding activities
                                         to be performed by or on behalf of CureVac or that fall within the scope of Sections
                                         9.5.1(i) to 9.5.1(iii) (inclusive), where Genmab does not have final decision-making
                                         in the JRC, shall be referred to the Alliance Managers for resolution. If the Alliance
                                         Managers facilitate resolution of all issues by the JRC members, the Research Target
                                         Research Plan shall be sent back to the JRC for immediate JRC approval. If within [*****]
                                         of such referral to the Alliance Managers the Reserved Target Research Plan is still
                                         not approved, the dispute shall be deemed automatically referred to the CDOs. If within
                                         [*****] of such referral the Reserved Target Research Plan is still not approved by the
                                         CDOs, no further action under this Section 5.2.1 shall be required and the relevant Target
                                         or Target Combination shall not be designated a Reserved Target or Reserved Target Combination,
                                         as appropriate, and, for avoidance of doubt, the dispute resolution mechanisms set forth
                                         in Section 17.5.2 shall thus not apply. For clarity, this would not prevent Genmab from
                                         initiating a new reservation process under Section 3.2.1. For avoidance of doubt, any
                                         Reservation Period shall not commence until the JRC (or the CDOs, as applicable) have
                                         approved the related Reserved Target Research Plan.

 

		5.2.2	Data
                                         Package. On a Reserved Target-by-Reserved Target basis, as soon as reasonably possible
                                         following completion of the activities under the applicable Reserved Target Research
                                         Plan, which shall, subject to the below, be completed by the Research Completion Deadline,
                                         the Parties shall provide the JRC with a data package containing the Development Data
                                         generated under the Reserved Target Research Plan and other information necessary for
                                         Genmab to evaluate its interest exercising an option with respect to the Reserved Target
                                         (“Reserved Target Data Package”). In addition to the Reserved Target
                                         Data Package, CureVac shall at the same time provide the LNP Technology License Documentation
                                         Package to Genmab. If the Parties cannot reasonably provide such complete Reserved Target
                                         Data Package, or if CureVac is unable to provide the LNP Technology License Documentation
                                         Package, or if certain activities in the Reserved Target Research Plan are delayed, by
                                         the Research Completion Deadline, and unless the Parties mutually agree an extension
                                         of the Research Completion Deadline and the Reservation Period (such agreement not to
                                         be unreasonably withheld if there are outstanding Development activities required under
                                         the Reserved Target Research Plan), the Reservation Period shall be extended to allow
                                         Genmab to evaluate its interest in exercising an option pursuant to Section 3.4 by the
                                         shorter of (i) [*****] after receipt by the JRC of the complete Reserved Target Data
                                         Package and LNP Technology License Documentation Package; or (ii) [*****] after the commencement
                                         of the Reservation Period where the corresponding Reserved Target Research Plan relates
                                         to a Single Antibody Product and [*****] after commencement of the Reservation Period
                                         where the corresponding Reserved Target Research Plan relates to a Cocktail Product.

 

    41

     

    

 

		5.2.3	Other
                                         Pre-IND Program Research Plan. On an Optioned Target-by-Optioned Target basis, within
                                         [*****] after the Reserved Target becomes an Optioned Target pursuant to Section 3.4,
                                         Genmab will provide a draft Development plan for a Product directed at the respective
                                         Optioned Target up to IND stage which sets forth the detailed Development activities
                                         to be performed by each Party up to filing of IND for such Product, a budget for activities
                                         to be performed by CureVac calculated by reference to the FTE Rate, success criteria,
                                         and a preliminary target product profile (“Other Pre-IND Program Research Plan”).
                                         Such Other Pre-IND Program Research Plan will be discussed and agreed in the JRC, and
                                         requires approval by CureVac with respect to any activities to be undertaken by CureVac
                                         pursuant to such Other Pre-IND Program Research Plan.

 

		5.3	Product
                                         Selection. When under (i) the First Program Research Plan (whether directed at the
                                         First Collaboration Target or a Replacement Target); or (ii) any Reserved Target Research
                                         Plan or Other Pre-IND Program Research Plan Genmab determines that a Product has been
                                         identified which it is selecting as a clinical candidate to conduct the remaining pre-IND
                                         Development activity and, if the same is successful, further Development through Clinical
                                         Studies and any further non-clinical Development, Genmab shall give written notice to
                                         CureVac of this fact (“Product Selection Notice” and “Product
                                         Selection” as appropriate). In such case, and within [*****] Genmab will either
                                         (i) in the case of a Product resulting from the First Program Research Plan provide to
                                         CureVac a detailed Development plan for such Product to reach IND together with an outline
                                         (high-level) Development Plan for such Product to reach Regulatory Approval (in the form
                                         of marketing authorization). Genmab will allow CureVac to comment on Manufacturing related
                                         matters in the Development plan for the Product to reach IND, such reasonable comments
                                         to be reflected by Genmab in a revised version of such Development Plan; or (ii) in the
                                         case of a Product resulting from an Other Pre-IND Program Research Plan Genmab shall
                                         provide to CureVac an outline (high-level) Development plan for such Product to reach
                                         Regulatory Approval (in the form of marketing authorization), (the plans at (i) and (ii)
                                         all being a “Product Development Plans”).

 

		5.4	Diligence
                                         by CureVac. CureVac will act in good faith, using Commercially Reasonable Efforts,
                                         to perform its assigned tasks and responsibilities as described in the R&D Plans,
                                         and in accordance with all Applicable Laws. With respect to any Opt-In Target and Opt-In
                                         Product, CureVac shall use Commercially Reasonable Efforts to further Develop the Opt-In
                                         Product to market authorization and to Commercialize the Opt-In Product.

 

		5.5	Diligence
                                         by Genmab. Genmab will use Commercially Reasonable Efforts to identify and Develop
                                         a Product during the First Collaboration Program and each Research Program; and, upon
                                         Product Selection or Option Exercise, as applicable, to further Develop each Product
                                         until market authorization. Further, Genmab shall use Commercially Reasonable Efforts
                                         to Commercialize each Product for which it obtains Regulatory Approval.

 

    42

     

    

 

		5.6	Development
                                         Data, Results and records. Up until filing of IND, the Parties will with reasonable
                                         intervals make available to one another through formal reports for review and discussion
                                         within the JRC all preclinical Development Data and other results of the preclinical
                                         Development conducted pursuant to any Program, and will keep such records (paper and
                                         electronic) as described herein. The Parties will maintain records of the preclinical
                                         Development Data and other results in sufficient detail as required from Regulatory Agencies
                                         and in good scientific manner appropriate for patent purposes, and in a manner that properly
                                         reflects all work done and results achieved in the performance of such Programs.

 

		5.7	Development
                                         by CureVac. CureVac will perform certain activities as agreed between the Parties
                                         and set forth in the R&D Plans. Subject only to the funding obligations of CureVac
                                         set forth in Section 5.1.1 above, [*****] at the FTE Rate. In addition to the FTE Rate, [*****]. The compensation is to be paid [*****] on a Calendar
                                         Quarter basis. Payments shall be made and within [*****] after receipt of an invoice,
                                         with supportive documentation detailing the FTE costs and out of pocket expenses applicable
                                         to CureVac’s efforts for such applicable Calendar Quarter period.

 

		5.8	Materials.
                                         CureVac will furnish to Genmab CureVac Materials for Development use in the Programs,
                                         including those which comprise, embody or incorporate CureVac Background Technology,
                                         as expressly set forth in the respective R&D Plan. In particular, CureVac will provide
                                         to Genmab the CureVac Materials as set forth in Exhibit 5.1.1. Genmab will furnish
                                         to CureVac Materials for research and Development use in the Programs, including those
                                         which comprise, embody or incorporate Genmab Background Technology, as expressly set
                                         forth in the respective R&D Plan. In particular, Genmab will provide to CureVac the
                                         Genmab Materials as set forth in Exhibit 5.1.1. Genmab will use the CureVac Materials
                                         and CureVac will use the Genmab Materials, as applicable (i) only in accordance with
                                         the R&D Plans and otherwise in accordance with the terms and conditions of this Agreement;
                                         (ii) not in human subjects, in clinical trials, or for diagnostic purposes involving
                                         human subjects, or for any animal studies, except as expressly provided for in R&D
                                         Plans; and (iii) not reverse engineer or chemically analyze the same except as expressly
                                         provided for (if at all) in R&D Plans. The Materials will remain the sole property
                                         of the Party supplying them and will be used by the recipient Party in compliance with
                                         all Applicable Laws and only to perform activities set forth in R&D Plans. The receiving
                                         Party shall not sell, transfer, disclose or otherwise provide access to the other Party’s
                                         Materials without the written consent of the providing Party, except that the receiving
                                         Party may allow access to the other Party’s Materials to its and its Affiliates’
                                         employees, officers, consultants, subcontractors and Sublicensees who require such access
                                         to perform its activities under this Agreement and solely for purposes consistent with
                                         this Agreement; provided that such employees, officers, consultants, subcontractors and
                                         Sublicensees are bound by agreement to retain and use the Materials in a manner that
                                         is consistent with the terms of this Agreement. THE MATERIALS ARE PROVIDED “AS
                                         IS”. NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, OF ANY KIND, ARE GIVEN
                                         BY THE PROVIDING PARTY WITH RESPECT TO ANY OF THE MATERIALS, INCLUDING THEIR CONDITION,
                                         MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. The receiving Party acknowledges
                                         the experimental nature of the Materials and that accordingly, not all characteristics
                                         of the Materials are necessarily known. Upon termination or expiration of this Agreement
                                         if earlier, any and all remaining Materials will, within [*****] after such event, be
                                         returned to the Party supplying them (or destroyed, if the supplying Party shall so specify,
                                         with such destruction confirmed in writing). The provision of Materials hereunder will
                                         not constitute any grant, option or license to or under such Materials, or any Patent
                                         Rights or Know-how of the supplying Party, except as expressly set forth herein.

 

    43

     

    

 

		5.9	Delays
                                         in Performance of Non-Clinical Development Activities. If, during the performance
                                         of any of the Programs, a Party reasonably believes that such Program cannot be performed
                                         in accordance with the respective R&D Plan (excluding the Product Development Plans,
                                         for which the obligations in this Section 5.9 shall not apply), such Party shall inform
                                         the JRC thereof. To the extent a Party reasonably believes that certain amendments to
                                         the R&D Plan (excluding the Product Development Plans) are necessary or advisable,
                                         such Party shall notify the JRC of such Party’s proposed amendments and the JRC
                                         shall review such proposed amendments and consider an update of the respective R&D
                                         Plan. The JRC can only amend any Reservation Period or Research Completion Deadline with
                                         consensus (i.e. Genmab shall not have casting vote in such matter).

 

		5.10	Regulatory
                                         Approvals of Product.

 

		5.10.1	Filing.
                                         Genmab shall prepare and file all INDs and NDAs and own all Regulatory Approvals
                                         and be responsible for all decisions in connection therewith for Regulatory Approvals
                                         of Products in the Field and in the Territory; provided, however, that for the
                                         First Collaboration Program (with respect to the First Collaboration Target but not the
                                         Replacement Target if applicable) CureVac shall review and comment on the portions of
                                         the first IND related to the Product where CureVac Manufacturing Technology such as CMC
                                         data is included in such IND filing. Such review shall be conducted at the agreed FTE
                                         Rate and subject to the agreed cost [*****]. For subsequent filings of the Product
                                         from the First Collaboration Program and for all other Products, upon CureVac’s
                                         request Genmab will to the extent reasonably possible allow CureVac at CureVac’s
                                         own cost to review and comment on (i) the portions of regulatory filings related to Products
                                         where CureVac Manufacturing Technology such as CMC data is included in such filings,
                                         and (ii) safety related documents. Genmab will take into good faith consideration any
                                         such comments provided by CureVac within [*****] of CureVac’s receipt of such draft
                                         filings. Notwithstanding the above, to the extent that Genmab requests CureVac to review
                                         any regulatory filing and safety related documents, [*****]. CureVac shall cooperate in these efforts as reasonably
                                         requested by Genmab, including by providing any CureVac Manufacturing Know-How reasonably
                                         required by Genmab for such Regulatory Approvals.

 

		5.10.2	Cross
                                         Referencing. To the extent reasonably required by Genmab to achieve or maintain regulatory
                                         clinical trial or marketing authorizations or to comply with any related requests from
                                         Regulatory Agencies related to the Products, CureVac shall authorize and hereby authorizes
                                         Genmab, its Affiliates and Sublicensees to cross-reference sections of other IND/regulatory
                                         dossiers of clinical trials or marketing authorizations of other products Controlled
                                         by CureVac and to any other relevant regulatory filings and any other relevant documentation
                                         Controlled by CureVac. Genmab shall inform CureVac in writing prior to any such cross-referencing.
                                         If CureVac desires to cross-reference sections of the IND/regulatory dossiers of the
                                         clinical trials or marketing authorizations related to the Products, Genmab shall consider
                                         such request in good faith and not unreasonably withhold its consent to such cross-referencing
                                         by CureVac.

 

    44

     

    

 

		5.10.3	Communications.
                                         Genmab shall have the sole right and be responsible for all regulatory interactions,
                                         including written communications and meetings with Regulatory Agencies, and safety management,
                                         including the reporting to the appropriate governmental authorities of all adverse events
                                         and any other information concerning the safety of Products. Prior to IND filing for
                                         a Product, Genmab will, as part of its regular updates through the JRC, inform CureVac
                                         of any material feedback from Regulatory Agencies relating to any Product. CureVac shall
                                         promptly notify Genmab in writing within [*****] of unannounced inspections by any Regulatory
                                         Agency and within a reasonable time in advance of an announced regulatory inspection
                                         with respect to Development, Manufacturing or Commercialization of a particular Product.

 

		5.10.4	Diligence
                                         (Regulatory). Genmab will use Commercially Reasonable Efforts to seek Regulatory
                                         Approval for the Products in the Field in the Major Market Countries.

 

		5.10.5	Global
                                         Safety Database. Genmab shall establish, hold (in-house or via an external vendor),
                                         and maintain the global safety database for Products with respect to information on adverse
                                         events concerning the Products, as and to the extent required by Applicable Law. If (a)
                                         any suspected unexpected serious adverse reactions (SUSAR) or any reportable serious
                                         adverse events (SAEs) may, in Genmab’s reasonable opinion, have a material impact
                                         on the Development of a Product or (b) a public announcement has to be made with respect
                                         to a SUSAR or SAE related to a Product, then in each case Genmab shall promptly notify
                                         CureVac in writing. If a public announcement has to be made with respect to any SUSAR
                                         or SAE related to a Product, Genmab shall, to the extent reasonably possible and provided
                                         that this can be done without risk of non-compliance with Applicable Law (including securities
                                         laws and stock exchange rules), notify CureVac thereof at least [*****] prior to making
                                         such public announcement to give CureVac an opportunity to comment.

 

		5.11	Subcontracts.
                                         Subject to the terms and conditions of this Agreement, the Parties may subcontract
                                         to Affiliates and Third Parties, including CROs and CMOs, portions of the Programs to
                                         be performed. Any subcontractor shall be required to enter into appropriate agreements
                                         with respect to non-disclosure of Confidential Information and ownership of any intellectual
                                         property developed in the course of subcontracted activities, unless such subcontracting
                                         would not require the transfer of the other Party’s Confidential Information to
                                         the Affiliate or Third Party subcontractor and there is no reasonable possibility of
                                         the creation of new intellectual property. Each subcontractor shall agree to reasonable
                                         audit rights. Each Party shall remain liable to the other Party for any act or omission
                                         of its subcontractor. Any subcontractor of CureVac shall be subject to Genmab’s
                                         prior written consent, such consent not to be unreasonably withheld. Exhibit 5.11
                                         contains a list of CureVac’s subcontractors which are approved for purposes
                                         of this Agreement, subject to the above. Genmab consents to the appointment of CureVac’s
                                         Affiliate company CureVac Real Estate GmbH as a subcontractor of CureVac for the purpose
                                         of Manufacturing Products under this Agreement and the Early Clinical Supply Agreement
                                         for the supply of Products to be used in Clinical Phase I Studies with respect to the
                                         First Collaboration Program (as opposed to any future Manufacture under future supply
                                         agreements that might be agreed between the Parties). Should CureVac Real Estate GmbH
                                         at any time no longer be an Affiliate of CureVac, CureVac shall inform Genmab of the
                                         details concerning the new structure, decision making and other relevant items of CureVac
                                         Real Estate GmbH. CureVac shall further ensure and confirm in writing to Genmab that
                                         as a result of CureVac Real Estate GmbH no longer being an Affiliate of CureVac there
                                         are no material changes, including no cost or timeline changes, that may affect Genmab
                                         with respect to the terms or operation of any then current supply agreement between the
                                         CureVac AG and CureVac Real Estate GmbH.

 

    45

     

    

 

		6.	MANUFACTURING
                                         AND COMMERCIALIZATION

 

		6.1	Manufacture
                                         of Products. Manufacture by CureVac of Products for use in preclinical activities
                                         during the Research Period will take place under the First Program Research Plan, the
                                         Reserved Target Research Plan and the Other Pre-IND Program Research Plans, as the case
                                         may be. For the supply of Products to be used in Clinical Phase I Studies with respect
                                         to the First Collaboration Program (including in relation to a Product based upon a Replacement
                                         Target Antibody), subject to Section 6.2, the Parties shall negotiate and enter into
                                         a clinical supply agreement under which CureVac shall Manufacture or have Manufactured
                                         such Products on Genmab’s behalf. For the supply of Products to be used in Clinical
                                         Phase I Studies with respect to any other Pre-IND Program, the Parties will on a Product-by-Product
                                         basis negotiate an amendment to the Early Clinical Supply Agreement in good faith, subject
                                         to Section 6.2, whereby CureVac shall Manufacture or have Manufactured such Product on
                                         Genmab’s behalf. For other Manufacture of Products, CureVac shall have the right
                                         to provide an offer to Genmab to Manufacture Product under the provisions of Section
                                         6.4.

 

		6.2	Early
                                         Clinical Supply Agreement. Within [*****] after the Effective Date, the Parties will
                                         enter into a clinical supply agreement and related agreements (including a quality agreement)
                                         according to which CureVac shall Manufacture or have Manufactured for Genmab by an approved
                                         subcontractor under Section 5.11 or by a CMO approved by Genmab, and will supply or have
                                         supplied to Genmab, Genmab’s demand for the Single Antibody Product which is the
                                         subject of the First Program Research Plan (whether related to the First Collaboration
                                         Target or any Replacement Target) to perform Clinical Phase I Studies (“Early
                                         Clinical Supply Agreement”). The Early Clinical Supply Agreement and related
                                         quality agreement will contain the key terms and conditions set forth in Exhibit 6.2.
                                         The Early Clinical Supply Agreement and the related quality agreement with respect thereto,
                                         shall determine, in accordance with Applicable Law, all Product quality standards for
                                         such Product to be used in clinical trials, including but not limited to stability, validation
                                         and pre-approval inspection preparation, specifications, assay methodology, facilities,
                                         equipment and storage conditions. With respect to the First Collaboration Program, if
                                         CureVac is unable to provide capacity via its own facilities or that of its approved
                                         subcontractor under Section 5.11 or another approved CMO within the agreed timelines,
                                         Genmab shall have the right to Manufacture and have Manufactured Products for Genmab
                                         for Genmab’s Clinical Phase I Studies as well as in connection with Genmab’s
                                         (or its Affiliates’ or Sublicensees’, as applicable) Manufacture of Products
                                         for Development and Commercialization by another supplier. In such event, CureVac shall
                                         transfer all CureVac Manufacturing Technology to such supplier of Genmab in accordance
                                         with Section 6.5 and any applicable terms of the Early Clinical Supply Agreement. In
                                         connection with the negotiation of the Early Clinical Supply Agreement, the Parties will
                                         agree on a plan for the transfer of CureVac Manufacturing Technology to Genmab, including
                                         estimated timelines, scope, resources and other relevant details (the “Tech
                                         Transfer Plan”). Such Tech Transfer Plan may be updated from time to time by
                                         mutual written agreement between the Parties, including in the event that the Parties
                                         negotiate an MSA pursuant to Section 6.4.2.

 

    46

     

    

 

		6.3	With
                                         respect to Other Pre-IND Programs and related Products, on a Product-by-Product basis,
                                         no later than [*****] prior to the anticipated commencement of Clinical Phase I Studies
                                         for such Product CureVac shall notify Genmab and inform Genmab whether CureVac or any
                                         approved subcontractor under Section 5.11 or other approved CMO already Manufacturing
                                         under the Early Clinical Supply Agreement has the capacity to Manufacture such Product
                                         for use in Clinical Phase I Studies within the timelines requested by Genmab. If CureVac
                                         gives notice that such capacity exists, the Parties will negotiate in good faith amendments
                                         to the Early Clinical Supply Agreement and related quality agreement to cover the Manufacture
                                         by CureVac or such approved subcontractor or approved CMO of such additional Product
                                         (arising from the relevant Other Pre-IND Program Research Plan) for use in Genmab’s
                                         Clinical Phase I Studies for such Product. If CureVac is unable to provide capacity to
                                         Manufacture such Product via its own facilities or that of its approved subcontractor
                                         or approved other CMO within the requested timelines, or the Parties are unable to agree
                                         on an amendment to the Early Clinical Supply Agreement with respect to such Product despite
                                         using good faith efforts to negotiate such amendment to the Early Clinical Supply Agreement,
                                         Genmab shall have the right to Manufacture and have Manufactured such Product for Genmab
                                         for Genmab’s Clinical Phase I Studies by another supplier. In such event, CureVac
                                         shall transfer all Know-How comprised in the CureVac Manufacturing Technology as reasonably
                                         required to Manufacture such Product to such supplier of Genmab in accordance with Section
                                         6.5 and the applicable terms of the Early Clinical Supply Agreement.

 

		6.4	Other
                                         Manufacture of Products for Development and Commercialization

 

		6.4.1	In
                                         relation to each Product, provided that CureVac has Manufactured and supplied such Product
                                         for use in Genmab’s Clinical Phase I Studies, then no later than [*****] prior
                                         to a requirement of Genmab for supplies of such Product for the first Clinical Phase
                                         II Study for such Product, Genmab shall submit to CureVac its non-binding forecast quantities,
                                         proposed delivery schedule for such Product quantities and other relevant criteria. Within
                                         [*****] of receipt of such forecast, CureVac shall indicate to Genmab if CureVac is able
                                         to supply such quantities (whether Manufactured by CureVac itself or an approved subcontractor
                                         or other approved CMO) in accordance with the criteria provided by Genmab; and proposed
                                         pricing and other high-level terms for such supply, which may include a proposal that
                                         any such approved subcontractor or approved CMO contract directly with Genmab.

 

		6.4.2	If
                                         Genmab declines to appoint CureVac, its approved subcontractor or other approved CMO,
                                         it shall give written notice to CureVac specifying in high-level the reasons why CureVac
                                         itself or an approved subcontractor or other approved CMO was not appointed to Manufacture
                                         the Product. If Genmab accepts the proposal made by CureVac for supplies of Product for
                                         the first Clinical Phase II Study and is agreeable to appoint CureVac, the Parties shall
                                         within [*****] negotiate in good faith a master services agreement (“MSA”)
                                         and related quality agreement and a first work order for the Manufacture and supply of
                                         such Product quantities, Manufactured to the specifications specified by Genmab, and
                                         for payment [*****] on customary market-based terms. Any such
                                         MSA shall contain detailed provisions for tech transfer of the Manufacturing process,
                                         e.g. in the event of a failure to supply by CureVac or its approved subcontractor or
                                         approved CMO or upon Genmab’s request. If Genmab does not accept the proposal made
                                         by CureVac or if the Parties are unable to reach agreement on the MSA within the above
                                         period despite exercising good faith efforts, Genmab shall have the right to choose another
                                         CMO to Manufacture the Products for Genmab. If, during Genmab’s negotiation of
                                         a supply agreement with another CMO, Genmab changes the criteria for such supply as were
                                         presented to CureVac, then Genmab will provide such updated criteria to CureVac so that
                                         CureVac can provide an updated proposal.

 

    47

     

    

 

		6.4.3	The
                                         process described in Sections 6.4.1 and 6.4.2 shall apply equally to the following circumstances
                                         (i) where CureVac itself or an approved subcontractor or other approved CMO have Manufactured
                                         Genmab’s requirements of a Product for Clinical Phase II Studies, in relation to
                                         Genmab’s requirements of such Product for Clinical Phase III Studies; and (ii)
                                         where CureVac itself or an approved subcontractor or other approved CMO have Manufactured
                                         Genmab’s requirements of a Product for Clinical Phase III or Pivotal Studies, in
                                         relation to Genmab’s requirements of such Product for Commercialization.

 

		6.5	Transfer
                                         of CureVac Manufacturing Technology. If (i) pursuant to the terms of this Agreement,
                                         the Early Clinical Supply Agreement and/or the MSA CureVac and/or its approved subcontractor
                                         or other approved CMO is obliged to transfer to Genmab or a CMO nominated by Genmab (which
                                         CMO shall fulfill the criteria specified in Section 6.6) the Know-How comprised in the
                                         CureVac Manufacturing Technology for the particular Product affected; or (ii) under Section
                                         6.2 or Section 6.4 Manufacture is not going to be conducted by CureVac or its approved
                                         subcontractor or other approved CMO for a particular Product, then (in each of (i) and
                                         (ii)) CureVac and/or its approved subcontractor or other approved CMO shall as soon as
                                         reasonably possible, and in accordance with the applicable Tech Transfer Plan and the
                                         timelines set out therein transfer to Genmab, or a CMO nominated by Genmab (which CMO
                                         shall fulfill the criteria specified in Section 6.6) the Know-How comprised in the CureVac
                                         Manufacturing Technology required to Manufacture the particular Product so that Genmab,
                                         an Affiliate or the appointed Third Party CMO can take over Manufacture of such Product
                                         for Genmab. If the particular Product has been Manufactured by CureVac’s approved
                                         subcontractor or other approved CMO, then CureVac shall see to it that the technology
                                         transfer shall also comprise all and any Know-How Controlled by such party that is required
                                         to Manufacture such Product. In the event of a technology transfer, the JRC or Collaboration
                                         Committee, as applicable, shall establish a Manufacturing Tech Transfer Sub-Committee,
                                         which shall oversee the tech transfer relating to such Product, subject to applicable
                                         provisions in the Early Clinical Supply Agreement or MSA regarding tech transfer and
                                         the applicable Tech Transfer Plan. CureVac shall use Commercially Reasonable Efforts
                                         to make available key employees with respect to carry out the Tech Transfer Plan and
                                         to provide the support needed to enable Genmab, or its designated CMO, to take over the
                                         Manufacture of the relevant Product. Such tech transfer for any particular Product shall
                                         only be carried out once, to representatives of the entity nominated by Genmab. Genmab
                                         will compensate CureVac and/or its approved subcontractor or other approved CMO for such
                                         tech transfer support work provided by CureVac and/or the approved subcontractor or other
                                         approved CMO at the FTE Rate. CureVac shall be responsible for ensuring that its approved
                                         subcontractor or other approved CMO complies with all and any obligations applicable
                                         to CureVac and/or the subcontractor or other approved CMO with respect to such technology
                                         transfer.

 

    48

     

    

 

		6.6	Third
                                         Party CMOs. If under Section 6.2 or Section 6.4 Genmab wishes to engage a Third Party
                                         CMO to Manufacture Products it must provide notice of such intent and the identity of
                                         the CMO to CureVac. If such Third Party CMO is (i) a direct competitor of CureVac within
                                         the field of development of mRNA-based products (such as, but not limited to, [*****]);
                                         or (ii) located inside [*****] at the time when
                                         Genmab wishes to engage such Third Party CMO, then Genmab’s engagement of such
                                         Third Party CMO to Manufacture Products requires CureVac’s prior written consent
                                         not to be unreasonably withheld. Upon Genmab’s request, in the event of (i) or
                                         (ii) above, CureVac shall within [*****] of receipt of such request notify Genmab if
                                         CureVac opposes to Genmab’s engagement of such Third Party CMO and otherwise CureVac
                                         shall be deemed to have consented to such engagement. If, in the event of (i) or (ii)
                                         above, CureVac consents to the appointment of such CMO nominated by Genmab, such consent
                                         may be conditional upon the Third Party CMO entering into direct undertakings with CureVac
                                         for the protection of Confidential Information and Know-How within CureVac Manufacturing
                                         Technology. For clarity, such CMO shall not be permitted to transfer any such Know-How
                                         to any other Third Party. For avoidance of doubt, Genmab shall not be required to obtain
                                         the prior consent of CureVac before engaging a Third Party CMO as allowed for under Section
                                         6.2 and Section 6.4 if such Third Party CMO is not comprised by (i) or (ii) above.

 

		6.7	Commercialization
                                         of Products. Subject only to the terms and conditions applying to the Opt-In Product,
                                         Genmab shall have all rights and responsibilities, and shall bear all costs associated
                                         with, the Commercialization of Products and will book all sales of Products. Genmab will
                                         use Commercially Reasonable Efforts to Commercialize each Products in the Major Market
                                         Countries where it obtains Regulatory Approval. In addition to the royalty reports provided
                                         by Genmab to CureVac under Section 10.6, beginning with the First Commercial Sale of
                                         the first Product and continuing, on a Product-by-Product basis, until expiry of the
                                         last Valid Claim, Genmab shall provide CureVac, at least [*****] with a written report summarizing the current status of, estimated
                                         timeline and high-level commercialization plans for the Commercialization of any Products.

 

		7.	CUREVAC’S
                                         OPT-IN AND CO-PROMOTION RIGHTS.

 

DEVELOPMENT & COMMERCIALIZATION
OF OPT-IN PRODUCTS.

 

		7.1	Opt-In.
                                         Subject to the terms and conditions of this Agreement, CureVac has the option to
                                         join Genmab [*****] [*****] on the Development, Manufacture and Commercialization of
                                         any [*****] Product that is a Cocktail Product, at CureVac’s sole election (“Opt-In”).
                                         If within [*****] of Genmab’s Option Exercise with respect to such Reserved Target
                                         Combination (then an Optioned Target Combination) which might result in a Cocktail Product,
                                         CureVac requests to receive an Opt-In Data Package (as defined below), Genmab shall within
                                         [*****] of such Option Exercise supply CureVac with (i) a comprehensive preclinical data
                                         package generated under the respective Program, including all Development Data available
                                         at such time; and (ii) a high-level draft Development plan (specifying in high-level
                                         the contemplated Clinical Studies and non-clinical studies to be conducted) up until
                                         and including contemplated Clinical Phase I Studies; and (iii) a proposed budget of costs,
                                         internal and external, for the draft Development Plan, and (iv) a copy of the documentation
                                         (with any reasonably required redactions, including redactions to exclude information
                                         not directly related to the Product data such as information from Genmab’s board
                                         of directors, financial information etc.) provided to Genmab’s portfolio board
                                         as basis for Genmab taking the decision to undertake Option Exercise in relation to the
                                         relevant Cocktail Product (“Opt-In Data Package”). Within [*****]
                                         of receipt of the Opt-In Data Package, CureVac shall notify Genmab whether or not CureVac
                                         wishes to Opt-In. Upon CureVac’s Opt-In and payment of the Opt-In Fee in accordance
                                         with Section 10.3 below, the Optioned Target Combination will become an “Opt-In
                                         Target” and any Product resulting therefrom will be an “Opt-In Product”.
                                         If CureVac requests an Opt-In Data Package the Option Exercise Fee under Section 10.2
                                         shall be deferred until [*****] after CureVac has given Genmab notice under this Section
                                         7.1, that CureVac is not exercising its right to Opt-In. For avoidance of doubt, if CureVac
                                         does not request any Opt-In Data Package within [*****] of the Option Exercise, Genmab
                                         shall have no obligation to provide such Opt-In Data Package and CureVac shall no right
                                         to Opt-In with respect to the particular Cocktail Product.

 

    49

     

    

 

		7.2	Joint
                                         Steering Committee. Within [*****] of CureVac Opt-In under Section 7.1 the Parties
                                         will establish a Joint Steering Committee as set out in Section 9.9 (“Joint
                                         Steering Committee”) which shall oversee the Development and Commercialization
                                         of the Opt-In Product. A first task of the Joint Steering Committee shall be to discuss
                                         any potential update to the Development plan submitted by Genmab to CureVac for the Opt-In
                                         Product. Until the Joint Steering Committee agrees on such update, the Development plan
                                         submitted by Genmab shall be the Opt-In R&D Plan (“Opt-In R&D Plan”)

 

		7.3	Opt-In
                                         Product – general principle for sharing of costs and profit. With respect to
                                         any Opt-In Target and Opt-In Product, all costs for the Development, Manufacturing and
                                         Commercialization of the Opt-In Product, as well as all profits generated by exploiting
                                         such Opt-In Product in the Field and in the Territory (including Net Sales and payments
                                         from Third Party licensees) will be [*****].

 

		7.4	Opt-In
                                         Product – sharing of Development and Manufacturing costs. Unless otherwise
                                         agreed in the Joint Development and Manufacturing Agreement, then the below shall apply
                                         with respect to sharing of Development and Manufacturing costs with respect to an Opt-In
                                         Product. Within [*****] of the end of each Calendar Quarter during Development of the
                                         Opt-In Product, each Party shall notify the other Party in writing of the Development
                                         and Manufacturing costs incurred by them and their Affiliates in that Calendar Quarter.
                                         Within [*****] thereafter the Parties shall agree a reconciliation such that [*****] the total costs for the Development and Manufacturing [*****], and the
                                         Party which has paid less than its [*****] share shall pay to the other Party the balancing
                                         amount required so that such total costs have been [*****]. Records and audit
                                         provisions the same as Section 10.8 shall apply to such Development and Manufacturing
                                         Costs.

 

		7.5	Co-Promotion and Co-Commercialization. [*****] in the [*****] with CureVac having a right to co-promote up to [*****] of the sales effort, provided
                                                                                                                                                   that upon Genmab’s prior written consent (which Genmab may give or withhold at its sole discretion) from the
                                                                                                                                                   commencement of such Commercialization until the end of the second full Calendar Year thereafter CureVac may use a contract
                                                                                                                                                   sales organization to assist it in respect of such co-promotion activities, but not thereafter. CureVac will lead the
                                                                                                                                                   Commercialization of the Opt-In Product by promoting and detailing in [*****] and detailing with its own sales force or, or
                                                                                                                                                   upon Genmab’s prior written consent (which Genmab may give or withhold at its sole discretion), using a contract sales
                                                                                                                                                   organization, provided, however, that Genmab shall be solely responsible for establishing and maintaining pricing in
                                                                                                                                                   all [*****] Genmab will book [*****] sales, with the exception of sales in [*****] where CureVac will book sales. Should
                                                                                                                                                   CureVac decide not to lead commercialization by promoting and detailing in [*****]. Genmab shall have the right to lead
                                                                                                                                                   commercialization and book sales in such countries, unless Genmab elects not to exercise such right, in which case the
                                                                                                                                                   Parties will jointly find a partner to handle the commercialization in such countries. Any sublicensing of the rights under
                                                                                                                                                   the Opt-In Program, including any rights to the Opt-In Product requires agreement by both Parties, and the Parties shall act
                                                                                                                                                   in good faith to arrive at a commercially sound and viable exploitation of the Opt-In Product.

 

    50

     

    

 

		7.6	Joint
                                         Development and Manufacturing Agreement. No later than [*****] following the date
                                         of CureVac’s exercise of its Opt-In rights, Genmab and CureVac shall in good faith
                                         negotiate and conclude the terms and conditions of the joint development and manufacture
                                         covering the Opt-In Product (“Joint Development and Manufacturing Agreement”).
                                         For clarity, with respect to Manufacturing the provisions of Section 6.2 and Section
                                         6.4 shall apply mutatis mutandis. The Joint Development and Manufacturing Agreement shall
                                         be consistent with this Agreement, including this Article 7, and shall cover the following
                                         additional provisions:

 

		(i)	provisions
                                         for the generation and approval of detailed development plans under the Opt-In R&D
                                         Plan, including protocols for Clinical Studies and the corresponding budget;

 

		(ii)	provisions
                                         concerning the appointment of CRO’s and CMO’s and other subcontractors;

 

		(iii)	provisions
                                         for handling regulatory matters including dealings with Regulatory Agencies;

 

		(iv)	provisions
                                         for the calculation of and sharing of costs for Development and for Manufacture of Product
                                         for Development reflecting Section 7.3;

 

		(v)	in
                                         circumstances where CureVac is supplying the Opt-In Product or any part of it, detailed
                                         supply provisions and an associated quality agreement;

 

    51

     

    

 

		(vi)	liability,
                                         indemnification and insurance during the period of Development and associated Manufacture;

 

		(vii)	the
                                         provisions of this Agreement that apply in such circumstances unchanged, for example
                                         concerning the Joint Steering Committee, assignment of rights with respect to the Opt-In
                                         Product, termination of the Opt-in Program, dispute resolution and others.

 

		7.7	Commercialization
                                         Plan and Commercialization Agreement. At least [*****] prior to anticipated First
                                         Commercial Launch and in no event later than [*****] after the first dosing of the first
                                         patient of the first Phase III Clinical Trial with respect to the Opt-In Product, the
                                         Joint Steering Committee shall prepare and approve an initial commercialization plan
                                         for the Opt-In Product for the balance of the then current calendar year plus the following
                                         [*****] The Joint Steering Committee shall, at an appropriate (at the Joint Steering
                                         Committee’s discretion) time following an Opt-In, but no later than [*****] prior
                                         to the anticipated First Commercial Sale of the Opt-In Product anywhere in the Territory
                                         as determined by the Joint Steering Committee, establish a joint commercialization team
                                         to be responsible for the operations related to Commercialization of the Opt-In Product.
                                         In addition the Parties will in good faith negotiate and agree on a commercialization
                                         agreement, which shall be consistent with the applicable provisions of this Agreement
                                         and shall govern in detail the co-promotion and co-commercialization provisions for the
                                         Opt-In Product based on the outline in Section 7.5 (“Commercialization Agreement”).
                                         In particular, the Commercialization Agreement will provide for:

 

		(i)	the
                                         establishment of a joint commercialization committee that will govern the Commercialization
                                         activities of the Opt-In Product and will be a subsidiary of the Joint Steering Committee
                                         (“Joint Commercialization Committee”);

 

		(ii)	detailed
                                         definitions of Commercialization Costs, profit and net profit that are to be [*****]
                                         by the Parties, and the terms for such calculation and sharing, reporting and audit rights;

 

		(iii)	detailed
                                         provisions for the operation of the Co-Promote, including the [*****] of first
                                         position, second position and third position details;

 

		(iv)	supervision
                                         and training by Genmab of the CureVac Co-Promote sales force in USA;

 

		(v)	the
                                         provision of promotional materials by Genmab;

 

		(vi)	compliance
                                         provisions;

 

		(vii)	Amendment
                                         to and updates of the commercialization plan;

 

		(viii)	Regulatory
                                         issues, dealings with Regulatory Agencies, recalls and medical inquiries and medical
                                         interaction,

 

    52

     

    

 

		(ix)	Public
                                         statements and other information concerning the Opt-In Product;

 

		(x)	Liability;

 

		(xi)	Indemnification;
                                         and

 

		(xii)	Use
                                         of subcontractors.

 

		7.8	Assignment
                                         of Rights and Obligations with respect to Opt-In Product

 

		7.8.1	Either
                                         Party shall have the right to make an assignment in full of its rights and obligations
                                         under this Agreement with regard to an Opt-In Product to the other Party or a Third Party
                                         as set out below.

 

		7.8.2	If
                                         a Party (“Assigning Party”) desires to make an assignment in full
                                         of all its rights and obligations, including without limitation its [*****] share and
                                         co-funding obligation, with respect to an Opt-In Product (“Opt-In Product Assignment”),
                                         the Assigning Party shall provide a written offer to the other Party (“Non-Assigning
                                         Party”), which offer shall include the entire proposed terms in relation to
                                         such Opt-In Product Assignment to the Non-Assigning Party, including the exclusive right
                                         to Develop, Manufacture and Commercialize the Opt-In Product, under all intellectual
                                         property and using all regulatory filings Controlled by the Assigning Party. Upon the
                                         Non-Assigning Party’s receipt of such written offer, a [*****] negotiation period
                                         (“Negotiation Period”) shall be initiated during which the Parties
                                         shall engage in good faith negotiations regarding the Assigning Party’s Opt-In
                                         Product Assignment offer. The Non-Assigning Party shall have the right to appoint a Third
                                         Party as assignee in relation to the Opt-In Product Assignment on the same terms as offered
                                         to the Non-Assigning Party. If the Parties have not reached an agreement regarding an
                                         Opt-In Product Assignment to the Non-Assigning Party or a Third Party assignee appointed
                                         by the Non-Assigning Party upon expiry of the Negotiation Period, the Assigning Party
                                         is entitled to offer the Opt-In Product Assignment to an independent Third Party on the
                                         same key financial and commercial terms as comprised by the Assigning Party’s latest
                                         written offer during the Negotiation Period to the Non-Assigning Party, provided that
                                         such Third Party prior to receiving such Opt-In Product Assignment offer has undertaken
                                         obligations of confidentiality that are at least as restrictive as the Parties’
                                         confidentiality obligations under this Agreement. Such negotiations with and assignment
                                         to an independent Third Party shall be finalized within [*****] after expiry of the Negotiation
                                         Period, unless otherwise mutually agreed in writing between the Parties. If such negotiations
                                         and assignment has not been finalized within said [*****] period, the Assigning Party
                                         shall be deemed to have provided an Opt-In Termination Notice to the Non- Assigning Party
                                         and Section 7.9 shall apply.

 

The Assigning Party shall keep
the Non-Assigning Party reasonably informed about the developments in relation to the Assigning Party’s negotiations with
any Third Party regarding an Opt-In Product Assignment. If the terms of offer from a Third Party differ from the key financial
and commercial terms as comprised by the Assigning Party’s latest written offer during the Negotiation Period to the Non-Assigning
Party, then the Non-Assigning party shall have the right to match such offer, before the Assigning Party may accept the offer
from the Third Party. Such right to match the offer shall be exercised within [*****] after the Non- Assigning Party’s receipt
of notice of the applicable key financial and commercial terms, and otherwise the Non-Assigning Party shall be deemed to have
forfeited its right of first refusal.

 

    53

     

    

 

		7.8.3	For
                                         the avoidance of doubt, until an Opt-In Product Assignment is duly executed and has become
                                         effective, all and any the Assigning Party’s rights and obligations under this
                                         Agreement shall continue to apply, including without limitation the co-funding obligation,
                                         and the Parties shall continue to use Commercial Reasonable Efforts to perform their
                                         obligations with respect to the Development and Commercialization of the Opt-In Product.

 

		7.9	Termination
                                         of the Opt-In Program. If under Section 7.8.2 an Assigning Party (in this Section
                                         7.9 “Terminating Party”) has given notice (or is deemed to have given
                                         notice) to the other Party that it terminates (“Opt-In Termination Notice”)
                                         the [*****] collaboration of the Opt-In Program and withdraws from the future Development,
                                         Manufacture and Commercialization of the Opt-In Target and the Opt-In Product, then within
                                         [*****] of receipt of such Opt-In Termination Notice, the non-terminating Party (“Non-Terminating
                                         Party”) shall give written notice to the Terminating Party whether the Non-Terminating
                                         Party wishes to assume sole responsibility for the Opt-In Program (which can include
                                         finding other collaboration partners or assignees for the Opt-In Program) or whether
                                         it wishes the Opt-In Program to terminate completely. Until such notice is given by the
                                         Non-Terminating Party, the Parties shall cooperate in the further Development, Manufacture
                                         and Commercialization of the Opt-In Product under the terms of this Agreement and the
                                         Commercialization Agreement (if the same exists by then) in a commercially reasonable
                                         manner. If the Non-Terminating Party gives notice that it intends to assume responsibility
                                         for the Opt-In Program and to so continue the further Development and commercialization
                                         of the Opt-In Product(s), the JSC shall within [*****] of such notice agree to a transition
                                         plan for transition of the conduct of the Opt-In Program to the Non- Terminating Party
                                         that shall include (i) transfer of all Development, Manufacturing and Commercialization
                                         activity and related regulatory approvals as soon as practicable, and, until then, for
                                         the period between termination of the collaboration and such transfer, reimbursement
                                         of the Terminating Party for the cost incurred by it in connection with such Development,
                                         Manufacturing and Commercialization activity; and (ii) payment of the cost of such transition
                                         by the Terminating Party, including FTEs of the Non-Terminating Party involved with the
                                         transition; and (iii) the grant of and other terms for an exclusive, fully paid up, royalty
                                         free, perpetual, irrevocable sub-licensable license through multiple tiers to all intellectual
                                         property Controlled by the Terminating Party and required by the Non-Terminating Party
                                         to continue the Opt-In Program and Commercialization of the Opt-In Product. If the Non-Terminating
                                         Party gives notice that it does not wish to assume responsibility for the Opt-In Program,
                                         the JSC shall within [*****] agree a wind-down plan for the Opt-In Program, the costs
                                         of which shall be borne by the Terminating Party.

 

		8.	CO-PROMOTION
                                         IN LIEU OF AN OPT-IN.

 

		8.1	Co-Promotion
                                         in lieu of an Opt-In. In the event Genmab has not started research on a Research
                                         Program Antibody Combination or does not exercise an option with respect to any Reserved
                                         Program Antibody Combination within the Option Period, and CureVac consequently cannot
                                         exercise its Opt-In right under Section 7.1 above, CureVac has the right to elect to
                                         Co-Promote [*****] Single Antibody Product which is granted Regulatory Approval (in the
                                         form of marketing authorization) in the [*****] (“Co-Promotion Product”;
                                         “Co-Promotion Territory”), subject to the terms and conditions set
                                         forth in Sections 8.1 and 8.2 and the Co-Promotion Agreement (“CureVac Co-Promotion
                                         Option”). No later than [*****] prior to the anticipated First Commercial Sale
                                         of any Single Antibody Product, Genmab shall give written notice to CureVac that this
                                         is anticipated, specifying the Single Antibody Product in question, and providing a data
                                         package on such Single Antibody Product which reasonably allows CureVac to evaluate its
                                         option to Co-Promote such Product. Within [*****] of receipt of both such notice and
                                         the data package, CureVac shall notify Genmab in writing whether CureVac is exercising
                                         the CureVac Co-Promotion Option in relation to such Single Antibody Product. For the
                                         avoidance of doubt, following CureVac’s exercise of its Co-Promotion Option, Genmab
                                         shall no longer be required to provide notice of anticipated First Commercial Sale to
                                         CureVac with respect to other Products.

 

    54

     

    

 

		8.2	Conclusion
                                         of a Co-Promotion Agreement. No later than [*****] following the date of CureVac’s
                                         exercise of the CureVac Co-Promotion Option, Genmab and CureVac shall in good faith negotiate
                                         and conclude the terms and conditions of a co-promotion agreement covering the Co-Promotion
                                         of the Co-Promotion Product in the Co-Promotion Territory (“Co-Promotion Agreement”).
                                         The Co-Promotion Agreement shall be consistent with this Article 7 and shall cover the
                                         following additional provisions:

 

		(i)	establishment
                                         of a Co-Promotion committee that will govern the Co-Promotion activities and will be
                                         a subsidiary of the Collaboration Committee (“Co-Promotion Committee”);

 

		(ii)	detailed
                                         provisions for the operation of the Co-Promote, including the equitable sharing of first
                                         line, second line and third line details based upon the principle that the CureVac sales
                                         force shall constitute, at the election of CureVac, up to [*****] of the overall number
                                         of sales representatives needed to promote the Co-Promotion Product in the Co-Promotion
                                         Territory upon First Commercial Sale of the Product in the Co-Promotion Territory, as
                                         determined by Genmab and in accordance with the Co-Promotion Territory Commercialization
                                         Plan;

 

		(iii)	at
                                         the latest [*****] prior to the estimated date of the First Commercial Sale of the Co-Promotion
                                         Product in the Co-Promotion Territory, Genmab will propose to the Co-Promotion Committee
                                         for discussion, comment, review, amendment and approval a plan to Commercialize the Co-Promotion
                                         Product in the Co-Promotion Territory for the period up to the end of the first full
                                         Calendar Year following first Commercial Sale (“Co-Promotion Territory Commercialization
                                         Plan”). The Co-Promotion Committee shall use best endeavors to agree the form
                                         of the first Co-Promotion Territory Commercialization Plan within [*****] of its initial
                                         submission. Not later than [*****] of each Calendar Year the Co-Promotion Committee shall
                                         prepare and agree an updated Co-Promotion Territory Commercialization Plan for the following
                                         Calendar Year;

 

		(iv)	performance
                                         criteria for CureVac sales force, and consequences of non-performance;

 

    55

     

    

 

		(v)	Genmab
                                         shall [*****] specifically related to CureVac’
                                         detailing efforts in relation to the given Product in the Co-Promote Territory. For avoidance
                                         of doubt, Genmab shall not be required to reimburse CureVac for any build-up or overhead
                                         costs of CureVac establishing a sales force for Products, including rent for office space;

 

		(vi)	such
                                         additional customary terms and conditions (including terms regarding training, marketing
                                         materials, responsibility for recalls and adverse event reporting, and maintenance of
                                         records relating to detail activities) as may be appropriate to provide for such co-promotion
                                         activities;

 

		(vii)	Compliance
                                         provisions; and

 

		(viii)	Termination
                                         provisions.

 

		9.	GOVERNANCE.

 

		9.1	Management.

 

		9.1.1	Alliance
                                         Management. Management of the collaborative alliance reflected in this Agreement
                                         will be under the responsibility of the individual designated in writing within [*****]
                                         of the Effective Date for CureVac (“CureVac Alliance Manager”) and
                                         of the individual designated in writing within [*****] of the Effective Date for Genmab
                                         (“Genmab Alliance Manager”, and together, the “Alliance Managers”).
                                         Each Alliance Manager will be the primary point of contact for the other Party on all
                                         matters relating to the operation of this Agreement other than Program activities.

 

		9.1.2	Program
                                         Management. Management of the activities under the Programs will be under the responsibility
                                         of the individual designated in writing within [*****] of the Effective Date for CureVac
                                         (“CureVac Project Leader”) and of the individual designated in writing
                                         within [*****] of the Effective Date for Genmab (“Genmab Project Leader”,
                                         and together with the CureVac Project Leader, the “Project Leaders”).
                                         Each Project Leader will be the primary point of contact for the other Party on all matters
                                         relating to the Program activities. After IND filing for a particular Product, the Project
                                         Leaders shall no longer be required, unless CureVac has exercised its Opt-In with respect
                                         to such Product (a Cocktail Product).

 

		9.2	Joint
                                         Research Committee.

 

		9.2.1	Establishment.
                                         Within [*****] after the Effective Date the Parties will establish a joint research
                                         committee (“Joint Research Committee” or “JRC”).
                                         The JRC will govern the collaboration represented by this Agreement up to IND filing
                                         for all Products. The JRC shall be comprised of [*****] representatives of CureVac and
                                         [*****] representatives of Genmab. Each Party may replace its JRC representatives at
                                         any time upon written notice to the other Party, provided, however, that each
                                         Party shall use Commercially Reasonable Efforts to ensure continuity on the JRC. The
                                         Alliance Manager of each Party should always attend meetings of the JRC. In addition,
                                         each Party may invite a reasonable number of participants, in addition to its representatives,
                                         to attend JRC meetings; provided that if either Party intends to have any Third Party
                                         (including any consultant) attend such a meeting, such Party shall provide prior written
                                         notice to the other Party. Such Party shall ensure that such Third Party is bound by
                                         confidentiality and non-use obligations consistent with the terms of this Agreement.

 

    56

     

    

 

		9.2.2	JRC
                                         Meetings. The JRC shall meet on a quarterly basis by teleconference, videoconference
                                         or in person, provided that at least every [*****] the meeting shall be in person (which
                                         in- person meeting will be held at alternate facilities of each Party), unless agreed
                                         otherwise by the JRC representatives The JRC will have a quorum if at least [*****] representatives
                                         of each Party is present or participating. Each Party will be responsible for all of
                                         its own expenses of participating in the JRC meetings. The Parties will endeavor to schedule
                                         meetings of the JRC at least [*****] in advance. Each Party may call special meetings
                                         of the JRC with at least [*****] prior written notice, except in exigent circumstances,
                                         to resolve particular matters requested by such Party and within the decision-making
                                         responsibility of the JRC. Genmab shall prepare the meeting agenda with input from CureVac,
                                         and Genmab shall chair the meeting.

 

		9.2.3	JRC
                                         Minutes. The Alliance Manager of Genmab shall record the minutes of each JRC meeting
                                         in writing. Such minutes shall be circulated by Genmab’s Alliance Manager to CureVac’
                                         Alliance Manager no later than [*****] following the meeting for review, comment and
                                         approval of CureVac. If no comments are received within [*****] of the receipt of the
                                         minutes by CureVac, unless otherwise agreed, they shall be deemed to be approved by CureVac.
                                         Furthermore, if the Parties are unable to reach agreement on the minutes within [*****]
                                         of the applicable meeting, the sections of the minutes that have been mutually agreed
                                         between the Parties by that date shall be deemed approved and, in addition, each Party
                                         shall record in the same document its own version of those sections of the minutes on
                                         which the Parties were not able to agree.

 

		9.3	JRC
                                         Functions and Powers. The JRC will be responsible generally for facilitating the
                                         Parties’ interactions under this Agreement and specifically for overseeing the
                                         Development activities up to IND filing. The JRC has no jurisdiction (i) to make any
                                         amendments to this Agreement, which right is reserved to the Parties; and (ii) no jurisdiction
                                         over any dispute relating to the validity, performance, construction or interpretation
                                         of this Agreement. The principal functions of the JRC will include:

 

		(i)	overseeing
                                         the First Collaboration Program on the First Collaboration Target or any Replacement
                                         Target and all Research Programs;

 

		(ii)	reviewing
                                         and approving the First Program Research Plan in relation to a Replacement Target, the
                                         Reserved Target Research Plans, and the Other Pre-IND Program Research Plans and considering
                                         and approving any amendments thereto;

 

		(iii)	For
                                         the First Collaboration Program (with respect to the First Collaboration Target, not
                                         the Replacement Target, if applicable), approving the budget for all Development activities
                                         up until IND. For the First Collaboration Program with respect to the Replacement Target,
                                         if applicable, and any other Programs approving the budget with respect to Development
                                         activities to be performed by CureVac up until IND;

 

    57

     

    

 

		(iv)	reviewing
                                         and deciding upon suitable LNP Technology and exclusivity status;

 

		(v)	exchanging
                                         preclinical Development Data and other technical information;

 

		(vi)	discussing
                                         Product-related Manufacturing;

 

		(vii)	creating
                                         Sub-Committees;

 

		(viii)	serving
                                         as a forum where Genmab as part of its regular updates to the JRC shall inform CureVac
                                         of any material feedback received from Regulatory Agencies in relation to any Product
                                         prior to IND filing;

 

		(ix)	discussing
                                         material regulatory filings and regulatory interactions related to the Products if required
                                         by Genmab or if such material regulatory filings contain information on CureVac Technology;

 

		(x)	fostering
                                         the collaborative relationship between the Parties;

 

		(xi)	resolving
                                         disputes between the Parties;

 

		(xii)	such
                                         other functions as agreed by the Parties.

 

		9.4	JRC
                                         Sub-Committees. From time to time, the JRC may establish sub-committees (each, a
                                         “Sub-Committee”) to oversee particular projects or activities, such
                                         as Sub-Committees on IP, CMC, Manufacturing tech transfer and/or supply chain matters.
                                         Each Sub-Committee shall undertake the activities delegated to it by the JRC. Subject
                                         to Section 9.6, during the process of establishing each Sub-Committee, such Sub-Committee
                                         and the JRC shall agree which matters such Sub-Committee will resolve on its own, and
                                         on which matters such Sub-Committee will advise the JRC for resolution by such matters
                                         by the JRC. Generally there shall be a range of matters specified by the JRC on which
                                         the Sub-Committee will make recommendations to the JRC for consideration by the JRC.
                                         Unless otherwise agreed between the Parties, the governance rules with respect to the
                                         JRC shall apply to the Sub-Committees mutatis mutandis, provided, however,
                                         that upon mutual agreement between the Parties a Sub-Committee may continue to operate
                                         even after the JRC is dissolved, as long as such Sub-Committee’s tasks are still
                                         ongoing. Subject to Section 9.6 deadlocks arising in any Sub-Committee will be referred
                                         to the JRC for resolution or, if the Sub-Committee continues after the JRC is dissolved,
                                         to the Collaboration Committee or Joint Steering Committee (solely for an Opt-In Product).

 

		9.5	JRC
                                         Decisions.

 

		9.5.1	Dispute
                                         Resolution. In conducting its activities, the JRC and each Sub-Committee shall operate
                                         and make decisions consistent with the terms of this Agreement. The JRC will seek to
                                         act by consensus. If the JRC cannot reach consensus or a dispute arises that cannot be
                                         resolved within the JRC, then such matter (except the matters (i) and (ii) below) shall
                                         be escalated to the Alliance Managers of each Party. The Alliance Managers should involve
                                         the relevant JRC members of each Party in such dispute resolution. If such matter is
                                         not resolved within [*****] after escalation to the Alliance Managers, Genmab may make
                                         final decisions for all matters within the purview of the JRC except:

 

    58

     

    

 

		(i)	disputes
                                         of a technical nature concerning use of the LNP Technology; and

 

		(ii)	disputes
                                         regarding proposed amendments to the budget for Development activities up until IND with
                                         respect to the First Collaboration Program (with respect to the First Collaboration Target,
                                         not the Replacement Target, if applicable) where such amendment would result in an increase
                                         of the total budget of more than [*****] percent compared to the latest approved budget.

 

		(iii)	disputes
                                         about Manufacture of Product by CureVac not subject to dispute resolution under the Early
                                         Clinical Supply Agreement or MSA, or disputes referred to the JRC from the Manufacturing
                                         Tech Transfer Sub-Committee.

 

If the JRC, after escalation
to the Alliance Managers, cannot reach consensus in relation to matters set out above in (i), (ii) and (iii) above, then such
matter shall be escalated to the CDO of each Party. If such matter is not resolved within [*****] after escalation to the CDOs,
the dispute resolution mechanisms set out in Section 17.5.2 shall apply.

 

		9.5.2	Restriction
                                         on Genmab Decision Making. Genmab shall not resolve such a matter in a manner that
                                         (a) would require CureVac to perform less or additional activities or incur additional
                                         expenses not contemplated by this Agreement or the R&D Plans (as each R&D Plan
                                         was initially agreed by the Parties or as it was last amended with CureVac’s consent),
                                         (b) excuses, reduces, or delays Genmab’s obligations under this Agreement, including
                                         with respect to payments to CureVac, (c) negates any consent right or other rights specifically
                                         granted or allocated to CureVac under this Agreement, or (d) amends, modifies, or waives
                                         compliances with the terms of this Agreement.

 

		9.6	IP
                                         Sub-Committee. Within [*****] of the Effective Date the JRC shall establish an IP
                                         Sub-committee comprising one patent attorney of each Party (“IP Representatives”).
                                         The IP Sub-committee shall be the forum for discussion and liaison between the Parties
                                         concerning filings to be made for Program Patent Rights, Other Inventions Patent Rights
                                         and Joint Patent Rights during the Research Period. For avoidance of doubt, the IP Sub-committee
                                         is not a decision-making forum, but serves as a forum for discussion where the Parties
                                         may coordinate and consult with each other with respect to any such filings.

 

		9.7	Information
                                         and Results. Except as otherwise provided in this Agreement, the Parties will make
                                         available and disclose to one another preclinical Development Data and other results
                                         of work conducted pursuant to each Program prior to and in preparation for the JRC meetings,
                                         by the deadline and in the level of detail, form and format to be designated by the JRC;
                                         provided, however, that, in any event, each Party shall to the extent reasonably
                                         possible provide the other Party with quarterly updates regarding its work pursuant to
                                         the Programs preferably [*****] prior to each JRC meeting.

 

    59

     

    

 

		9.8	Collaboration
                                         Committee (All Programs except an Opt-In Program). The Parties agree to establish
                                         Collaboration Committee(s) for all Programs except an Opt-In Program.

 

		9.8.1	Formation;
                                         Duration. Within [*****] after IND filing for a Program, the Parties shall establish
                                         a Collaboration Committee (the “Collaboration Committee”) that will
                                         oversee the Development of the Products within such Program as set forth in this Section
                                         9.8.

 

		9.8.2	Composition.
                                         Each Collaboration Committee will be comprised of [*****] named representatives of
                                         each Party. Each Collaboration Committee will be led by [*****] chair appointed by Genmab.
                                         Within [*****] after IND filing for a Product, each Party shall notify the other Party
                                         of its initial representatives on the respective Collaboration Committee. Each Party
                                         may replace one or more of its representatives effective upon written notice to the other
                                         Party.

 

		9.8.3	Function
                                         and Powers of the Collaboration Committee. The Collaboration Committee will:

 

		a.	receive written reports or presentations
                                         from Genmab of its progress with each Product Development Plan summarizing Genmab’s
                                         Development activities and the results thereof with respect to the applicable Product
                                         and discuss at meetings the status, progress, and results of the Development of the respective
                                         Product in the Territory;

 

		b.	if CureVac exercises its Co-Promote
                                         Right with respect to a Product, direct and oversee the Co-Promotion Committee on all
                                         significant issues and resolve disputed matters that may arise at the Co-Promotion Committee,
                                         except as otherwise set out in the Co-Promotion Agreement. For clarity, the Collaboration
                                         Committee shall not have any right to amend the Co-Promotion Agreement;

 

		c.	in circumstances in which CureVac
                                         is supplying the Product or any part of the Product, discuss matters relating to Manufacturing;
                                         and

 

		d.	perform any and all tasks and responsibilities
                                         that are expressly attributed to the Collaboration Committee under this Agreement or
                                         as otherwise agreed by the Parties in writing.

 

		9.8.4	Meetings.
                                         The Collaboration Committee will meet [*****] after its formation and during
                                         the remainder of the Term. The Collaboration Committee may conduct such meetings by telephone,
                                         videoconference, or in person as determined by the chair. Each Party’s Alliance
                                         Manager will ensure that its Collaboration Committee members receive adequate notice
                                         of such meetings. Genmab may call special meetings of the Collaboration Committee with
                                         at least [*****] prior written notice, except in exigent circumstances, to resolve particular
                                         matters requested by Genmab and within the decision-making responsibility of the Collaboration
                                         Committee. Meetings of the Collaboration Committee fulfill the requirements of this Section
                                         9.8.4 only if at least [*****] representatives of each Party participate in such meeting.
                                         Each Party may invite a reasonable number of participants, in addition to its representatives,
                                         to attend Collaboration Committee meetings. Each Party is responsible for its own expenses
                                         incurred in connection with participating in and attending all such meetings. The Alliance
                                         Manager of Genmab shall record the minutes of each Collaboration Committee meeting in
                                         writing. Such minutes shall be circulated by Genmab’s Alliance Manager to CureVac’
                                         Alliance Manager no later than [*****] following the meeting for review and comments
                                         of CureVac. If no comments are received within [*****] of the receipt of the minutes
                                         by CureVac, unless otherwise agreed, they shall be deemed to be approved by CureVac.
                                         Furthermore, if the Parties are unable to reach agreement on the minutes within [*****]
                                         of the applicable meeting, the sections of the minutes that have been mutually agreed
                                         between the Parties by that date shall be deemed approved and, in addition, each Party
                                         shall record in the same document its own version of those sections of the minutes on
                                         which the Parties were not able to agree.

 

    60

     

    

 

		9.8.5	Collaboration
                                         Committee Decisions. In conducting its activities, the Collaboration Committee and
                                         each Sub-Committee (as applicable) shall operate and make decisions consistent with the
                                         terms of this Agreement. The Collaboration Committee will seek to act by consensus. If
                                         the Collaboration Committee cannot reach consensus or a dispute arises that cannot be
                                         resolved within the Collaboration Committee, then such matter shall be escalated to the
                                         Alliance Managers of each Party. The Alliance Managers should involve the relevant Collaboration
                                         Committee members of each Party in such dispute resolution. If such matter is not resolved
                                         within [*****] after escalation to the Alliance Managers, Genmab may make final decisions
                                         for all matters within the purview of the Collaboration Committee except disputes about
                                         the Manufacture by CureVac of Product which shall be governed by the relevant supply
                                         agreement, if applicable.

 

		9.9	Joint
                                         Steering Committee (Opt-In Program). The Parties agree to establish and operate a
                                         Joint Steering Committee for the Opt-In Program as required by Section 7.2 and as set
                                         forth below in this Section 9.9.

 

		9.9.1	Composition.
                                         The Joint Steering Committee will be comprised of [*****] named representatives of
                                         each Party. The chair of the Joint Steering Committee will alternate each calendar year,
                                         with Genmab to chair the first year. Within [*****] after an Opt-Inby CureVac, each Party
                                         shall notify the other Party of its initial representatives on the Joint Steering Committee.
                                         Each Party may replace one or more of its representatives effective upon written notice
                                         to the other Party.

 

		9.9.2	Function
                                         and Powers of the Joint Steering Committee. The Joint Steering Committee shall:

 

		(i)	direct,
                                         coordinate and supervise the Development of the Opt-In Product, including discuss and
                                         agree to any update to the applicable R&D Plan;

 

		(ii)	discuss
                                         and agree on matters relating to Manufacturing of Opt-In Product;

 

    61

     

    

 

		(iii)	once
                                         it has been formed, direct and oversee the Joint Commercialization Committee on all significant
                                         issues, and resolve disputed matters that may arise at the Joint Steering Committee;

 

		(iv)	establish
                                         subcommittees as determined to be reasonably necessary or useful by the Joint Steering
                                         Committee, and oversee any operating subcommittee on all significant issues, and resolve
                                         disputed matters that may arise at the subcommittees; and

 

		(v)	perform
                                         any and all tasks and responsibilities that are expressly attributed to the Joint Steering
                                         Committee under this Agreement or as otherwise agreed by the Parties in writing.

 

		9.9.3	Meetings.
                                         The will meet [*****] after its formation and for as long as
                                         the Parties jointly Develop, Manufacture and/or Commercialize the Opt-In Product. The
                                         Joint Steering Committee may conduct such meetings by telephone, videoconference, or
                                         in person as determined by the chair, provided, however, that the Joint Steering
                                         shall to the extent reasonably possible meet in person at least [*****] every calendar
                                         year. Each Party’s Alliance Manager will ensure that its Joint Steering Committee
                                         members receive adequate notice of such meetings. A Party may call special meetings of
                                         the Joint Steering Committee with at least [*****] prior written notice, except in exigent
                                         circumstances, to resolve particular matters requested by a Party and within the decision-making
                                         responsibility of the Joint Steering Committee. Meetings of the Joint Steering Committee
                                         fulfill the requirements of this Section 9.9.3 only if at least [*****] representatives
                                         of each Party participate in such meeting. Each Party may invite a reasonable number
                                         of participants, in addition to its representatives, to attend Joint Steering Committee
                                         meetings; provided that if either Party intends to have any Third Party (including any
                                         consultant) attend such a meeting, such Party shall provide prior written notice to the
                                         other Party. Such Party shall ensure that such Third Party is bound by confidentiality
                                         and non-use obligations consistent with the terms of this Agreement. Each Party is responsible
                                         for its own expenses incurred in connection with participating in and attending all such
                                         meetings. The Alliance Manager of the Party chairing the meeting shall record the minutes
                                         of the Joint Steering Committee meeting in writing. Such minutes shall be circulated
                                         to the other Party’s Alliance Manager no later than [*****] following the meeting
                                         for review, comment and approval of the other Party. If no comments are received within
                                         [*****] of the receipt of the minutes by the other Party, unless otherwise agreed, they
                                         shall be deemed to be approved by the other Party. Furthermore, if the Parties are unable
                                         to reach agreement on the minutes within [*****] of the applicable meeting, the sections
                                         of the minutes that have been mutually agreed between the Parties by that date shall
                                         be deemed approved and, in addition, each Party shall record in the same document its
                                         own version of those sections of the minutes on which the Parties were not able to agree.

 

		9.9.4	Decisions.
                                         A quorum of at least [*****] Joint Steering Committee member appointed by each Party
                                         shall be present at or shall otherwise participate in each Joint Steering Committee meeting.
                                         Each Party has one vote in the decisions of the Joint Steering Committee. Decisions of
                                         the Joint Steering Committee shall be unanimous. If the members of the Joint Steering
                                         Committee cannot agree on a particular issue, the issue shall be escalated pursuant to
                                         Section 17.5, unless otherwise explicitly provided for in the Joint Development and Manufacturing
                                         Agreement and/or Commercialization Agreement.

 

    62

     

    

 

		9.9.5	Subcommittees.
                                         The Joint Steering Committee may establish and disband such subcommittees as deemed
                                         necessary by the Joint Steering Committee. In addition, the Joint Steering Committee
                                         shall establish the Joint Commercialization Committee as provided for in Section 7.7(i).
                                         Each such subcommittee will consist of the same number of representatives designated
                                         by each Party, which number shall be mutually agreed by the Parties. Each Party may change
                                         its representatives on written notice to the other Party or send a substitute representative
                                         to any subcommittee meeting. Each Party’s representatives and any substitute for
                                         a representative shall be bound by the obligations of confidentiality set forth in Section
                                         13. Except as expressly provided in this Agreement, no subcommittee has the authority
                                         to bind the Parties hereunder and each subcommittee will report to the Joint Steering
                                         Committee. Each Party is responsible for its own expenses incurred in connection with
                                         participating in and attending all such meetings. If a dispute arises that cannot be
                                         resolved by a subcommittee, either Party may refer such dispute to the Joint Steering
                                         Committee for resolution.

 

		9.9.6	Authority.
                                         The Joint Steering Committee and any subcommittees have only the powers assigned
                                         expressly to it in this Section 9 and elsewhere in this Agreement, and does not have
                                         any power to amend, modify, or waive compliance with this Agreement. Each Party retains
                                         the rights, powers, and discretion granted to it under this Agreement and neither Party
                                         may delegate or vest such rights, powers, or discretion in the Joint Steering Committee
                                         or subcommittee unless expressly provided for in this Agreement or the Parties expressly
                                         so agree in writing.

 

		10.	CONSIDERATION.

 

		10.1	Upfront
                                         Payment. In partial consideration for the exclusive licenses granted hereunder, Genmab
                                         shall pay to CureVac a non-refundable and non-creditable fee in the amount of Ten Million
                                         US Dollars (US$10,000,000) within [*****] after Genmab’s receipt
                                         of an invoice of the respective amount from CureVac.

 

		10.2	Option Exercise Fee. In partial consideration for the exclusive options granted
                                                                                                                                                    hereunder for up to three (3) Reserved Targets, Genmab shall pay to CureVac on an Option Exercise-by-Option Exercise basis a
                                                                                                                                                    non-refundable and non-creditable (except as otherwise explicitly provided for in the Agreement) Option Exercise Fee in the
                                                                                                                                                    amount of [*****] i.e., a maximum of Thirty Million US Dollars (US$30,000,000) for all potential options hereunder
                                                                                                                                                    (“Option Exercise Fee”). Such payment shall be made within [*****] after Genmab’s receipt of an
                                                                                                                                                    invoice of the respective amount from CureVac; provided, however, that a Reservation Fee paid by Genmab to CureVac for
                                                                                                                                                    the corresponding Reserved Target shall be deducted from the Option Exercise Fee, [*****].

 

		10.3	Product
                                         Selection Fee. Genmab shall pay CureVac a one time non-refundable and non-creditable
                                         fee of five million USD ($5,000,000) upon Product Selection by a Product Selection Notice covering a Product
                                         based upon the First Program Antibody or a Replacement Target Antibody, as applicable.
                                         Such payment shall be made within [*****] after Genmab’s receipt of an invoice
                                         of the respective amount from CureVac.

 

		10.4	Opt-In
                                         fee. If CureVac exercises its option to Opt-In under Section 7.1 above, CureVac shall
                                         pay Genmab a non-refundable and non-creditable Opt-In fee of Three Million Dollars (US$ 3,000,000) within [*****] after
                                         CureVac’s receipt of an invoice of the respective amount from Genmab; and no Option
                                         Exercise Fee shall be payable by Genmab for the respective Optioned Target. If the Option
                                         Exercise Fee has already been paid, CureVac shall reimburse such payment to Genmab within
                                         [*****] of receipt of invoice.

 

    63

     

    

 

		10.5	Development
                                         and Regulatory Milestone Payments. In addition to the payments under Sections 10.1,
                                         to 10.4 inclusive, in further consideration for the exclusive licenses granted hereunder,
                                         and subject to the terms and conditions set forth in this Agreement, Genmab shall make
                                         the following non-refundable and non-creditable Development and regulatory milestone
                                         payments to CureVac:

 

		10.5.1	Single
                                         Antibody Products. On a Single Antibody Product-by-Single Antibody Product basis,
                                         the following payments shall be made for all Single Antibody Products (including the
                                         First Collaboration Program – including if it is amended to cover a Replacement
                                         Target, and any Other Pre-IND Program, as applicable):

 

	Development
    Milestone Event	In
    US$ Million
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]

 

	Regulatory
    Milestone Event	1st
    BLA/MAA	2nd
    BLA/MAA
	[*****]	[*****]	[*****]
	[*****]	[*****]	[*****]
	[*****]	[*****]	[*****]
	[*****]	[*****]	[*****]

 

	Sales
    Milestone event	In
    US$ Million
	Genmab
    shall make the following one-off, sales-based milestone payments, for the Calendar Year in which aggregated annual worldwide
    Net Sales exceed for the first time the following amounts:
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]

 

    64

     

    

 

		10.5.2	Cocktail
                                         Products. On a Cocktail Product-by-Cocktail Product basis, the following payments
                                         shall be made for all Cocktail Products (with the exception of any Opt-In Product):

 

	Development
    Milestone Event	In
    US$ Million
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]

 

	Regulatory
    Milestone Event	1st
    BLA/MAA	2nd
    BLA/MAA
	[*****]	[*****]	[*****]
	[*****]	[*****]	[*****]
	[*****]	[*****]	[*****]
	[*****]	[*****]	[*****]

 

	Sales
    Milestone event	In
    US$ Million
	Genmab
    shall make the following one-off, sales-based milestone payments, for the Calendar Year in which aggregated annual worldwide
    Net Sales exceed for the first time the following amounts:
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]

 

If any one of the milestone
events under Section 10.5 is not required for the Development of a Product, such milestone payment shall become payable upon achieving
the respective milestone event following the milestone event which was not required, [*****]. For purposes of clarity, the maximum
aggregate amount payable by Genmab pursuant to this Section 10.5 is [*****] for each Single Antibody Product, and [*****] for
each Cocktail Product.

 

		10.5.3	Obligation
                                         to Inform. Genmab shall inform CureVac on the occurrence of a milestone event under
                                         Sections 10.5.1 and 10.5.2 [*****] after
                                         the occurrence thereof.

 

    65

     

    

 

		10.5.4	Milestone
                                         Payment Terms. Each milestone payment shall be due and payable within [*****] after
                                         the receipt of the respective invoice by Genmab. Notwithstanding the foregoing, each
                                         sales milestone payment shall be paid together with the royalty payments for the Calendar
                                         Quarter during which the respective milestone has been achieved.

 

		10.6	Royalties.

 

		10.6.1	Royalty
                                         Rates. As further consideration for the rights and licenses granted by CureVac to
                                         Genmab under this Agreement, Genmab shall pay royalties to CureVac in the following amounts,
                                         in all cases considered on a Product-by-Product basis:

 

Single Antibody Products:

 

	Aggregate
    annual Net Sales of each Single Antibody Product (Product-by-Product)	Royalty
    Rate
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]

 

Cocktail Products (with the
exception of any Opt-In Product):

 

	Aggregate
    annual Net Sales of each Cocktail Product (except any Opt-In Product) (Product-by-Product)	Royalty
    Rate
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]
	[*****]	[*****]

 

		10.6.2	Royalty
                                         Calculation. The royalties shall be calculated on the basis of aggregate annual Net
                                         Sales in the Territory Product-by-Product, with the royalty tiers set out above being
                                         calculated on a Product-by-Product basis from First Commercial Sale until the expiration
                                         of the applicable Royalty Term. Examples of royalty calculations are included in the
                                         enclosed Exhibit 10.6.2.

 

		10.6.3	Royalty
                                         Term. Genmab’s obligation to pay royalties shall begin, on a country-by-country
                                         basis, with the First Commercial Sale, and expire, on a country-by-country and a Product-by-Product
                                         basis, upon the later of (i) expiry or abandonment of the last to expire Valid Claim
                                         in such country that Covers such Product; (ii) expiry of Regulatory Exclusivity for the
                                         respective Product in such country; or (iii) ten (10) years from the date of First Commercial
                                         Sale of the respective Product (“Royalty Term”).

 

    66

     

    

 

		10.6.4	FTO
                                         License. If, during the Term, Genmab reasonably concludes, on the advice of patent
                                         counsel, that it might be required to seek a license under certain Third Party Patent
                                         Rights in order to have freedom to operate in practicing or making use of the CureVac
                                         Background Technology and/or LNP Technology by the Development, Manufacture, Commercialization
                                         or other exploitation of Products in accordance with this Agreement in any country (“FTO
                                         License”), Genmab shall be free to take such FTO License, and the circumstances
                                         of Sections 10.6.5 and 10.6.6 may be applicable, subject to their provisions. Before
                                         taking such FTO License, Genmab will consult with CureVac in good faith regarding the
                                         need for such FTO License and other available options, such as seeking to invalidate
                                         certain claims of the relevant Third Party Patent Rights.

 

		10.6.5	Third
                                         Party Payments–Granted Patent Rights in the Disclosure Letter. Subject to Section
                                         10.6.9, with respect to Third Party Patent Rights referenced in the Disclosure Letter
                                         that are granted as of the Effective Date, and subject to compliance with the procedures
                                         of Section 10.6.4, in the event Genmab seeks and obtains an FTO License under such Third
                                         Party Patent Rights and is required to make any payments (milestone, royalties or other
                                         payments, including settlement payments) to one or more Third Party licensors to obtain
                                         such license, then milestone payments and/or royalties due to CureVac for the respective
                                         Product shall be reduced by [*****] of the amount of such Third Party licensor payments
                                         payable by Genmab until Genmab has been reimbursed [*****] of all such payments. For
                                         clarity, subject to Section 10.6.9 Genmab shall also have the right to reduce milestone
                                         payments and royalties to CureVac by [*****] of any payments made by Genmab to CureVac
                                         under Section 2.8 with respect to any Third Party IP of the type the subject of this
                                         10.6.5. The Parties acknowledge and agree that this mechanism for deduction of Third
                                         Party payments does not imply in any way that the Third Party Patent Rights referenced
                                         in the Disclosure Letter may constitute any risk with respect to freedom to operate.

 

		10.6.6	Other
                                         Third Party Payments. Subject to Section 10.6.9, with respect to Third Party Patent
                                         Rights not referenced in the Disclosure Letter or Third Party Patent Rights referenced
                                         in the Disclosure letter that are not granted as of the Effective Date, and subject to
                                         compliance with the procedures of Section 10.6.4 in the event Genmab seeks and obtains
                                         an FTO License under such Third Party Patent Rights and is required to make any payments
                                         (milestone, royalties or other payments, including settlement payments) to one or more
                                         Third Party licensors to obtain such license, then royalties due to CureVac for the respective
                                         Product shall be reduced by [*****] of the amount of such Third Party licensor payments
                                         payable by Genmab until Genmab has been reimbursed in full for [*****] of all such payments.
                                         For clarity, subject to Section 10.6.9, Genmab shall also have the right to reduce royalties
                                         to CureVac by [*****] of any payments made by Genmab to CureVac under Section 2.8 with
                                         respect to any Third Party IP of the type the subject of this Section 10.6.6. The Parties
                                         acknowledge and agree that this mechanism for deduction of Third Party payments does
                                         not imply in any way that the Third Party Patent Rights referenced in the Disclosure
                                         Letter may constitute any risk with respect to freedom to operate.

 

		10.6.7	Countries
                                         Without Patent Protection. During the Royalty Term with respect to the First Collaboration
                                         Target and the related Product and subject to Section 10.6.9, in countries where sales
                                         of the Product do not or no longer fall under any Valid Claim, but where Regulatory Exclusivity
                                         is still in effect, royalties set forth above in Section 10.6.1 shall be reduced by [*****]
                                         for Net Sales in such country in the first [*****] period during which no Valid Claim
                                         exists, but Regulatory Exclusivity is in effect, [*****] for Net Sales in such country
                                         in the second [*****] period during which no Valid Claim exists, but Regulatory Exclusivity
                                         is in effect, and [*****] for Net Sales in such country for the remainder of the Royalty
                                         Term. For avoidance of doubt, in countries where sales of Products do not or no longer
                                         fall under any Valid Claim and Regulatory Exclusivity is not available or has expired,
                                         royalties set forth above in Section 10.6.1 shall be reduced by [*****] for Net Sales
                                         in such country. During the Royalty Term with respect to any Optioned Target or Optioned
                                         Target Combination, as applicable, and the related Products and subject to Section 10.6.9,
                                         in countries where sales of Products do not or no longer fall under any Valid Claim,
                                         royalties set forth above in Section 10.6.1 shall be reduced by [*****] for Net Sales
                                         in such country.

 

    67

     

    

 

		10.6.8	Generic
                                         Competition. In countries where Generic Products are being marketed by a Third Party,
                                         royalties set forth above shall be further reduced by the greater of: (a) [*****] for
                                         Net Sales in such country as long as such Generic Product is on the market in such country;
                                         or (b) [*****] for Net Sales in such country in circumstances where the total unit sales
                                         of such Generic Products in such country in a Calendar Year equal or exceed [*****] of
                                         the total sales in such country of the respective Product and Generic Products combined.

 

		10.6.9	Cumulative
                                         Deductions. Notwithstanding the above, any royalty reduction made pursuant to Section
                                         10.6.5, Section 10.6.6, Section 10.6.7 and/or Section 10.6.8 or reimbursements made under
                                         Section 2.8 that are creditable against royalties shall in no event reduce the applicable
                                         royalty rate for such Products sold in the respective country to less than [*****] for
                                         Single Antibody and [*****] for Cocktail Products. For avoidance of doubt, in the event
                                         that the minimum royalty rates are reached in connection with royalty deductions made
                                         pursuant to Section 2.8, Section 10.6.5 and/or Section 10.6.6, Genmab shall be allowed
                                         to reduce its future royalty payments, always subject to the above royalty floor, until
                                         Genmab has been settled in full with respect to its right to deduct payments made to
                                         any Third Party licensor or reimbursements to Curevac, as applicable.

 

		10.6.10	Blended
                                         Royalties. With respect to a potential step down in royalty rates to account for
                                         the expiry of certain Patent Rights, the Parties acknowledge and agree that the CureVac
                                         Technology licensed under this Agreement may justify royalty rates and/or royalty terms
                                         of differing amounts for sales of Products in the Territory, which rates could be applied
                                         separately to Products involving the exercise of CureVac Patent Rights in the Territory
                                         and/or the incorporation of CureVac Know-How, and that if such royalties were calculated
                                         separately, royalties relating to the CureVac Patent Rights in the Territory and royalties
                                         relating to the CureVac Know-How would last for different terms. For practicality reasons
                                         the Parties have agreed on a blended royalty rate. For clarity, this Section 10.6.10
                                         solely explains the rationale behind the royalty rates agreed on by the Parties and does
                                         not modify any of the other provisions of this Agreement.

 

		10.6.11	Royalty
                                         Payments. Within [*****] after the end of each Calendar Quarter in which any Net
                                         Sales occur, Genmab shall calculate the royalty payments owed to CureVac and shall remit
                                         to CureVac the amount owed to CureVac. All royalty payments shall be computed by converting
                                         the Net Sales in each country in the Territory into the currency of US Dollars, using
                                         the monthly exchange rates as customarily used by Genmab in preparing its audited financial
                                         statements for the applicable Calendar Quarter.

 

    68

     

    

 

		10.7	Reports.
                                         Each royalty payment shall be accompanied by a written report describing the Net
                                         Sales of each Product sold by or on behalf of Genmab, its Affiliates and Sublicensees
                                         during the applicable Calendar Quarter for each country in which sales of any Product
                                         occurred, specifying: [*****].

 

		10.8	Records.
                                         Genmab, its Affiliates and/or its Sublicensees shall keep and maintain records of
                                         sales of the Product(s) so that the royalties payable and the royalty reports may be
                                         verified. Such records shall upon reasonable written notice be open to inspection during
                                         business hours for a [*****] period after the Calendar Quarter to which such records
                                         relate, but in any event not more than once per calendar year, by a nationally recognized
                                         independent certified public accountant selected by CureVac reasonably acceptable to
                                         Genmab and retained at CureVac’s expense. Said accountant shall sign a confidentiality
                                         agreement prepared by Genmab and reasonably acceptable to CureVac and shall then have
                                         the right to audit the records kept pursuant to this Agreement to confirm Net Sales,
                                         royalties and other payments for a period covering not more than [*****] following the
                                         Calendar Quarter to which they pertain. If said examination of records reveals any underpayment(s)
                                         of the royalty payable, then Genmab shall promptly pay the balance due to CureVac, and
                                         if the underpayment(s) is/are more than [*****] then Genmab shall also bear the expenses
                                         of said accountant. If said examination of records reveals any overpayment(s) of royalty
                                         payable, then CureVac shall credit the amount overpaid against Genmab’s future
                                         royalty payment(s) (and if no further payments are due, shall be refunded by CureVac
                                         at the request of Genmab).

 

		10.9	Participation
                                         Payment. In the event Genmab grants a sublicense to a Third Party (i.e., a Sublicensee)
                                         for a Product expressing the First Program Antibody before [*****], Genmab shall pay
                                         to CureVac a one time payment of Ten Million US Dollars (US$ 10,000,000), in addition to the milestone and royalty payments
                                         to be made under this Article 10.

 

		10.10	Payment
                                         Terms.

 

		10.10.1	All
                                         payments by Genmab to CureVac shall be made by wire transfer payment in US dollars, except
                                         with respect to payments of FTE costs which shall be made in Euros, and shall be remitted
                                         to the following bank account:

 

[*****]

 

Invoices shall be issued to
Genmab A/S, or to the assignee Affiliate as specified in Section 17.1 on a Program-by-Program basis. Invoices shall be sent to
Genmab by email at the following address and stating the following VAT number or as otherwise designated by Genmab in writing:

 

Genmab B.V.
 [*****]

 

    69

     

    

 

		10.10.2	Payments
                                         not paid within [*****] after the due date under this Agreement shall bear interest at
                                         an annual rate of [*****] above the three-month-LIBOR rate of the respective currency
                                         for the time period in which such amount is outstanding, as disclosed from time to time
                                         by the European Central Bank which applied on the due date. Calculation of interest will
                                         be made for the exact number of days in the interest period based on a year of 360 days
                                         (actual/360) by Genmab.

 

		10.11	Taxes.

 

		10.11.1	Each
                                         Party shall be responsible for its own income taxes assessed by a tax or other authority
                                         except as otherwise set forth in this Agreement.

 

		10.11.2	The
                                         Parties acknowledge and agree that it is their mutual objective and intent to optimize,
                                         to the extent feasible and in compliance with Applicable Laws, taxes payable with respect
                                         to their collaborative efforts under this Agreement and that they shall use reasonable
                                         efforts to cooperate and coordinate with each other to achieve such objective.

 

		10.11.3	CureVac
                                         shall bear and pay any and all taxes levied on account of any payments made to it under
                                         this Agreement. If any taxes are required to be withheld by Genmab from any payment to
                                         be made to CureVac under this Agreement, Genmab shall (a) deduct such taxes from the
                                         payment to be made to CureVac, (b) timely pay the taxes to the proper taxing authority,
                                         and (c) send proof of payment to CureVac with an explanation of payment of such taxes
                                         within [*****] following such payment. If Genmab had a duty to withhold taxes in connection
                                         with any payment it made to CureVac but Genmab failed to withhold, and such taxes were
                                         assessed against and paid by Genmab, then CureVac shall, at Genmab’s request and
                                         upon receipt of proof of Genmab’s payment of such taxes, reimburse to Genmab the
                                         amount equivalent to such taxes (including interest but excluding penalties) paid by
                                         Genmab. For purposes of this Section 10.11.3, each Party shall provide the other with
                                         reasonably requested assistance to enable the due deduction by Genmab or CureVac, as
                                         applicable, and appropriate recovery by CureVac or Genmab, as applicable, which assistance
                                         includes provision of any tax forms and other information that may be reasonably necessary
                                         for Genmab or CureVac not to withhold tax.

 

		10.11.4	All
                                         payments due to the terms of this Agreement are expressed to be exclusive of value added
                                         tax (VAT) or similar indirect taxes. VAT/indirect taxes shall be added to the payments
                                         due to the terms if legally applicable.

 

 

		11.	INTELLECTUAL
                                         PROPERTY.

 

		11.1	Background Technology. As between the Parties, all right, title and interest in and to
                                                                                                                                                    all [*****] shall be Controlled by [*****] and all right, title and interest in and to all [*****] shall be Controlled by [*****]. As between the Parties, each Party shall have the sole right, in its sole discretion and at its sole expense, to
                                                                                                                                                    prosecute, maintain and defend Patent Rights within its Background Technology; provided, however, that CureVac shall
                                                                                                                                                    consider in good faith the interests of Genmab in the prosecution, maintenance and defense of [*****].

 

    70

     

    

 

		11.2	Disclosure
                                         of Inventions. During the Research Period, on a Collaboration Target-by- Collaboration
                                         Target basis, each Party shall as soon as reasonably practical disclose to the other
                                         Party, through the forum of the IP Sub Committee, the making, conception, or reduction
                                         to practice of any Inventions. After the Research Period, each Party shall as soon as
                                         reasonably practical disclose to the other Party, through the forum of the IP Sub Committee
                                         if it is continued after the Research Period, or otherwise through the Alliance Manager,
                                         the making, conception, or reduction to practice of any Invention that may be owned in
                                         part or in whole by the other Party pursuant to this Section 11.

 

		11.3	Ownership
of Inventions. The Parties agree that all right, title and interest in any and all Inventions (including all Patent Rights
resulting from such Inventions and all Know-How embodied in such Inventions) shall be owned as follows, [*****].

 

		11.3.1	Genmab
                                         Inventions. Genmab shall own all right, title and interest in and to

 

		(A)	[*****] and

 

		(B)	[*****]

 

Any such Invention as described
under (A) or (B) above shall be considered an Invention of Genmab (“Genmab Invention”). The types of inventions
listed in Section 2 of Exhibit 11.3 are all Inventions that are not to be considered a [*****] as applicable.

 

    71

     

    

 

		11.3.2	CureVac
Inventions. CureVac shall own all right, title and interest in and to all Inventions that [*****] Controlled by [*****] and
can be [*****]. The types of Inventions listed in [*****]. Any such Invention as described above in this Section 11.3.2 shall be considered
an Invention of CureVac (“CureVac Invention”).

 

		11.3.3	Other Inventions; Joint Inventions. For all other Inventions (i.e., Inventions that do
                                                                                                                                                      not fall within the categories described in Section 11.3.1 or 11.3.2 above) that are invented by or on behalf of Genmab
                                                                                                                                                      and/or CureVac (including the non-limiting example set out in Section 3 of Exhibit 11.3) (“Other
                                                                                                                                                      Inventions”), [*****]. Any such Other Invention shall be referred to as “Genmab Other Invention”
                                                                                                                                                      if owned by Genmab, and as “CureVac Other Invention” if owned by CureVac. Except to the extent either
                                                                                                                                                      Party is restricted by the licenses granted to the other Party under this Agreement or the other terms of this Agreement,
                                                                                                                                                      each Party shall have the right to [*****] the Other Invention under any Other Invention Patent Right and related Know-How,
                                                                                                                                                      i.e., shall have a [*****] license to such Other Invention, and any consent
                                                                                                                                                      from the other Party as may be required under Applicable Law for a Party to practice and exploit such Other Invention and
                                                                                                                                                      Other Invention Patent Right and related Know-How shall hereby be given by the other Party. If the
                                                                                                                                                      Parties [*****] shall be jointly owned by the Parties (“Joint
                                                                                                                                                      Invention”). Except to the extent either Party is restricted by the licenses granted to the other Party under this
                                                                                                                                                      Agreement or the other terms of this Agreement, each Party may freely practice and exploit its interest in the Joint
                                                                                                                                                      Inventions, Joint Patent Rights and related Know-How, and any consent from the other Party as may be required under
                                                                                                                                                      Applicable Law for a Party to practice and exploit such Joint Inventions and Joint Patent Rights shall hereby be given by the
                                                                                                                                                      other Party. For the avoidance of doubt, the licenses granted under this Section 11.3.3 do not include any license to use any
                                                                                                                                                      Background Technology of the other Party.

 

		11.4	Assignment and transfer of Inventions. To give effect to the ownership principles
                                                                                                                                                    described in Section 11.3 each Party shall assign and transfer, and hereby assigns and transfers, to such other Party (or
                                                                                                                                                    with respect to assignments and transfers to Genmab, to Genmab A/S or Genmab B.V. as designated by Genmab in writing on a
                                                                                                                                                    Program-by-Program basis) [*****] as the case may be, of its present and future rights, interest and title to any such
                                                                                                                                                    Invention that is to vest in the other Party pursuant to the ownership principles described in Section 11.3, and the other
                                                                                                                                                    Party shall accept and hereby accepts such assignment and transfer (“Assigned Invention”). At the written
                                                                                                                                                    instruction of the other Party, the transferring Party agrees to make or procure all such assignments from its employees,
                                                                                                                                                    consultants and subcontractors as are necessary to give effect to the provisions of this Section 11.4 and to assist the
                                                                                                                                                    transfer in every way reasonably required by the transferee (i) to obtain Patent Rights to such Assigned Invention in any and
                                                                                                                                                    all countries for which Patent Rights are being sought; and (ii) to maintain and defend Patent Rights in all Assigned
                                                                                                                                                    Inventions which have been or may be assigned as provided above. The transferring Party shall execute and deliver, and cause
                                                                                                                                                    its employees, consultants and subcontractors to execute and deliver, all such documents, instruments and other papers and
                                                                                                                                                    take all such other action which the transferee may reasonably request in order to give effect to the provisions of this
                                                                                                                                                    Section 11.4.

 

    72

     

    

 

		11.5	Cooperation.
                                         Each Party represents and agrees that all its employee(s), contractor(s) and agent(s)
                                         will be obligated under a binding written agreement or otherwise to assign to such Party
                                         all Inventions discovered, created, conceived, developed or reduced to practice by such
                                         employee(s), contractor(s) or agent(s) in connection with this Agreement. Notwithstanding
                                         anything to the contrary herein, to the extent the German Laws on Employee Inventions
                                         (Arbeitnehmererfindungsgesetz) applies, each Party shall claim the unlimited use
                                         of any Invention discovered, created, conceived, developed or reduced to practice in
                                         accordance with such laws. Regardless of which Party is the ultimate assignee of an Invention
                                         under this Agreement, each Party shall be solely responsible for payments to be made
                                         to its employees or other persons engaged by such Party in consideration for the Invention
                                         under the German Laws on Employee Inventions, or any corresponding laws in other countries.
                                         For clarity, each Party shall be and remain solely responsible towards its own employees
                                         for compliance with the requirements of the German Laws on Employee Inventions (Arbeitnehmererfindungsgesetz)
                                         if applicable.

 

		11.6	Non-exclusive
                                         License to Generally Applicable Patent Rights. Except to the extent CureVac is restricted
                                         by the licenses granted to Genmab under this Agreement or the other terms of this Agreement,
                                         Genmab hereby grants to CureVac, and CureVac hereby accepts, a fully paid-up, royalty-free,
                                         perpetual, irrevocable, worldwide, non-exclusive, transferable and sub-licensable (through
                                         multiple tiers) license to freely practice and use the Generally Applicable Patent Rights
                                         for activities in connection with the CureVac Background Technology, CureVac Technology,
                                         Know-How generated by CureVac outside this Agreement and/or the LNP Technology, in each
                                         case to the extent that such activities are outside the scope of this Agreement. For
                                         the avoidance of doubt, subject to the provisions of Section 13.4.4 CureVac shall not
                                         have any right to use, exploit or disclose any Confidential Information of Genmab in
                                         connection with such activities.

 

		11.7	Filing,
                                         Prosecution, Maintenance and Defense.

 

		11.7.1	CureVac
                                         Program Patent Rights. Subject to Section 11.7.3 below, CureVac shall have the first
                                         right, but not the obligation, to file, prosecute, maintain and defend the CureVac Program
                                         Patent Rights throughout the Territory at its sole expense. Upon Genmab’s request,
                                         CureVac shall keep Genmab advised of the status of prosecution of all such Patent Rights
                                         included within the CureVac Program Patent Rights, and shall give Genmab before filing
                                         or response to office actions, as applicable, reasonable opportunity to review and comment
                                         upon the text of any applications or amendments for CureVac Program Patent Rights. CureVac
                                         shall not unreasonably refuse to address any of Genmab’s comments made in accordance
                                         with this Section 11.7.1. Notwithstanding the above, prior to filing any application
                                         for a CureVac Invention that may disclose, in part or in full, a Genmab Invention, Other
                                         Invention or Joint Invention, CureVac shall provide Genmab with a copy of the draft application
                                         and provide Genmab with at least [*****] to review and comment upon the text of such
                                         draft application. If Genmab notifies CureVac within the above [*****] deadline that
                                         Genmab desires to file an application for a Genmab Invention, Joint Invention or Genmab
                                         Other Invention, the Parties shall coordinate the filing of the application for a CureVac
                                         Invention with the filing of Genmab’s application for such Genmab Invention, Other
                                         Invention or Joint Invention so that CureVac’s application and Genmab’s application
                                         are filed on the same day or otherwise filed in a way that secures and protects each
                                         of the Parties’ interest. CureVac shall promptly give notice to Genmab of the grant,
                                         lapse, revocation, surrender or invalidation of any CureVac Program Patent Rights for
                                         which CureVac is responsible for the filing, prosecution and maintenance. CureVac shall
                                         give notice to Genmab of any desire to not file patent applications claiming CureVac
                                         Program Patent Rights on a country by country basis and, in such cases, shall permit
                                         Genmab, in its sole discretion, to file such patent applications at its own expense and
                                         in its own name. If Genmab elects to file, such Patent Right shall be deemed a Genmab
                                         Patent Right and CureVac shall execute such documents and perform such acts at CureVac’s
                                         reasonable expense as may be reasonably necessary for Genmab to perform such filing.
                                         For avoidance of doubt, CureVac will not include a Genmab Invention, Other Invention
                                         or Joint Invention in a separate patent claim of a patent application to be filed by
                                         CureVac without Genmab’s prior written consent.

 

    73

     

    

 

		11.7.2	Genmab
                                         Program Patent Rights. Genmab shall have the sole right, but not the obligation,
                                         at its sole expense, to file, prosecute, maintain and defend the Genmab Program Patent
                                         Rights throughout the Territory in good faith consistent with its customary patent policy
                                         and its reasonable business judgment and shall consider in good faith the reasonable
                                         interests of CureVac in so doing. Upon CureVac’s request, Genmab shall keep CureVac
                                         advised of the status of prosecution of all Royalty Product Patent Rights. Notwithstanding
                                         the above, prior to filing any application for a Genmab Invention that may disclose,
                                         in part or in full, a CureVac Invention, Other Invention or Joint Invention, Genmab shall
                                         provide CureVac with a copy of the draft application and provide CureVac with at [*****]
                                         to review and comment upon the text of such draft application. If CureVac notifies Genmab
                                         within the above [*****] deadline that CureVac desires to file an application for a CureVac
                                         Invention or CureVac Other Invention, the Parties shall coordinate the filing of the
                                         application for a Genmab Invention with the filing of CureVac’s application for
                                         such CureVac Invention or CureVac Other Invention so that CureVac’s application
                                         and Genmab’s application are filed on the same day or otherwise filed in a way
                                         that secures and protects each of the Parties’ interest, such as by agreeing to
                                         follow the principles for filing, prosecution, maintenance and defense outlined in Section
                                         11.7.3. For avoidance of doubt, Genmab will not include a CureVac Invention, Other Invention
                                         or Joint Invention in a separate patent claim of a patent application to be filed by
                                         Genmab without CureVac’s prior written consent.

 

		11.7.3	Filing,
                                         Prosecution, Maintenance and Defense of certain Patents claiming both Genmab Inventions
                                         and CureVac Inventions. Notwithstanding the above in Section 11.7.1, if Genmab reasonably
                                         finds that the planned filing of a patent application by CureVac claiming a CureVac Invention
                                         may be damaging to Genmab’s possibilities of obtaining adequate Patent Rights for
                                         a particular Product, Genmab shall have the right to request in writing, through the
                                         IP Sub- Committee or the Alliance Manager, as applicable, and providing detailed reasons
                                         that CureVac does not file such application at that time, always giving due consideration
                                         to CureVac’s interest in obtaining an adequate patent protection of the CureVac
                                         Inventions and Genmab’s interest in obtaining an adequate patent protection for
                                         Genmab Inventions and that particular Product. For avoidance of doubt, [*****]. As a result of such written
                                         request from Genmab, CureVac will not file such application at such time. Instead, CureVac
                                         can file such application on the earlier of (i) [*****] after Genmab has promptly informed
                                         CureVac in writing that Genmab has obtained sufficient data to support an application
                                         for Patent Rights for a Genmab Invention relating to the Product making use of such CureVac
                                         Invention, or (ii) [*****] following Product Selection under Section 5.3 or Option Exercise
                                         under Section 3.4 (whichever occurs sooner) according to the R&D Plan relating to
                                         the Product which is the subject of the Genmab patent application; or (iii) when Genmab
                                         decides not to pursue Product Selection under Section 5.3 or Option Exercise under Section
                                         3.4 for that particular Product. [*****]. If CureVac believes it would
                                         be beneficial that such Genmab application should contain claims for such CureVac Invention,
                                         it may request Genmab to include the relevant CureVac Invention in the Genmab filing,
                                         and Genmab shall consider such request in good faith. Subject to the restrictions of
                                         the licenses granted by CureVac to Genmab under this Agreement and any other restrictions
                                         explicitly set out in this Agreement, Genmab shall and hereby does grant to CureVac,
                                         and CureVac shall and hereby does accept, an exclusive, worldwide, fully paid, perpetual,
                                         fully transferable license, with the right to grant sublicenses in multiple tiers, under
                                         any such Genmab Program Patent Rights covering a CureVac Invention to practice and exploit
                                         such CureVac Invention and only such CureVac Invention. In addition, upon CureVac’s
                                         request, Genmab shall collaborate in good faith with CureVac with a view to filing, where
                                         possible, specific divisional application(s) claiming such CureVac Invention(s), that
                                         would be prosecuted, maintained and defended under the control of CureVac and at its
                                         expense, and, to the extent possible without damaging Genmab’s patent position
                                         with respect to a given Product, which divisional application(s) shall be assigned to
                                         CureVac for its further prosecution, maintenance and defense at CureVac’s cost.
                                         Such assigned divisional Patent Rights shall then be deemed CureVac Program Patent Rights.
                                         Upon such filing of a divisional application, Genmab shall abandon the patent claim(s)
                                         for such CureVac Invention.

 

    74

     

    

 

		11.7.4	CureVac
                                         Other Invention Patent Rights. CureVac shall have the first right, but not the obligation,
                                         to file, prosecute, maintain and defend Patent Rights for CureVac Other Inventions (“CureVac
                                         Other Invention Patent Rights”) throughout the Territory, at its sole expense,
                                         and CureVac shall as soon as reasonably practicable give notice to Genmab of any desire
                                         to not file patent applications claiming CureVac Other Invention Patent Rights or to
                                         cease prosecution and/or maintenance and/or defense of CureVac Other Invention Patent
                                         Rights on a country by country basis and, in such cases, shall permit Genmab, in its
                                         sole discretion, to file such patent applications or to continue prosecution or maintenance
                                         or defense of such CureVac Other Invention Patent Rights (in which case thereafter they
                                         will be deemed a Genmab Other Invention Patent Right) at its own expense and in its own
                                         name. At the latest [*****] before filing, and except where CureVac has given up the
                                         right to prosecute as provided above, CureVac shall give Genmab an opportunity to review
                                         and comment upon the text of any application with respect to any CureVac Other Invention
                                         Patent Right, shall consult with Genmab with respect thereto, shall not unreasonably
                                         refuse to address any of Genmab’s comments and supply Genmab with a copy of the
                                         application as filed, together with notice of its filing date and serial number. CureVac
                                         shall keep Genmab reasonably informed of the status of the actual and prospective prosecution,
                                         maintenance and defense, including but not limited to any substantive communications
                                         with the competent patent offices that may affect the scope of such filings, and CureVac
                                         shall to the extent reasonably possible give Genmab a timely, prior opportunity to review
                                         and comment upon any such substantive communication and shall consult with Genmab with
                                         respect thereto, and shall not unreasonably refuse to address any of Genmab’s comments.
                                         Notwithstanding anything to the contrary above, prior to filing any application for a
                                         CureVac Other Invention that may disclose, in part or in full, a Genmab Invention, CureVac
                                         shall provide Genmab with a copy of the draft application and provide Genmab with at
                                         least [*****] to review and comment upon the text of such draft application. If Genmab
                                         notifies CureVac within the above [*****] deadline that Genmab desires to file an application
                                         for a Genmab Invention, the Parties shall coordinate the filing of the application for
                                         a CureVac Other Invention with the filing of Genmab’s application for such Genmab
                                         Invention so that the CureVac application and Genmab application are filed on the same
                                         day or otherwise filed in a way that secures and protects each of the Parties’
                                         interest.

 

		11.7.5	Genmab
                                         Other Invention Patent Rights. Genmab shall have the first right, but not the obligation,
                                         to file, prosecute, maintain and defend Patent Rights for Genmab Other Inventions (“Genmab
                                         Other Invention Patent Rights”) throughout the Territory, at its sole expense,
                                         and Genmab shall as soon as reasonably practicable give notice to CureVac of any desire
                                         to not file patent applications claiming Genmab Other Invention Patent Rights or to cease
                                         prosecution and/or maintenance and/or defense of Genmab Other Invention Patent Rights
                                         on a country by country basis and, in such cases, shall permit CureVac, in its sole discretion,
                                         to file such patent applications or to continue prosecution or maintenance or defense
                                         of such Genmab Other Invention Patent Rights (in which case thereafter they will be deemed
                                         a CureVac Other Invention Patent Right) at its own expense and in its own name. At the
                                         latest [*****] before filing, and except where Genmab has given up the right to prosecute
                                         as provided above, Genmab shall [*****]. Notwithstanding
                                         anything to the contrary above, prior to filing any application for a Genmab Other Invention
                                         that may disclose, in part or in full, a CureVac Invention, Genmab shall provide CureVac
                                         with a copy of the draft application and provide CureVac with at least [*****] to review
                                         and comment upon the text of such draft application. If CureVac notifies Genmab within
                                         the above [*****] deadline that CureVac desires to file an application for a CureVac
                                         Invention, the Parties shall coordinate the filing of the application for a Genmab Other
                                         Invention with the filing of CureVac’s application for such CureVac Invention so
                                         that the CureVac application and Genmab application are filed on the same day or otherwise
                                         filed in a way that secures and protects each of the Parties’ interest.

 

    75

     

    

 

		11.8	Joint
                                         Patent Rights.

 

		11.8.1	Genmab
                                         shall have the first right, but not the obligation, to file, prosecute, maintain and
                                         defend Patent Rights relating to Joint Inventions (“Joint Patent Rights”)
                                         throughout the Territory, at its sole expense, and Genmab shall give timely notice to
                                         CureVac, and, if during the Research Period, with a copy to the IP Sub-Committee, of
                                         any desire to not file patent applications claiming Joint Patent Rights or to cease prosecution
                                         and/or maintenance of Joint Patent Rights on a country-by-country basis and, in such
                                         cases, shall permit CureVac, in its sole discretion, to file such patent applications
                                         or to continue prosecution, maintenance or defense of such Joint Patent Rights at its
                                         own expense. At the latest [*****] before filing, the prosecuting Party shall give the
                                         non-prosecuting Party an opportunity to review and comment upon the text of any application
                                         with respect to such Joint Patent Right, shall consult with the non-prosecuting Party
                                         with respect thereto, shall not unreasonably refuse to address any of the non-prosecuting
                                         Party’s comments and supply the non-prosecuting Party with a copy of the application
                                         as filed, together with notice of its filing date and serial number. The prosecuting
                                         Party shall keep the non-prosecuting Party reasonably informed of the status of the actual
                                         and prospective prosecution, and maintenance, including but not limited to any substantive
                                         communications with the competent patent offices that may affect the scope of such filings,
                                         and the prosecuting Party shall give the non-prosecuting Party a timely, prior opportunity
                                         to review and comment upon any such substantive communication and shall consult with
                                         such non- prosecuting Party with respect thereto, and shall not unreasonably refuse to
                                         address any of such non-prosecuting Party’s comments.

 

		11.9	Patent
                                         Term Extension. [*****]. It is acknowledged
                                         that Genmab has the ultimate decision-making authority with regard to the filing for
                                         Patent Term Extensions, but Genmab agrees that when making that decision it shall not
                                         unreasonably take any action or inaction that causes CureVac significant financial detriment, [*****]. CureVac shall
                                         cooperate with Genmab with regard to obtaining Patent Term Extensions and shall provide
                                         to Genmab prompt and reasonable assistance as requested by Genmab, at Genmab’s
                                         expense, including by taking such action as may be required of the patent holder under
                                         any Applicable Laws to obtain such Patent Term Extension. [*****].

 

		12.	ENFORCEMENT
                                         AND DEFENSE.

 

		12.1	Notice.
                                         Each Party shall notify the other Party in writing as soon as reasonably possible
                                         upon learning of any actual or suspected infringement by a Third Party of any CureVac
                                         Patent Rights, Genmab Patent Rights, CureVac Other Invention Patent Right, Genmab Other
                                         Invention Patent Right, Joint Patent Right or Patent Rights comprised in the LNP Technology
                                         Controlled by CureVac that may adversely affect any Program Antibody, Program Antibody
                                         Combination or Product in the Field in the Territory (“Relevant Infringement”),
                                         or of any claim by a Third Party alleging the invalidity, unenforceability, or non-infringement
                                         of any CureVac Patent Rights, Genmab Patent Rights, CureVac Other Invention Patent Right,
                                         Genmab Other Invention Patent Right or Joint Patent Right.

 

    76

     

    

 

		12.2	Enforcement.

 

		12.2.1	CureVac
                                         Patent Rights, Patent Rights in LNP Technology, CureVac Other Invention Patent Rights.
                                         Except as set forth in Section 12.2.2 below, as between the Parties, CureVac will
                                         have the first right, but not the obligation, to seek to abate any Relevant Infringement
                                         of any CureVac Patent Right, Patent Rights comprised in the LNP Technology Controlled
                                         by CureVac (to the extent CureVac is authorized to do so by the LNP Technology licensor)
                                         or CureVac Other Invention Patent Right by a Third Party, or to file suit against any
                                         such Third Party for such Relevant Infringement, and CureVac shall bear all the expense
                                         of such suit or abatement of such Relevant Infringement. Genmab may, at its own expense,
                                         be represented in any such action by counsel of its own choice. If CureVac does not bring
                                         such legal action within the earlier of (i) [*****] after the notice provided pursuant
                                         to Section 12.1, or (ii) within [*****] prior to any deadline under Applicable Law for
                                         bringing such legal action; or if CureVac decides to discontinue any ongoing legal action,
                                         Genmab may bring and control any legal action in connection with such Relevant Infringement
                                         of CureVac Patent Rights, Patent Rights comprised in the LNP Technology (to the extent
                                         possible under CureVac’s license to such LNP Technology) or CureVac Other Invention
                                         Patent Rights at its own expense as it reasonably determines appropriate.

 

		12.2.2	Genmab
                                         Patent Rights. As between the Parties, Genmab will have the sole right, but not the
                                         obligation, to seek to abate any infringement of Genmab Patent Rights by a Third Party,
                                         or to file suit against any such Third Party for such infringement. Genmab shall bear
                                         all the expense of such suit or abatement of infringement. With respect to any infringement
                                         by a Third Party of a Genmab Patent Right where such infringement relates to a claim
                                         for a CureVac Invention included in such Genmab Patent Right pursuant to Section 11.7.3,
                                         Genmab agrees to collaborate with CureVac in good faith at CureVac’s cost to enforce
                                         such claim against such Third Party infringement  [*****]; provided that in the reasonable opinion of Genmab such enforcement
                                         will not entail any significant risk with respect to upholding an adequate patent protection
                                         for Genmab Inventions and the Product.

 

		12.2.3	Genmab
                                         Other Invention Patent Right and Joint Patent Rights. Genmab shall have the first
                                         right, but not the obligation, to seek to abate any infringement of Genmab Other Invention
                                         Patent Rights or Joint Patent Rights by a Third Party, or to file suit against any such
                                         Third Party for such infringement, and Genmab shall bear all the expense of such suit
                                         or abatement of infringement. CureVac may, at its own expense, be represented in any
                                         such action by counsel of its own choice. If Genmab does not bring such legal action
                                         within the earlier of (i) [*****] after the notice provided pursuant to Section 12.1,
                                         or (ii) within [*****] prior to any deadline under Applicable Law for bringing such legal
                                         action; or if Genmab decides to discontinue any ongoing legal action, CureVac may bring
                                         and control any legal action in connection with such infringement of Genmab Other Invention
                                         Patent Rights and Joint Patent Rights at its own expense as it reasonably determines
                                         appropriate.

 

		12.2.4	Assistance.
                                         The non-enforcing Party shall provide such assistance as the enforcing Party shall
                                         reasonably request in connection with any action or suit hereunder to prevent or enjoin
                                         any such infringement or unauthorized use of a CureVac Patent Right or Genmab Patent
                                         Right, including agreeing to be joined as a party to such action or suit and executing
                                         legal documents as reasonably requested by the enforcing Party. Such assistance will
                                         be provided by a Party, at the enforcing Party’s cost.

 

    77

     

    

 

		12.3	Defense.

 

		12.3.1	Defense
                                         of CureVac Patent Rights, Patent Rights in LNP Technology and CureVac Other Invention
                                         Patent Rights. Except as set forth in subsection 12.3.2 below, as between the Parties,
                                         CureVac will have the first right, but not the obligation, to defend against a declaratory
                                         judgment action or other action challenging any CureVac Patent Right or Patent Right
                                         comprised in LNP Technology Controlled by CureVac or CureVac Other Invention Patent Rights.

 

		12.3.2	Defense
                                         of Genmab Other Invention Patent Rights and/or Joint Patent Rights. As between the
                                         Parties, Genmab will have the first right, but not the obligation, to defend against
                                         a declaratory judgment action or other action challenging any Genmab Other Invention
                                         Patent Right or Joint Patent Rights. Genmab shall bear all the expense of such defense.

 

		12.3.3	Taking
                                         over the defense. If the Party first responsible for such defense does not take steps
                                         to defend (or have defended) within a commercially reasonably time period, or elects
                                         not to continue any such defense (in which case it will promptly provide notice thereof
                                         to the other Party), then (A) in the case of an election by CureVac not to defend (or
                                         have defended) a CureVac Patent Right, Patent Right in LNP Technology Controlled by CureVac
                                         or CureVac Other Invention Patent Right, Genmab shall have the right, but not the obligation,
                                         to defend such CureVac Patent Right, Patent Right in LNP Technology (to the extent possible
                                         under CureVac’s license to such LNP Technology) or CureVac Other Invention Patent
                                         Right with respect to a Program Antibody, Program Antibody Combination or Product; provided,
                                         however, that Genmab shall bear all the expenses of such suit, and (B) in the case
                                         of an election by Genmab not to defend a Genmab Other Invention Patent Right or Joint
                                         Patent Right, CureVac shall have the right, but not the obligation, to take action or
                                         bring suit to defend such Patent Right; provided, however that CureVac shall bear all
                                         the expenses of such suit.

 

		12.3.4	Control.
                                         Notwithstanding the foregoing, any response to a Third Party infringer’s counterclaim
                                         of invalidity or unenforceability of any CureVac Patent Rights, Patent Right in LNP Technology
                                         Controlled by CureVac (to the extent authorized under CureVac’s license to such
                                         LNP Technology), CureVac Other Invention Patent Rights, Genmab Other Invention Patent
                                         Rights or Joint Patent Right shall be controlled by the Party who controls the relevant
                                         enforcement proceeding pursuant to this Article 12 unless otherwise mutually agreed by
                                         the Parties in writing.

 

		12.3.5	Defense
                                         of Genmab Patent Rights. As between the Parties, Genmab shall have the sole right,
                                         but not the obligation, to defend against a declaratory judgment action or other action
                                         challenging any Genmab Patent Right. Genmab shall bear all the expenses of such defense.
                                         With respect to any defense of a Genmab Patent Right where such defense relates to a
                                         claim for a CureVac Invention included in such Genmab Patent Right pursuant to Section
                                         11.7.3, Genmab agrees to collaborate with CureVac in good faith at CureVac’s cost
                                         to defend such claim against such declaratory judgment action or other action challenging
                                         such claim [*****]; provided
                                         that in the reasonable opinion of Genmab such defense will not entail any significant
                                         risk with respect to upholding an adequate patent protection for Genmab Inventions and
                                         the Product.

 

    78

     

    

 

		12.4	Participation.
                                         With respect to any infringement or defensive action identified above in this Article
                                         12, the enforcing or defending Party shall keep the other Party updated and reasonably
                                         consult with the other Party with respect to any such action, it being understood that
                                         in such consultation the enforcing or defending Party shall take the other Party’s
                                         comments reasonably into account, provided, however, that the enforcing or defending
                                         Party will have the right to make the final determination in the event of any disagreement
                                         between the Parties related to any decision in connection with such action.

 

		12.5	Damages.
                                         Unless otherwise agreed by the Parties, all monies recovered upon the final judgment
                                         or settlement of any infringement action relating to the Development, Manufacture or
                                         Commercialization of Product(s) under this Agreement which may be controlled by either
                                         Genmab or CureVac and described in this Article 12, in each case will be used as follows:

 

		(i)	first
                                         to reimburse the controlling Party, and thereafter the non-controlling Party, for each
                                         of their reasonable out-of-pocket costs and expenses relating to the action;

 

		(ii)	second, the remaining recovery shall then be used to compensate each Party for the respective
                                                                                                                                                 damages suffered from the infringement of the respective Patent Right based on a lost profits calculation, provided that in
                                                                                                                                                 the event the remaining portion of the recovery is not sufficient to compensate each Party’s damages, such compensation
                                                                                                                                                 shall be paid on a pro-rata share based on the respective damages/lost profits suffered, provided, however, if such
                                                                                                                                                 respective damages/lost profits suffered cannot be reasonably ascertained, then (a) with respect to an action controlled by
                                                                                                                                                 Genmab, Genmab shall receive [*****] of the recovery and CureVac shall receive [*****] except in the event that the recovery
                                                                                                                                                 relates to an Opt-In Product in which case the recovery shall be [*****] and (b) with respect to an action controlled by
                                                                                                                                                 CureVac, the recovery shall be [*****];

 

		(iii)	third,
                                         the remaining portion of any such recovery to be allocated between the Parties in the
                                         same ratio used for the calculation under Section 12.5(ii).

 

		12.6	Consent
                                         and Consultation. Neither Party shall settle any claim or demand in any such litigation
                                         admitting the invalidity or non-infringement of the other Party’s Patent Rights
                                         (for clarity, including Joint Patent Rights), or otherwise materially negatively impacting
                                         the other Party’s rights or interests under this Agreement without the prior written
                                         consent of the other Party, which consent shall not be unreasonably withheld or delayed.
                                         In addition to the foregoing, to the extent any action initiated by Genmab involves any
                                         infringement of CureVac Patent Rights, Genmab will consult with CureVac regarding issues
                                         relating to such CureVac Patent Rights, and take CureVac’s input into good faith
                                         consideration.

 

    79

     

    

 

		12.7	Defense
                                         and Settlement of Third Party Claims.

 

		12.7.1	If
                                         the Development, Manufacture or Commercialization of any Program Antibody, Program Antibody
                                         Combination or Product in any country in accordance with this Agreement or other activity
                                         of either of the Parties pursuant to the Agreement is alleged by a Third Party to infringe
                                         a Third Party’s Patent Right, the Party becoming aware of such allegation shall
                                         promptly notify the other Party. CureVac has the first right, but not the obligation,
                                         to control any defense of any such claim involving alleged infringement of Third Party
                                         rights by CureVac’s activities under any Program at its own expense and by counsel
                                         of its own choice, and Genmab may, at its own expense, choose to be represented in any
                                         such action by counsel of its own choice. Genmab has the sole right to control any defense
                                         of any such claim involving alleged infringement of Third Party rights by Genmab’s
                                         activities under the Program at its own expense and by counsel of its own choice, and
                                         CureVac may, at its own expense, choose to be represented in any such action by counsel
                                         of its own choice. Neither Party may settle any patent infringement litigation under
                                         this Section 12.7.1 in a manner that admits the invalidity or unenforceability of the
                                         other Party’s Patent Rights or Joint Patent Rights or imposes on the other Party
                                         restrictions or obligations or other liabilities, without the written consent of such
                                         other Party, which consent shall not be unreasonably withheld. Notwithstanding the above,
                                         with respect to any Opt-In Product, the Parties shall mutually agree on a common strategy
                                         for the defense of any such claim involving alleged infringement of Third Party rights.

 

		12.7.2	If
                                         a Third Party sues Genmab or CureVac or any of their Affiliates, distributors or permitted
                                         Sublicensees alleging that Genmab’s practice of a right granted by CureVac to Genmab
                                         hereunder through the Development, Manufacture and/or Commercialization of any Program
                                         Antibody, Program Antibody Combination or Product pursuant to this Agreement infringes
                                         or will infringe said Third Party’s Patent Rights, then, upon the defending Party’s
                                         request and in connection with the defense of any such Third Party infringement suit,
                                         the non-defending Party shall provide reasonable assistance to the defending Party for
                                         such defense and/or shall join in any such action if reasonably required by the defending
                                         Party in order to defend such claim or to assert all available defenses and claims, and
                                         to cooperate reasonably with the defending Party. The defending Party shall not enter
                                         into a settlement that imposes a financial obligation upon the non-defending Party or
                                         which limits the scope or invalidates any Patent Right of either Party without such Party’s
                                         prior written consent, which consent shall not be unreasonably withheld or delayed, and
                                         in any settlement the defending Party shall always take into consideration the interest
                                         of the non-defending Party.

 

		12.8	Common
                                         Interest Disclosures. With regard to any information (including materials) disclosed
                                         pursuant to this Agreement by one Party to the other Party regarding intellectual property
                                         rights owned or controlled by Third Parties, the Parties agree that they have a common
                                         legal interest in determining whether, and to what extent, Third Party intellectual property
                                         rights may affect the Development, Manufacturing and/or Commercialization of any Product,
                                         and have a further common legal interest in defending against any actual or prospective
                                         Third Party claims based on allegations of misuse or infringement of intellectual property
                                         rights relating to the Development, Manufacturing and/or Commercialization of any Product.
                                         Accordingly, the Parties agree that all such information obtained by one Party from the
                                         other Party will be used solely for purposes of the Parties’ common legal interests
                                         with respect to the conduct of this Agreement. All information will be treated as protected
                                         by the attorney-client privilege, the work product privilege, and any other privilege
                                         or immunity that may otherwise be applicable. By sharing any information, neither Party
                                         intends to waive or limit any privilege or immunity that may apply to the shared information.
                                         Neither Party shall have the authority to waive any privilege or immunity on behalf of
                                         the other Party without such other Party’s prior written consent, nor shall the
                                         waiver of privilege or immunity resulting from the conduct of one Party be deemed to
                                         apply against any other Party.

 

    80

     

    

 

		13.	CONFIDENTIALITY.

 

		13.1	Obligation
                                         of Confidentiality. As of and after the Effective Date, all Confidential Information
                                         disclosed, revealed or otherwise made available to one Party or its Affiliates (“Receiving
                                         Party”) by or on behalf of the other Party (“Disclosing Party”)
                                         under, or as a result of, this Agreement is made available to the Receiving Party solely
                                         to permit the Receiving Party to exercise its rights, and perform its obligations, under
                                         this Agreement. The Receiving Party shall not use any of the Disclosing Party’s
                                         Confidential Information for any other purpose, and shall not disclose, reveal or otherwise
                                         make any of the Disclosing Party’s Confidential Information available to any other
                                         person, firm, corporation or other entity, without the prior written authorization of
                                         the Disclosing Party, except as explicitly stated in this Article 13.

 

		13.2	Additional
                                         Obligations.

 

		13.2.1	Appropriate
                                         Safeguards. In furtherance of the Receiving Party’s obligations under Section
                                         13.1 hereof, the Receiving Party shall take all reasonable steps, and shall implement
                                         all appropriate and reasonable safeguards, to seek to prevent the unauthorized use or
                                         disclosure of any of the Disclosing Party’s Confidential Information.

 

		13.2.2	Unauthorized
                                         Use or Disclosure. The Receiving Party shall furnish the Disclosing Party with written
                                         notice immediately of it becoming aware and indicating details of any unauthorized use
                                         or disclosure of any of the Disclosing Party’s Confidential Information by any
                                         employee, officer, director, consultant, CRO, CMO, contractors, agent(s), consultant(s),
                                         and Sublicensees (in the case of Genmab), or Financial Partner of/the Receiving Party,
                                         and shall take all actions reasonably required in order to prevent any further unauthorized
                                         use or disclosure of the Disclosing Party’s Confidential Information. Notwithstanding
                                         the foregoing, the Receiving Party remains responsible and liable for any unauthorized
                                         use by any employee, officer, director, consultant, CRO, CMO, contractors, agent(s),
                                         consultant(s), and Sublicensees (in the case of Genmab), or Financial Partner of the
                                         Receiving Party.

 

		13.3	Limitations.
                                         The Receiving Party’s obligations under Sections 13.1 shall not apply to the
                                         extent that the Receiving Party can demonstrate by competent written evidence that any
                                         of the Disclosing Party’s Confidential Information:

 

		(i)	is
                                         known by the Receiving Party at the time of its receipt, and not through a prior disclosure
                                         by or on behalf of the Disclosing Party;

 

		(ii)	is
                                         in the public domain by use and/or publication before its receipt from the Disclosing
                                         Party, or thereafter enters the public domain through no fault of the Receiving Party;

 

    81

     

    

 

		(iii)	is
                                         subsequently disclosed to the Receiving Party by a Third Party who may lawfully do so
                                         and is not under an obligation of confidentiality regarding the Confidential Information;
                                         or

 

		(iv)	is
                                         developed by the Receiving Party independently of Confidential Information or material
                                         received from the Disclosing Party.

 

		13.4	Authorized
                                         Disclosures.

 

		13.4.1	Necessary
                                         Disclosures. Each Party may disclose the other Party’s Confidential Information
                                         as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably
                                         necessary in the following instances:

 

		(i)	disclosure
                                         to judicial, governmental or other regulatory agencies or authorities in connection with
                                         the filing, prosecution, maintenance and defense of Patent Rights as permitted by this
                                         Agreement;

 

		(ii)	disclosure
                                         to judicial, governmental or other regulatory agencies or authorities to gain or maintain
                                         approval, authorizations or the like to Develop, Manufacture or Commercialize a given
                                         Product that such Party has a license or right to Develop, Manufacture or Commercialize
                                         hereunder in a given country or jurisdiction;

 

		(iii)	prosecuting
                                         or defending litigation as permitted by this Agreement;

 

		(iv)	disclosure
                                         to its and its Affiliates’ employees, officers, directors, consultants, CROs, CMOs,
                                         contractors, agent(s), consultant(s), and to Sublicensees (in the case of Genmab), in
                                         each case on a need-to-know basis for the purposes as expressly authorized and contemplated
                                         by this Agreement, including for the Development, Manufacturing and/or Commercialization
                                         of the Program Antibodies or Products (or for such entities to determine their interest
                                         in performing such activities) in accordance with this Agreement, on the condition that
                                         such Affiliates or Third Parties agree to be bound by confidentiality and non-use obligations
                                         that substantially are no less stringent than those confidentiality and non-use provisions
                                         contained in this Agreement;

 

		(v)	disclosure
                                         to such Party’s attorneys, independent accountants or financial advisors for the
                                         sole purpose of enabling such attorneys, independent accountants or financial advisors
                                         to provide advice to the Receiving Party, on the condition that such attorneys, independent
                                         accountants and financial advisors agree to be bound by the confidentiality and non-use
                                         obligations contained in this Agreement; or

 

		(vi)	disclosure
                                         to any bona fide potential or actual investor, insurer, acquirer, merger partner, Sub-Licensee
                                         (in the case of Genmab) or other bona fide potential or actual financial partner or funding
                                         source (“Financial Partner”) solely for the purpose of evaluating
                                         or carrying out an actual or potential investment, acquisition, license or collaboration,
                                         and to any related persons directly connected with such activity being contemplated with
                                         the Financial Partner, such as an advisory firm or investment bank; provided that in
                                         connection with such disclosure, the Disclosing Party shall inform each disclosee of
                                         the confidential nature of such Confidential Information and disclosure shall be subject
                                         to the agreement of each disclosee to be bound by confidentiality and non-use obligations
                                         that substantially are no less stringent than those confidentiality and non-use provisions
                                         contained in this Agreement.

 

    82

     

    

 

		13.4.2	Required
                                         Disclosures. If a Party is required by judicial, governmental or administrative process,
                                         including to comply with Applicable Laws (including stock exchange rules) or pursuant
                                         to Section 13.4.1(iii), to disclose Confidential Information that is subject to the non-disclosure
                                         provisions of Section 13.1, such Party shall to the extent reasonably possible provide
                                         the other Party with reasonable advance notice of the disclosure that is being sought
                                         in order to provide the other Party an opportunity to challenge or limit the disclosure
                                         obligations. Confidential Information that is disclosed by judicial, governmental or
                                         administrative process shall remain otherwise subject to the confidentiality and non-use
                                         provisions of this Article 13, and the Party disclosing Confidential Information pursuant
                                         to judicial, governmental or administrative process shall take all steps reasonably necessary,
                                         including without limitation to seek an order of confidentiality, to ensure the continued
                                         confidential treatment of such Confidential Information.

 

		13.4.3	Disclosure
                                         to the LNP Technology provider. [*****] solely to the extent required under the agreement
                                         between the LNP Technology provider and CureVac, and in any case provided that such LNP
                                         Technology provider agrees to be bound by confidentiality and non-use obligations that
                                         substantially are no less stringent than those confidentiality and non-use provisions
                                         contained in this Agreement.

 

		13.4.4	Disclosure to a sublicensee of CureVac of the rights granted in Section 11.6. [*****].
                                                                                                                                                      For avoidance of doubt, CureVac may not disclose any other Confidential Information of Genmab to such sublicensee, including
                                                                                                                                                      Genmab Know-How relating to such Generally Applicable Patent Rights which is not disclosed in said Patent Rights.

 

		13.5	Survival.
                                         All of the Receiving Party’s obligations under this Article 13 hereof, with
                                         respect to the protection of the Disclosing Party’s Confidential Information, shall
                                         for a period of [*****] survive the expiration or termination of this Agreement for any
                                         reason whatsoever.

 

    83

     

    

 

		13.6	Public
                                         Announcements, Press Releases. The Parties shall issue a press release in the form
                                         attached hereto as Exhibit 13.6 at an agreed time promptly after the Effective
                                         Date. Thereafter, except as otherwise expressly permitted in this Agreement, and except
                                         as may be required by Applicable Law, including the listing standards or agreements of
                                         any national or international securities exchange, neither Party shall issue any press
                                         release or public statement disclosing information relating to this Agreement or the
                                         transactions contemplated hereby or the terms hereof without the prior written consent
                                         of the other Party, not to be unreasonably withheld, conditioned, or delayed; provided,
                                         that notwithstanding the foregoing, to the extent reasonably possible on prior notice
                                         to CureVac, and in reasonable time for CureVac to consider if the content requires an
                                         announcement by CureVac, Genmab may make disclosures relating to the development or commercialization
                                         of a Product, including publication of the results of research or development activities,
                                         any clinical trial conducted on a Product whether or not conducted by Genmab, Regulatory
                                         Filings, Regulatory Approvals or any health or safety matter related to a Product. For
                                         all other public disclosures, subject to Section 13.7, if either Party desires to issue
                                         a press release or other public statement disclosing information relating to this Agreement
                                         or the transactions contemplated hereby or the terms hereof, the issuing Party will provide
                                         the other Party with a copy of the proposed press release or public statement. The issuing
                                         Party shall specify with each such proposed press release or public statement, taking
                                         into account the urgency of the matter being disclosed, a reasonable period of time within
                                         which the Receiving Party may provide any comments on such proposed press release or
                                         public statement (but in no event less than [*****], unless reasonably necessary to comply
                                         with Applicable Law). If the reviewing Party provides any comments, the Parties will
                                         consult on such proposed press release or public statement and work in good faith to
                                         prepare a mutually acceptable proposed press release or public statement. For avoidance
                                         of doubt, neither Party may make such other public disclosure without the other Party’s
                                         prior written consent, unless reasonably necessary to comply with any Applicable Law.
                                         Each Party may repeat any information relating to this Agreement that has already been
                                         publicly disclosed in accordance with this Section 13.6, provided such information continues
                                         as of such time to be accurate.

 

		13.7	Publication.
                                         With respect to any paper or presentation proposed for disclosure by Genmab that
                                         includes Confidential Information of CureVac (excluding any information that falls under
                                         the exceptions of Section 13.6), CureVac may review and comment and approve any such
                                         proposed paper or presentation, such approval not to be unreasonably withheld, conditioned,
                                         or delayed. Genmab shall submit to CureVac the proposed publication or presentation (including
                                         posters, slides, abstracts, manuscripts, marketing materials and written descriptions
                                         of oral presentations) at least [*****] prior to the date of submission for publication
                                         or the date of presentation, whichever is earlier, of any of such submitted materials.
                                         CureVac shall review such submitted materials and respond to Genmab as soon as reasonably
                                         possible, but in any case, within [*****] ([*****]) after receipt thereof. [*****]. For avoidance of doubt,
                                         CureVac shall not make any publication without Genmab’s prior written consent.

 

    84

     

    

 

		14.	INDEMNIFICATION
                                         AND REPRESENTATIONS AND WARRANTIES.

 

		14.1	Indemnification by Genmab. Genmab will defend, indemnify and hold CureVac and its
                                                                                                                                                    Affiliates and their directors, officers, employees, consultants, agents and contractors (the “CureVac Indemnified
                                                                                                                                                    Parties”) harmless from and against [*****] resulting or arising from (A) [*****] (B) [*****] or (iii) [*****]; except, in each case, to the extent caused
                                                                                                                                                    by the negligence or willful misconduct of any of the CureVac Indemnified Parties. CureVac will give Genmab prompt notice of
                                                                                                                                                    any such claim or lawsuit. Such notice shall include a reasonable identification of the alleged facts giving rise to such
                                                                                                                                                    claim for indemnification. The failure to deliver written notice to CureVac within a reasonable time after the commencement
                                                                                                                                                    of any action with respect to a claim shall only relieve CureVac of its indemnification obligations if and to the extent
                                                                                                                                                    CureVac is actually and materially prejudiced thereby. Without limiting the foregoing indemnity, Genmab will have the right
                                                                                                                                                    to compromise, settle or defend any such claim or lawsuit (to the extent subject to indemnity by Genmab as set forth herein);
                                                                                                                                                    provided that (i) no offer of settlement, settlement or compromise by Genmab shall be binding on CureVac without its prior
                                                                                                                                                    written consent, not to be unreasonably withheld, conditioned or delayed, unless such settlement fully releases CureVac
                                                                                                                                                    without any liability, loss, cost or obligation incurred by CureVac and in no event shall any settlement or compromise admit
                                                                                                                                                    or concede that any aspect of any of the CureVac Patent Rights, CureVac Other Invention Patent Rights or the Joint Patent
                                                                                                                                                    Rights is invalid or unenforceable or adversely affect the scope of any of the CureVac Patent Rights, CureVac Other Invention
                                                                                                                                                    Patent Rights or the Joint Patent Rights; and (ii) Genmab shall not have authority to admit any wrongdoing or misconduct on
                                                                                                                                                    the part of CureVac Indemnified Parties, any licensor of LNP Technology or contractors except with CureVac’s prior
                                                                                                                                                    written consent.

 

		14.2	Indemnification by CureVac. CureVac will defend, indemnify and hold Genmab and its
                                                                                                                                                    Affiliates and their directors, officers, employees, consultants, agents, Sublicensees and contractors (the “Genmab
                                                                                                                                                    Indemnified Parties”) harmless from and against any and all losses, liabilities, claims, suits, proceedings,
                                                                                                                                                    expenses, fees, recoveries and damages, including reasonable legal expenses and costs including attorneys’ fees,
                                                                                                                                                    resulting or arising out of any claim by any Third Party resulting or arising from (i) [*****] or (ii) [*****] or (iii)
                                                                                                                                                    [*****] except, in each case, to the extent caused by the negligence or willful misconduct of any of the Genmab Indemnified
                                                                                                                                                    Parties. Genmab will give CureVac prompt notice of any such claim or lawsuit. Such notice shall include a reasonable
                                                                                                                                                    identification of the alleged facts giving rise to such claim for indemnification. The failure to deliver written notice to
                                                                                                                                                    CureVac within a reasonable time after the commencement of any action with respect to a claim shall only relieve CureVac of
                                                                                                                                                    its indemnification obligations if and to the extent CureVac is actually and materially prejudiced thereby. Without limiting
                                                                                                                                                    the foregoing indemnity, CureVac will have the right to compromise, settle or defend any such claim or lawsuit (to the extent
                                                                                                                                                    subject to indemnity by CureVac as set forth herein); provided that (A) no offer of settlement, settlement or compromise by
                                                                                                                                                    CureVac shall be binding on Genmab without its prior written consent, not to be unreasonably withheld, conditioned or
                                                                                                                                                    delayed, unless such settlement fully releases Genmab without any liability, loss, cost or obligation incurred by Genmab and
                                                                                                                                                    in no event shall any settlement or compromise admit or concede that any aspect of any of the Genmab Program Patent Rights,
                                                                                                                                                    Genmab Other Patent Rights or the Joint Patent Rights is invalid or unenforceable or adversely affect the scope of any of the
                                                                                                                                                    Genmab Program Patent Rights, Genmab Other Patent Rights or the Joint Patent Rights; and (B) CureVac shall not have authority
                                                                                                                                                    to admit any wrongdoing or misconduct on the part of any Genmab Indemnified Parties except with Genmab’s prior written
                                                                                                                                                    consent.

 

    85

     

    

 

		14.3	Additional
                                         Indemnification Procedures. The indemnifying Party shall notify the indemnified Party
                                         of its intentions as to the defense of the claim in writing within [*****] after the
                                         indemnifying Party’s receipt of notice of the claim from the indemnified Party.
                                         If the indemnifying Party assumes the defense of a claim against an indemnified Party,
                                         the indemnifying Party shall have no obligation or liability under this Article 14 as
                                         to any claim for which settlement or compromise of such claim or an offer of settlement
                                         or compromise of such claim is made by the indemnified Party without the prior written
                                         consent of the indemnifying Party. The indemnified Party shall reasonably cooperate with
                                         the indemnifying Party in its defense of the claim (including copying and making documents
                                         and records available for review and making persons within its control available for
                                         pertinent testimony in accordance with the confidentiality provisions of Article 14)
                                         at the indemnifying Party’s reasonable, pre-approved expense. If the indemnifying
                                         Party assumes defense of the claim, the indemnified Party may participate in, but not
                                         control, the defense of such claim using attorneys of its choice and at its sole cost
                                         and expense (i.e., with such cost and expense not being covered by the indemnifying Party).
                                         If the indemnifying Party does not agree to assume the defense of the claim asserted
                                         against the indemnified Party (or does not give notice that it is assuming such defense),
                                         or if the indemnifying Party assumes the defense of the Claim in accordance with this
                                         Section 14.3, but yet fails to defend or take other reasonable, timely action, in response
                                         to such claim asserted against the indemnified Party, the indemnified Party shall have
                                         the right to defend or take other reasonable action to defend its interests in such proceedings,
                                         and shall have the right to litigate, settle or otherwise dispose of any such claim;
                                         provided, however, that no Party shall have the right to settle a claim in a manner
                                         that would adversely affect the rights granted to the other Party hereunder, or would
                                         materially conflict with this Agreement, without the prior written consent of the Party
                                         entitled to control the defense of such claim, which consent shall not be unreasonably
                                         withheld, delayed or conditioned.

 

		14.4	CureVac
                                         Representations and Warranties. Subject to the disclosures in the attached Exhibit
                                         14.4 (“Disclosure Letter”) CureVac represents and warrants to Genmab
                                         as of the Effective Date that:

 

		(i)	it
                                         is the sole and exclusive owner of the Patent Rights listed in Exhibit 1.59;

 

		(ii)	to
                                         CureVac’s knowledge, all inventors have assigned their rights to the Patent Rights
                                         listed in Exhibit 1.59 to CureVac, and there have been no inventorship or ownership
                                         challenges with respect to these Patent Rights;

 

		(iii)	CureVac
                                         has the full right, power and authority to grant the rights and licenses it purports
                                         to grant hereunder, and neither CureVac nor any of its Affiliates has granted any Third
                                         Party any rights or licenses that would interfere or be inconsistent with Genmab’s
                                         rights and licenses hereunder;

 

    86

     

    

 

		(iv)	to
                                         CureVac’s knowledge, use of the CureVac Technology by Genmab in accordance with
                                         the terms of this Agreement, including Genmab’s further Development, Manufacturing
                                         and/or Commercialization of each Product will not infringe on the rights of any Third
                                         Party, including any Third Party intellectual property rights;

 

		(v)	to
                                         CureVac’s knowledge, CureVac has received no written notice of or any written demand
                                         relating to any threatened or pending litigation which would reasonably lead it to believe
                                         that Genmab’s exercise of any rights granted by CureVac under this Agreement in
                                         respect of the CureVac Technology will infringe any Patent Rights or misappropriate other
                                         intellectual property right of any Third Party;

 

		(vi)	to
                                         CureVac’s knowledge, CureVac has received no currently pending administrative proceedings
                                         or litigation or threatened administrative proceedings or litigation seeking to invalidate
                                         or otherwise challenge any Curevac Patent Right(s);

 

		(vii)	CureVac
                                         has not given any written notice to any Third Party asserting infringement by such Third
                                         Party of any of the CureVac Technology and, to CureVac’s knowledge, there is no
                                         unauthorized use, infringement or misappropriation of the CureVac Technology;

 

		(viii)	CureVac
                                         Controls all right, title and interest in and to the CureVac Technology;

 

		(ix)	The
                                         CureVac Technology is free and clear of all encumbrances, security interests, options,
                                         and charges of any kind;

 

		(x)	To
                                         CureVac’s knowledge, the CVCMs are not required for the Development, Manufacture
                                         or Commercialization of Products under this Agreement;

 

		(xi)	CureVac
                                         has provided to Genmab an accurate, current copy of the BioNTech License and Roche License,
                                         respectively, and it will not without Genmab’s prior written consent amend the
                                         BioNTech License or Roche License in any way that may have an adverse effect on the licenses
                                         granted to Genmab herein;

 

		(xii)	CureVac
                                         has provided to Genmab accurate, current and redacted copies via the data room of (i)
                                         the Acuitas License and (ii) the Arcturus License and (iii) License Agreement for [*****]
                                         between CureVac AG and GeneArt AG dated [*****] including any amendments thereto; and
                                         (iv) Licensed Agreement between CureVac AG and TriLink Biotechnologies LLC, including
                                         any amendments thereto; and CureVac will not without Genmab’s prior written consent
                                         amend or terminate any of these agreements in any way that may have an adverse effect
                                         on the licenses granted to Genmab herein; and

 

    87

     

    

 

		(xiii)	to
                                         CureVac’s knowledge, CureVac is not in material breach of the Acuitas License or
                                         Arcturus License, there is no current dispute under the Acuitas License or Arcturus License
                                         and any such agreement is in full force and effect in accordance with its terms.

 

		14.5	Genmab
                                         Representations and Warranties. Genmab represents and warrants to CureVac that at
                                         the time of [*****]. For avoidance
                                         of doubt, such representation and warranty shall only apply with respect to the Antibody
                                         or Antibody Combination to be included in the Product and shall not apply to any Curevac
                                         Technology, Other Technology or LNP Technology.

 

		14.6	Representations,
                                         Warranties of the Parties to Each Other. CureVac and Genmab each represents and warrants
                                         and covenants with respect to itself only as of the Effective Date that:

 

		(i)	the
                                         execution, delivery and performance of this Agreement have been duly authorized by all
                                         necessary action on the part of such Party, its officers and directors, and does not
                                         conflict with, violate, or breach any agreement to which such Party is a party, or such
                                         Party’s corporate charter, bylaws or similar organizational documents;

 

		(ii)	this
                                         Agreement constitutes a legal, valid and binding obligation of such Party that is enforceable
                                         against it in accordance with its terms, except as such enforceability may be limited
                                         by general principles of equity or to applicable competition, bankruptcy, insolvency,
                                         reorganization, moratorium, liquidation and other similar laws relating to, or affecting
                                         generally, the enforcement of applicable creditors’ rights and remedies;

 

		(iii)	it
                                         is a company or corporation duly organized, validly existing, and in good standing under
                                         the laws of the jurisdiction in which it is incorporated;

 

		(iv)	it
                                         has not, and will not, after the Effective Date and during the Term, grant any right
                                         to any Third Party that would conflict with the rights granted to the other Party hereunder
                                         (but only while such rights remain in effect in accordance with the terms of this Agreement);
                                         and

 

		(v)	it
                                         has not, and will not, after the Effective Date and during the Term, knowingly use any
                                         employee, agent, contractor or consultant in connection with the Development or Commercialization
                                         of Products who has been debarred by any governmental authority, or, to such Party’s
                                         knowledge, is the subject of debarment proceedings by a governmental authority.

 

		14.7	Compliance
                                         with Law. Each Party shall comply with all Applicable Laws in its performance of
                                         activities contemplated under this Agreement.

 

    88

     

    

 

		14.8	Diligence
                                         of Genmab. [*****]. CureVac acknowledges and agrees that it has provided all information
                                         relating to CureVac Technology that CureVac reasonable believes is necessary for Genmab
                                         to conduct and complete a proper due diligence relating to the Collaboration Targets
                                         and Products, and that it has answered truthfully to all questions of Genmab relating
                                         to the due diligence of the CureVac Technology.

 

		14.9	Disclaimer
                                         THE REPRESENTATIONS AND WARRANTIES OF THE PARTIES SET FORTH IN THIS AGREEMENT ARE
                                         THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES OF THE PARTIES RELATING TO OR MADE
                                         IN CONNECTION WITH THIS AGREEMENT, AND NEITHER PARTY MAKES OR HAS MADE ANY REPRESENTATIONS
                                         OR WARRANTIES NOT EXPRESSLY SET FORTH IN THIS AGREEMENT. CUREVAC AND GENMAB ARE NOT RELYING
                                         ON, AND EACH HEREBY DISCLAIMS, ALL REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY CONTAINED
                                         HEREIN (WHETHER EXPRESS OR IMPLIED), INCLUDING WITH RESPECT TO EACH OF THEIR RESEARCH,
                                         DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, WHETHER THE PRODUCTS CAN BE SUCCESSFULLY
                                         DEVELOPED OR MARKETED, THE ACCURACY, PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL
                                         OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR
                                         PURPOSE WHATSOEVER OF THE PRODUCTS, OR THE NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL
                                         PROPERTY RIGHTS.

 

		14.10	Limitation
                                         of Liability. IN NO EVENT SHALL EITHER CUREVAC OR GENMAB BE LIABLE FOR REMOTE, SPECULATIVE,
                                         PUNITIVE OR EXEMPLARY, OR OTHER SPECIAL DAMAGES, INCLUDING LOST PROFITS, ARISING OUT
                                         OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY (OTHER THAN (A) PUNITIVE
                                         OR EXEMPLARY DAMAGES REQUIRED TO BE PAID TO (I) A THIRD PARTY PURSUANT TO A NON-APPEALABLE
                                         ORDER OF A COURT OF COMPETENT JURISDICTION IN CONNECTION WITH A THIRD PARTY CLAIM FOR
                                         WHICH THE INDEMNIFIED PARTY IS ENTITLED TO INDEMNIFICATION HEREUNDER OR (II) A PARTY
                                         PURSUANT TO A NON-APPEALABLE ORDER OF A COURT OF COMPETENT JURISDICTION IN CONNECTION
                                         WITH A VIOLATION OF PATENT OR OTHER INTELLECTUAL PROPERTY RIGHTS, (B) SUCH DAMAGES ARISING
                                         OUT OF ANY BREACH OF ARTICLE 13 OR (C) SUCH DAMAGES ARISING OUT OF THE GROSS NEGLIGENCE
                                         OR WILLFUL MISCONDUCT OF THE LIABLE PARTY). Notwithstanding the foregoing, it is expressly
                                         understood and agreed that nothing contained in this Section 14.10 shall limit, alter,
                                         or waive in any manner or respect any defenses available to any Person, any burdens of
                                         proof or legal standards required to be met by any Person under Applicable Laws or any
                                         indemnification rights or obligations of either Party.

 

    89

     

    

 

 

		15.	TERM
                                         AND TERMINATION.

 

		15.1	Term.
                                         The term of this Agreement will commence on the Effective Date and end on the expiration
                                         of all applicable royalty payment obligations to CureVac under this Agreement, unless
                                         terminated earlier according to the terms and conditions of this Agreement (“Term”).
                                         Upon expiry of this Agreement in a country and provided and to the extent that this Agreement
                                         is not terminated after such expiry by CureVac in accordance with Sections 15.4 and 15.5,
                                         Genmab’s licenses under Article 2 for such country shall become a fully paid-up,
                                         perpetual, and non-exclusive license.

 

		15.2	Termination
                                         by CureVac. CureVac is entitled to terminate this Agreement in its entirety, if Genmab
                                         has not made a Product Selection in relation to the First Collaboration Program within
                                         [*****] after the Effective Date or has not exercised an Option within the Option Period.

 

		15.3	Termination
                                         at Will by Genmab. Genmab may terminate this Agreement in its entirety or on a Program-by-Program
                                         (excluding any Opt-In Program), at any time without cause upon (i) [*****] prior written
                                         notice to CureVac before the end of the last to expire Research Period (to be determined
                                         on a Program-by-Program basis or (ii) upon [*****] prior written notice to CureVac after
                                         the end of the last to expire Research Period (to be determined on a Program-by-Program
                                         basis). In the event Genmab decides to cease permanently the further research and Development
                                         under the First Collaboration Program, or under any Other Pre-IND Program, including
                                         the Development of a Product resulting from any such Program, it shall promptly inform
                                         the JRC or Collaboration Committee, as applicable, hereof for discussion with the JRC/Collaboration
                                         Committee, and unless otherwise agreed within the JRC/Collaboration Committee, Genmab
                                         shall terminate this Agreement with respect to the First Collaboration Target and First
                                         Program Antibody, or the Optioned Target and respective Other Program Antibody, as applicable.
                                         For the termination of an Opt-In Program the terms and conditions of Sections 7.8 and
                                         7.9 shall apply. During such termination periods, as applicable, the Parties shall cooperate
                                         in the wind down of activities under this Agreement or under the Program being terminated
                                         in a commercially reasonable manner.

 

		15.4	Termination
                                         for Cause by Either Party. In the event that either Party (“Breaching Party”)
                                         commits a material breach or default of any of its obligations hereunder of a general
                                         nature under this Agreement or in relation to any specific Program (“Program
                                         Breach”) the other Party hereto (“Non-Breaching Party”)
                                         may give the Breaching Party written notice of such material breach or default, and shall
                                         request that such material breach or default be cured as soon as reasonably practicable.
                                         In the event that the Breaching Party fails to cure such breach or default within [*****] after
                                         the date of the Non-Breaching Party’s written notice thereof (in the event of default
                                         of payment within [*****] after the date of the Non- Breaching Party’s notice),
                                         the Non-Breaching Party may (i) terminate this Agreement in the event of a material breach
                                         of general nature; or (ii) terminate the Program in the case of a Program Breach, by
                                         giving written notice of termination to the Breaching Party. In the event the Breaching
                                         Party indicates in writing that it will be unable or is unwilling to cure the breach,
                                         this Agreement or the Program, as applicable, may be terminated by the Non-Breaching
                                         Party with immediate effect. If following the Commercialization of a Product the breach
                                         relates to one country only or a group of countries of the Territory the Non-Breaching
                                         Party shall only have the right to terminate this Agreement in relation to such country
                                         or countries. If the Breaching Party in good faith disputes such material breach or disputes
                                         the failure to cure or remedy such material breach and provides written notice of that
                                         dispute to the Non-Breaching Party within the [*****] period, then the matter will be
                                         addressed under the dispute resolution provisions in Section 17.5, and the Non-Breaching
                                         Party may not terminate this Agreement, or the Program as applicable, until it has been
                                         determined under such dispute resolution procedure that the Non-Breaching Party is in
                                         material breach of this Agreement or has committed a Program Breach, as the case may
                                         be. Termination of this Agreement in accordance with this Section 15.4 shall not affect
                                         or impair the Non-Breaching Party’s right to pursue any legal remedy, including
                                         the right to recover damages, for any harm suffered or incurred by the Non-Breaching
                                         Party as a result of such breach or default.

 

    90

     

    

 

		15.5	[*****].

 

		15.6	Termination
                                         Generally. The termination of the Agreement in whole or in part under this Section
                                         15 shall not create any obligations to undo or refund (in Dutch “ongedaanmakingsverbintenissen”)
                                         services rendered and payments made in accordance with the Agreement prior to the effective
                                         date of the termination.

 

		16.	CONSEQUENCES
                                         OF TERMINATION.

 

		16.1	Termination
                                         Due to CureVac’s Breach. If Genmab terminates this Agreement or a Program under
                                         Section 15.3, the rights and obligations of the Parties hereunder shall terminate (either
                                         in their entirety or in relation to the particular Program) as of the effective date
                                         of such termination and there shall be the following consequences (to be interpreted
                                         on a Program basis in the event of termination of a Program)

 

		(i)	no
                                         later than [*****] after the effective date of such termination, each Party shall return
                                         or cause to be returned to the other Party or, at the other Party’s option, destroy
                                         (and certify in writing the destruction of) all Confidential Information in tangible
                                         form received from the other Party and all copies in any medium thereof; provided,
                                         however, that each Party may retain any Confidential Information reasonably necessary
                                         for such Party’s continued practice under any license(s) which do not terminate
                                         pursuant to this Section 16.1, and may retain the Confidential Information solely for
                                         the purpose of ensuring its compliance with this Agreement and Applicable Law by electronic
                                         files created in the ordinary course of business during automatic system back-up procedures
                                         pursuant to its electronic record retention and destruction practices that apply to its
                                         own general electronic files and information so long as such electronic files are (A)
                                         maintained only on centralized storage servers (and not on personal computers or devices),
                                         (B) not accessible by any of its personnel (other than its information technology specialists),
                                         and (C) are not otherwise accessed subsequently except with the written consent of the
                                         other Party or as required by law. Such retained copies of documents and Confidential
                                         Information shall remain subject to the confidentiality and non-use obligations set forth
                                         in this Agreement;

 

    91

     

    

 

		(ii)	Subject
                                         to Section 16.1(iii) below CureVac shall, within [*****] after the effective date of
                                         such termination return or cause to be returned to Genmab all substances or compositions
                                         delivered or provided by Genmab, as well as any other Genmab Material provided by Genmab
                                         in any medium;

 

		(iii)	each
                                         Party shall pay all amounts then due and owing as of the termination effective date;

 

		(iv)	CureVac
                                         shall provide access to Genmab, to the extent not previously provided, to the CureVac
                                         Know-How (other than the Know-How included in the CureVac Manufacturing Technology) in
                                         its possession or under its Control relating to the Collaboration Targets and Products;

 

		(v)	Unless
                                         otherwise explicitly agreed in the Early Clinical Supply Agreement or any MSA, termination
                                         shall not affect the operation of the Early Clinical Supply Agreement or any MSA;

 

		(vi)	effective
                                         only in the event of such termination, CureVac hereby grants to Genmab an exclusive (even
                                         as to CureVac) and sublicensable license in the Field and in the Territory under the
                                         CureVac Technology to Develop, Manufacture and Commercialize any Products identified
                                         prior to termination, provided, however, that any payment obligations under Article
                                         10 shall survive the termination of the Agreement in consideration for the exclusive
                                         license of Genmab under this Section 16.1(vi); and

 

		(vii)	except
                                         as set forth in this Section 16.1 and for the surviving provisions set forth in Section
                                         16.3 below, the rights and obligations of the Parties hereunder shall terminate.

 

For the avoidance of doubt,
the rights and obligations of Genmab and CureVac under this Section 16.1 in the event of a termination due to CureVac’s
breach shall not exceed or be in any way broader than the rights and obligation of Genmab and CureVac under the Agreement.

 

		16.2	Termination
                                         Due to Genmab’s Breach under 15.4, [*****], CureVac’s termination under Section 15.2 or Genmab’s termination
                                         under Section 15.3. If CureVac terminates this Agreement as a whole or with respect
                                         to a specific Program under Sections 15.2, 15.4 or 15.5, or if Genmab terminates this
                                         Agreement as a whole or with respect to a specific Program under Section 15.3, the rights
                                         and obligations of the Parties hereunder with respect to the specific Program or all
                                         Programs, as the case may be, shall terminate as of the effective date of such termination
                                         and:

 

    92

     

    

 

		(i)	Genmab’s
                                         licenses under Article 2 of this Agreement and any sub-licenses under Article 4 shall
                                         automatically lapse and all of CureVac’s rights to the CureVac Technology automatically
                                         revert back to CureVac;

 

		(ii)	no
                                         later than [*****] after the effective date of such termination, each Party shall return
                                         or cause to be returned to the other Party or, at the other Party’s option, destroy
                                         (and certify in writing the destruction of), all Confidential Information of the Disclosing
                                         Party in tangible form received from the other Party and all copies in any medium thereof;
                                         provided, however, that each Party may retain any Confidential Information reasonably
                                         necessary for such Party’s continued practice under any license(s) which do not
                                         terminate pursuant to this Article 16, and may retain the Confidential Information solely
                                         for the purpose of ensuring its compliance with this Agreement and Applicable Law by
                                         electronic files created in the ordinary course of business during automatic system back-up
                                         procedures pursuant to its electronic record retention and destruction practices that
                                         apply to its own general electronic files and information so long as such electronic
                                         files are (A) maintained only on centralized storage servers (and not on personal computers
                                         or devices), (B) not accessible by any of its personnel (other than its information technology
                                         specialists), and (C) are not otherwise accessed subsequently except with the written
                                         consent of the other Party or as required by law. Such retained copies of documents and
                                         Confidential Information shall remain subject to the confidentiality and non-use obligations
                                         set forth in this Agreement;

 

		(iii)	each
                                         Party shall pay all amounts then due and owing as of the termination effective date;

 

		(iv)	at
                                         the request of CureVac, Genmab grants to CureVac a non-exclusive, royalty-free, perpetual
                                         and worldwide license [*****] under the Genmab
                                         Program Patent Rights required to Develop, Manufacture and/or Commercialize products
                                         containing one or more mRNA construct(s) that is/are designed to express an Antibody
                                         or Antibody Combination, as applicable, directed at the respective Collaboration Target(s)
                                         or Collaboration Target Combination(s) covered by the termination. For clarity, such
                                         unblocking license to Genmab Program Patent Rights shall only comprise rights to target
                                         class-related or target-related Genmab Inventions, including the examples of Inventions
                                         set out in Exhibit 11.3, Sections 2(b), 2(c), 2(d), 2(e), 2(f), 2(g) (solely to
                                         the extent referring to Sections 2(b), 2(c), 2(d), 2(e) or 2(f)), 2(h) (solely to the
                                         extent referring to Sections 2(b), 2(c), 2(d), 2(e) or 2(f) via Section 2(g)), 2(q),
                                         2(r), 2(u) and 2(v), and shall not include a license to any specific Antibody sequence(s),
                                         Program Antibody(-ies), Program Antibody Combination(s) or Products nor any rights in
                                         Genmab Background Technology; and

 

		(v)	at
                                         the request of CureVac, Genmab will enter into good faith discussions with CureVac regarding
                                         the possibility of [*****]. For avoidance of doubt, neither
                                         Party shall have any obligation to enter into any agreement regarding [*****] comprised by the termination.

 

    93

     

    

 

		16.3	Effect
                                         of Expiration or Termination; Survival. Expiration or termination of this Agreement
                                         shall not relieve the Parties of any obligation accruing prior to such expiration or
                                         termination. Any expiration or termination of this Agreement shall be without prejudice
                                         to the rights of either Party against the other accrued or accruing under this Agreement
                                         prior to expiration or termination. The provisions of Articles 1, (to the extent required
                                         to give effect to other surviving provisions), 11, 12, 13 and 16 and Sections 2.5, 2.7,
                                         5.8, 14.1, 14.2, 14.3, 14.9, 14.10, 17.3, 17.4, 17.5, 17.7, 17.8, 17.11, 17.12, 17.13,
                                         17.14 and all other provisions contained in this Agreement that by their explicit terms
                                         or from which it is clear from the context survive expiration or termination of this
                                         Agreement, and any schedules contained in this Agreement to which reference is made in
                                         any surviving term, shall survive the expiration or termination of this Agreement. In
                                         the event of a termination of this Agreement with respect to only one of the Programs,
                                         and continuation of other Programs under this Agreement, the termination and consequences
                                         of termination provisions only apply to the terminated Program, and the Agreement will
                                         remain in full force and effect with respect to the continuing Programs.

 

		17.	GENERAL
                                         PROVISIONS.

 

		17.1	Assignment.
                                         This Agreement may not be assigned or otherwise transferred by either Party without
                                         the prior written consent of the other Party, which consent will not be unreasonably
                                         withheld, conditioned or delayed; provided, however, each of the Parties may,
                                         without such consent, but with notification, assign this Agreement and its rights and
                                         obligations hereunder to any of its Affiliates or in connection with the transfer or
                                         sale of all or substantially all of the portion of its business to which this Agreement
                                         relates or in the event of its merger or consolidation with a Third Party. Further, Genmab
                                         may, without such consent but with notification, assign its rights and obligations on
                                         a Program-by-Program basis to an Affiliate [*****]. Any permitted assignee will assume
                                         all obligations of its assignor under this Agreement in writing concurrent with the assignment.
                                         Any purported assignment in violation of this Section 17.1 will be void. Except as otherwise
                                         provided herein, this Agreement shall be binding upon and inure to the benefit of the
                                         Parties and their successors and permitted assignors under this Section 17.1.

 

		17.2	Force
                                         Majeure. If the performance of any part of this Agreement by either Party, or any
                                         obligation under this Agreement, is prevented, restricted, interfered with or delayed
                                         by reason of any cause beyond the reasonable control of the Party liable to perform,
                                         unless conclusive evidence to the contrary is provided, the Party so affected shall,
                                         upon giving written notice to the other Party, be excused from such performance to the
                                         extent of such prevention, restriction, interference or delay, provided that the affected
                                         Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of
                                         non-performance and shall continue performance with the utmost dispatch whenever such
                                         causes are removed. When such circumstances arise and persist for a period of at least
                                         [*****], the Parties shall discuss what, if any, modification of the terms of this Agreement
                                         may be required in order to arrive at an equitable solution.

 

    94

     

    

 

		17.3	Notices.
                                         All notices which are required or permitted hereunder shall be in writing and sufficient
                                         if delivered personally, sent by e-mail, sent by internationally-recognized overnight
                                         courier or sent by registered or certified mail, postage prepaid, return receipt requested,
                                         addressed as follows:

 

		(i)	if
                                         to CureVac, addressed to:

 

		 	CureVac AG
	 	 	Attention:	Chief Executive Officer
	 	 	 	with copy to: General Counsel
	 	 	Address:	Paul-Ehrlich-Str. 15
	 	 	 	72076 Tübingen, Germany
	 	 	Email:	[*****]

 

		(ii)	if
                                         to Genmab, addressed to:

 

		 	Genmab
                                         A/S
	 	 	Attention: [*****]
	 	 	

                                         Email: [*****]
	 	 	 
	 	 	or
	 	 	 
	 	 	[*****]
	 	 	 
	 	 	or
	 	 	 
	 	 	[*****]

 

or to such other address(es)
as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice
shall be deemed to have been given: (a) when delivered if personally delivered or sent by e-mail on a Business Day (or if delivered
or sent on a non-business day, then on the next Business Day); (b) on the Business Day after dispatch if sent by nationally-recognized
overnight courier; or (c) on the [*****] Business Day following the date of mailing, if sent by mail.

 

		17.4	Governing
                                         Law. This Agreement and all disputes arising hereunder, shall be exclusively governed
                                         by, and interpreted and enforced in accordance with the laws of the Netherlands, without
                                         reference to its conflict of laws principles. The United Nations Convention of International
                                         Contracts on the Sale of Goods (the Vienna Convention) does not apply to this Agreement.

 

    95

     

    

 

		17.5	Dispute
                                         Resolution.

 

		17.5.1	Unless
                                         otherwise set forth in this Agreement, in the event of any dispute arising out of or
                                         in connection with this Agreement, including any alleged breach under this Agreement
                                         or any dispute relating to the validity, performance, construction or interpretation
                                         of this Agreement, the Parties shall refer such dispute to the CEO (or its C-level delegate)
                                         of CureVac and the CEO (or its C-level delegate) of Genmab. If the dispute has not been
                                         settled pursuant to the said rules within [*****] following the reference of the dispute
                                         to the senior management representatives of the Parties, either Party may submit the
                                         dispute to final and binding arbitration.

 

		17.5.2	Any
                                         dispute arising out of or in connection with this Agreement, including any issue relating
                                         to the validity, performance, construction or interpretation of this Agreement, which
                                         cannot be resolved amicably between the Parties after following the procedure set forth
                                         in Section 17.5.1, shall be submitted to and settled by arbitration in accordance with
                                         the NAI Arbitration Rules of the Netherlands Arbitration Institute (the “NAI”)
                                         in effect on the date of the commencement of the arbitration proceedings. The existence,
                                         nature and details of any such dispute(s), and all communications between the Parties
                                         related thereto, shall be considered Confidential Information of the Parties and shall
                                         be treated in accordance with the terms of Article 12 above. Any Confidential Information
                                         may be disclosed by either Party to counsel, experts or other advisors on the arbitration
                                         under obligations of confidentiality. The decision of the arbitrators shall be final
                                         and binding upon the Parties. The location of arbitration will be Amsterdam, the Netherlands.
                                         The arbitration will be heard and determined by [*****] arbitrator, who will be jointly
                                         selected by Genmab and CureVac. If, within [*****] following the date upon which a claim
                                         is received by the respondent, the Parties cannot agree on a mutually appointed arbitrator,
                                         the arbitration will be heard and determined by [*****] arbitrators, with [*****] arbitrator
                                         being appointed by each Party and the [*****] arbitrator being appointed by the NAI directly
                                         (without application of the list procedure of article 14 NAI Arbitration Rules). The
                                         language of the arbitration proceeding will be English. Notwithstanding the provisions
                                         of this Section 17.5.2, each Party shall have the right to seek interim injunctive relief
                                         in any court of competent jurisdiction as such Party deems necessary to preserve its
                                         rights and to protect its interests.

 

		17.6	Severability.
                                         If any provision of this Agreement is determined by any court or administrative tribunal
                                         of competent jurisdiction to be invalid or unenforceable, the Parties shall negotiate
                                         in good faith a replacement provision that is commercially equivalent, to the maximum
                                         extent permitted by Applicable Law, to such invalid or unenforceable provision. The invalidity
                                         or unenforceability of any provision of this Agreement shall not affect the validity
                                         or enforceability of the other provisions of this Agreement. Nor shall the invalidity
                                         or unenforceability of any provision of this Agreement in one country or jurisdiction
                                         affect the validity or enforceability of such provision in any other country or jurisdiction
                                         in which such provision would otherwise be valid or enforceable.

 

		17.7	Entire
                                         Agreement and Amendments. This Agreement, together with all Exhibits attached hereto,
                                         constitutes the entire agreement between the Parties regarding the subject matter hereof
                                         (including the Products), and supersedes all prior agreements, understandings and communications
                                         between the Parties, with respect to the subject matter hereof (including the Products),
                                         including the Confidentiality Agreements and Material Transfer Agreement. The foregoing
                                         may not be interpreted as a waiver of any remedies available to either Party as a result
                                         of any breach prior to the Effective Date, by the other Party of its obligations under
                                         the Confidentiality Agreements or Material Transfer Agreement. No modification or amendment
                                         of this Agreement shall be binding upon the Parties unless in writing and executed by
                                         the duly authorized representative of each of the Parties; this shall also apply to any
                                         change of this Section 17.7.

 

    96

     

    

 

		17.8	Waivers.
                                         The failure by either Party hereto to assert any of its rights hereunder, including
                                         the right to terminate this Agreement due to a breach or default by the other Party hereto,
                                         shall not be deemed to constitute a waiver by that Party of its right thereafter to enforce
                                         each and every provision of this Agreement in accordance with its terms.

 

		17.9	Counterparts.
                                         This Agreement may be executed in any number of counterparts, each of which shall
                                         be deemed an original but all of which together shall constitute one and the same instrument.

 

		17.10	Independent
                                         Contractors. The Parties are independent contractors and this Agreement shall not
                                         constitute or give rise to an employer-employee, agency, partnership or joint venture
                                         relationship among the Parties and each Party’s performance hereunder is that of
                                         a separate, independent entity.

 

		17.11	Language.
                                         This Agreement, and any amendments or modifications thereto, shall be executed in
                                         the English language. No translation, if any, of this Agreement into any other language
                                         shall be of any force or effect in the interpretation of this Agreement or in determination
                                         of the intent of either of the Parties hereto.

 

		17.12	Headings.
                                         The headings are placed herein merely as a matter of convenience and shall not affect
                                         the construction or interpretation of any of the provisions of this Agreement.

 

		17.13	Third
                                         Parties. None of the provisions of this Agreement shall be for the benefit of or
                                         enforceable by any Third Party which shall be a Third Party beneficiary to this Agreement.

 

		17.14	Costs.
                                         Except as is otherwise expressly set forth herein, each Party shall bear its own
                                         expenses in connection with the activities contemplated and performed hereunder.

 

— Signature page follows —

 

    97

     

    

 

In Witness Whereof, the Parties
have executed this Agreement to be effective as of the Effective Date.

 

	Signed on behalf of	 
	Genmab B.V.	 
	 	 
	/s/ Jan van de Winkel	 
	Signature of Authorized Officer	Jan van de Winkel
	Name of Authoirzed Officer (please print)	President & CEO
	Date Signed	19 December 2019
	 	 
	Signed on behalf of	 
	Genmab B.V.	 
	 	 
	/s/ David Eatwell	 
	Signature of Authorized Officer	David Eatwell
	Name of Authorized Officer (please print)	Executive Vice President
                                         & CFO
	Date Signed	19 December 2019
	 	 
	Signed on behalf of	 
	CureVac AG	 
	 	 
	Signature of Authorized Officer	 
	Name of Authorized Officer (please print)	 
	Date Signed	 
	 	 
	/s/ Franz-Werner Haas	 
	Signed on
behalf of	Franz-Werner Haas
	CureVac AG	Chief Operating Officer
	 	 
	Signature of Authorized Officer	 
	Name of Authorized Officer (please print)	 
	Date Signed	 
	 	 
	/s/ Daniel Menichella	 
	CEO, CureVac AG	Daniel Menichella
	 	CEO, CureVac AG

 

    98

     

    

 

Exhibit
1.13

Patent Rights licensed to BioNTech

 

[*****]

 

    99

     

    

  

Exhibit
1.54

CureVac Know How

 

[*****]

 

    100

     

    

 

Exhibit
1.59

CureVac Patent Rights

 

[*****]

 

    101

     

    

 

Exhibit
1.77

First Program Antibody

 

[*****]

 

    102

     

    

 

 

Exhibit
1.90

Genmab Know-How

 

[*****]
 

    103

     

    

 

Exhibit
1.111

LNP Technology

 

[*****]

 

    104

     

    

 

Exhibit
1.144

Other Technologies

 

[*****]

 

    105

     

    

 

Exhibit
3.2.2

Templates for clearance of proposed Research Program Antibody

and Research Program Antibody Combination

 

The Research Program Antibody and Research
Program Antibody Combination shall be described by providing available information in the following table:

 

	[*****]	[*****]	[*****]	[*****]	[*****]	[*****]
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 

 

The Research Program Antibody and Research
Program Antibody Combination shall be described by providing the following information for each Antibody:

 

		[*****]	

 

    106

     

    

 

Exhibit
5.1.1

FIRST PROGRAM RESEARCH PLAN

 

[*****]

 

    107

     

    

 

Exhibit 5.11

Approved Subcontractors

 

[*****]

 

    108

     

    

 

 Exhibit 6.2

Early Clinical Supply – Key Terms

 

[*****]

 

    109

     

    

 

Exhibit 10.6.2

Example of royalty calculations for Single Antibody Products

 

[*****]

 

    110

     

    

  

Exhibit 11.3

List of non-limiting examples of ownership of different types of potential Inventions

 

[*****]

 

    111

     

    

 

Exhibit 13.6

Press Release

 

Company Announcement

 

		·	Genmab
                                         and CureVac enter broad strategic partnership

 

		·	Companies
                                         to conduct joint research on first program; option for Genmab to initiate three additional
                                         programs during 5-year research term

 

		·	Genmab
                                         will provide CureVac with a USD 10 million upfront payment and make an equity investment
                                         in CureVac of 20 million euro

 

		·	CureVac
                                         eligible to receive milestones between USD 275 million and USD 368 million for each of
                                         the potential product candidates, depending on specific product concept

 

Copenhagen,
Denmark and Tübingen, Germany, xx, xxx, 2019 – Genmab A/S (Nasdaq: GMAB) and CureVac, AG announced today that Genmab
and CureVac have entered into a research collaboration and license agreement. This strategic partnership will focus
on the research and development of differentiated mRNA-based antibody products by combining CureVac’s mRNA technology and
know-how with Genmab’s proprietary antibody technologies and expertise.

 

    112

     

    

  

“As part of Genmab’s effort to
fundamentally transform cancer treatment we have once again entered into a collaboration that will further provide us with the
potential to lead innovation in the antibody space,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “CureVac’s
unique mRNA technology, which uses the body’s own ability to produce specific proteins from nucleic acid, combined with
Genmab’s world-class antibody expertise and robust proprietary technology platforms could create multiple novel options
for the treatment of patients with cancer.”

 

“We are delighted to partner with Genmab.
Through our agreement focused on mRNA encoding antibodies, we will continue to demonstrate the robustness of our mRNA technology,”
said Daniel L. Menichella, Chief Executive Officer of CureVac. “We believe that the collaboration with Genmab represents
the first antibody deal in the field of mRNA. It is our hope that the collaboration will be successful for patients, the two companies
and their shareholders.”

 

Under the terms of the agreement Genmab will
provide CureVac with a USD 10 million upfront payment. Genmab will also make a 20 million euro equity investment in CureVac. The
companies will collaborate on research to identify an initial product candidate and CureVac will contribute a portion of the overall
costs for the development of this product candidate, up to the time of an Investigational New Drug Application. Genmab would thereafter
be fully responsible for the development and commercialization of the potential product, in exchange for undisclosed milestones
and tiered royalties to CureVac. The agreement also includes three additional options for Genmab to obtain commercial licenses
to CureVac’s mRNA technology at pre-defined terms, exercisable within a five-year period. If Genmab exercises any of these
options, it would fund all research and would develop and commercialize any resulting product candidates with CureVac eligible
to receive between USD 275 million and USD 368 million in development, regulatory and commercial milestone payments for each product,
dependent on the specific product concept. In addition, CureVac is eligible to receive tiered royalties in the range from mid-single
digits up to low double digits per product. CureVac would retain an option to participate in development and/or commercialization
of one of the potential additional programs under pre-defined terms and conditions.

 

Today’s news does not impact Genmab’s
2019 Financial Guidance.

 

About Genmab

 

Genmab is a publicly traded, international
biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of
cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple
myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab
is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation
of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline.
Genmab’s technology base consists of validated and proprietary next generation antibody technologies - the DuoBody®
platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies,
the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing
therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization.
The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab
has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with core
sites in Utrecht, the Netherlands and Princeton, New Jersey, U.S.

  

About CureVac AG

 

CureVac is a leading clinical stage company
in the field of messenger RNA (mRNA) technology with more than 19 years’ expertise in developing and optimizing this versatile
molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of mRNA as a data carrier to
instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies
for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac
has received significant investments, amongst others from dievini Hopp BioTech holding and
the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations,
including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.

 

For more information, please visit www.curevac.com
or follow us on Twitter at @CureVacAG.

 

    113

     

    

 

Forward Looking Statement for
Genmab

 

This Company Announcement contains forward
looking statements. The words “believe”, “expect”, “anticipate”, “intend” and
 “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements. The important factors that could cause our actual
results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development
of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes
and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion
of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available
on www.genmab.com and the risk factors included in Genmab’s final prospectus for our U.S. public
offering and listing and other filings with the U.S. Securities and Exchange Commission (SEC), which are available
at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking
statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after
the date made or in relation to actual results, unless required by law.

 

Genmab A/S and/or its subsidiaries own the
following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®;
DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®;
DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX®
is a trademark of Janssen Pharmaceutica NV.

 

Genmab Contacts:

Marisol Peron, Corporate Vice President,
Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

 

For Investor Relations:

Andrew Carlsen, Senior Director, Investor
Relations

T: +45 3377 9558; E: acn@genmab.com

 

CureVac Contact:

Thorsten Schüller, Director Communication

T: +49 7071 9883 -1577; E: Thorsten.Schueller@curevac.com

 

    114

     

    

 

Exhibit 14.4

Disclosure Letter

 

[*****]

 

    115Exhibit 10.2

 

 EXECUTION COPY

CONFIDENTIAL

 

 REDACTED

Certain identified information, indicated
by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive
harm if publicly disclosed.

 

DEVELOPMENT
AND LICENSE AGREEMENT

 

This DEVELOPMENT
AND LICENSE AGREEMENT (“Agreement”), effective as of November 9, 2017 (the “Effective Date”),
is made by and between CureVac AG, a German stock corporation organized under the laws of Germany, having its principal place of
business at Paul-Ehrlich-Strasse 15, 72076 Tuebingen, Germany (“CureVac”), and CRISPR Therapeutics AG, a Swiss
corporation organized under the laws of Switzerland (“CRISPR”), having its principal place of business at Baarerstrasse
14, 6300 Zug, Switzerland. CureVac and CRISPR are each sometimes referred to herein as a “Party” and collectively
as the “Parties.”

 

RECITALS

 

A.       WHEREAS,
CRISPR has an interest in developing and accessing Cas9 mRNA Constructs (as defined below) for use in gene editing therapeutics.

 

B.       WHEREAS,
CureVac has a proprietary mRNA technology platform, and an interest in developing Cas9 mRNA Constructs for CRISPR for gene editing
applications;

 

C.       WHEREAS,
the Parties intend to collaborate with the goals of identifying and optimizing Cas9 mRNA Constructs for certain Programs (as defined
below); and

 

D        WHEREAS,
CRISPR and CureVac will enter into a supply agreement, under which CureVac will supply CRISPR such optimized Cas9 mRNA Constructs
for use in gene editing applications in certain Programs.

 

NOW, THEREFORE,
the Parties hereby agree as follows:

 

Article 1

DEFINITIONS

 

1.1          “Affiliate”
means any Person that directly or indirectly is controlled by, controls or is under common control with another Person. For the
purposes of this definition, the term “control” (including with correlative meanings, the terms “controlled by”
and “under common control with”) as used with respect to a Person means (a) in the case of a corporate entity, direct
or indirect ownership of voting securities entitled to cast 50% or more of the votes in the election of directors, (b) in the case
of a non-corporate entity, direct or indirect ownership of 50% or more of the equity interests with the power to direct the management
and policies of such entity, or (c) any other arrangement whereby a Person controls or has the right to control the board of directors
or equivalent governing body or management of a corporation or other entity. For the avoidance of doubt, on the Effective Date
Casebia Therapeutics LLP (“Casebia”) is an Affiliate of CRISPR for all purposes under this Agreement. Regarding
CureVac, Affiliate shall not include Mr. Dietmar Hopp and dievini Hopp BioTech holding GmbH & Co. KG and/or any other entity
controlled by Mr. Hopp and/or dievini Hopp BioTech holding GmbH & Co. KG. Any such Person shall only be an Affiliate for purposes
of this Agreement when and as long as it meets the requirements of this Section 1.1.

 

     

     

    

 

1.2          “Applicable
Law” means any federal, state, local or foreign law (including, common law), statute or ordinance, or any rule, regulation,
judgment, order, writ or decree of or from any court, Regulatory Authority or other governmental authority having jurisdiction
over or related to the subject item that may be in effect from time to time.

 

1.3          “Background
Intellectual Property” shall mean, as applicable, CRISPR Background Intellectual Property or CureVac Background Intellectual
Property.

 

1.4          “Calendar
Quarter” means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30,
and December 31; provided, however, that (a) the first Calendar Quarter of any particular period shall extend from the commencement
of such period to the end of the first complete Calendar Quarter thereafter, and (b) the last Calendar Quarter shall end upon the
expiration or termination of this Agreement.

 

1.5          “Calendar
Year” means each successive period of twelve (12) months commencing on January 1 and ending on December 31.

 

1.6          “Cas9
mRNA Construct” [*****].

 

1.7          “Combination
Product” shall have the meaning set forth in Section 1.60 below.

 

1.8          “Commercial
Supply Agreement” means an agreement for the supply of Cas9 mRNA Constructs for use by CRISPR, its Affiliates and Sublicensees
in Pivotal Clinical Trials and Commercialization.

 

1.9          "Commercially
Reasonable Efforts" shall mean, with respect to the efforts to be expended by a Party with respect to any objective, the
reasonable, diligent, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar
objective under similar circumstances. It is understood and agreed that with respect to the Development and Commercialization of
Licensed Products by CRISPR, such efforts shall be substantially equivalent to those efforts and resources commonly used by similarly
situated biotechnology companies with resources similar to CRISPR in the European Union and the United States for products owned
by them or to which they have rights, which products are at a similar stage in its Development or product life and are of similar
market potential taking into account all scientific, commercial and other factors that such pharmaceutical company would take into
account, including efficacy, safety, approved labelling, the competitiveness of alternative products in the marketplace, the expected
and actual market exclusivity of the Licensed Products, and the likelihood of receipt of a Regulatory Approval given the Regulatory
Authority involved.

 

1.10        “Commercialization”
shall mean any and all activities directed to the preparation for sale of, offering for sale of, or sale of Licensed Products,
including activities related to marketing, promoting, labelling, packaging, distributing, importing and exporting such Licensed
Products, and interacting with Regulatory Authorities regarding any of the foregoing. When used as a verb, to “Commercialize”
and “Commercializing” shall mean to engage in Commercialization, and “Commercialized” has
a correlative meaning.

 

1.11        “Competitive
Infringement” shall have the meaning set forth in Section 8.4(b).

 

    2

     

    

 

1.12        “Confidential
Information” means subject to the exceptions in Section 6.2, the information of any nature and in any form that
a Party may learn of (including, but not limited to, all documents and/or all data, nucleic acid and protein sequences, chemical
structures, software and/or hardware samples, models, methods, descriptions, Know-How, processes, applications and/or knowledge,
whether patentable or not), in the performance of the Agreement, and in particular any confidential information relating to the
Licensed Intellectual Property, Licensed Products, names of business partners, business strategy, developing strategy, data regarding
Licensed Products, their prices and markets, that a Party may receive in the performance of this Agreement. The Know-How within
the Licensed Intellectual Property for use in the Field and the terms and conditions of this Agreement are Confidential Information
of both Parties.

 

1.13        “Controlled”
or “Controls” means, when used in reference to a subject item or a right, the legal authority or right of a
Party (or any of its Affiliates) (whether by ownership or license, other than pursuant to this Agreement) to grant the right to
use such item or right to the other Party, or to otherwise disclose proprietary or trade secret information to such other Party,
without violating the terms of any agreement or other arrangement by which such Party is bound.

 

1.14        “Cover”
means, with respect to a particular subject matter at issue and the relevant Patent Rights and Know-How, that, but for a license
granted to a Party under a claim included in such Patent Rights or under the Know-How, or such Party’s ownership or Control
of such Patent Rights or Know-How, the manufacture, use, sale, offer or sale or importation by such Party of the subject matter
at issue would infringe such claim or exploit or otherwise use such Know-How or, in the case of a Patent Right that is a patent
application, would infringe a claim in such patent application if it were to issue as a patent in a particular country or countries.

 

1.15        “CRISPR
Background Intellectual Property” means CRISPR Background Know-How and CRISPR Background Patent Rights and that is not
Foreground Intellectual Property. The CRISPR Background Intellectual Property as of the Effective Date is identified in Attachment
A hereto.

 

1.16        “CRISPR
Background Know-How” means any Know-How Controlled by CRISPR as of the Effective Date or thereafter during the Term that
is reasonably necessary or useful for the Parties to conduct activities under the Development Program and/or to Develop, Manufacture
and Commercialize Licensed Products in accordance with this Agreement.

 

1.17        “CRISPR
Background Patent Rights” means any Patent Rights Controlled by CRISPR as of the Effective Date or thereafter during
the Term that are reasonably necessary or useful for the Parties to conduct the activities under the Development Program and/or
to Develop, Manufacture and Commercialize Licensed Products in accordance with this Agreement.

 

1.18        “CRISPR
Improvement” means any improvement, change, modification, variation, revision, update or enhancement to the CRISPR Background
Intellectual Property.

 

1.19        “CRISPR
System” means a system comprising one or more of the following:

 

(a)         [*****]

 

(b)         [*****] and

 

    3

     

    

 

(c)         
[*****]

 

1.20        “CureVac
Background Intellectual Property” means the CureVac Background Patent Rights and CureVac Background Know-How, and that
is not Foreground Intellectual Property. The CureVac Background Intellectual Property is identified in Attachment B hereto.
For clarity, CureVac Background Intellectual Property does not include Patent Rights and Know-How in-licensed by CureVac from Acuitas
Therapeutics, Inc. and from PharmaJet, Inc.

 

1.21        “CureVac
Background Know-How” means all Know-How Controlled by CureVac or its Affiliates as of the Effective Date or thereafter
during the Term that is reasonably necessary or useful for Parties to conduct the activities under the Development Program and/or
to Develop, Manufacture and Commercialize Licensed Products.

 

1.22        “CureVac
Background Patent Rights” means all Patent Rights Controlled by CureVac or its Affiliates as of the Effective Date or
thereafter during the Term that are reasonably necessary or useful for the Parties to conduct the activities under the Development
Program and/or to Develop, Manufacture and Commercialize Licensed Products.

 

1.23        “CureVac
Competitor” means a pharmaceutical and/or biotechnological company that has a primary focus of its business in the development,
manufacture (for its own account) or commercialization of therapeutic products or services (for its own account) in the field of
pDNA and/or mRNA provided that the Parties acknowledge and agree that the term “CureVac Competitor” does not include
contract manufacturing organizations, contract research organizations, or entities that do work on a fee-for-services basis as
contract manufacturers for others. For clarity, Boehringer Ingelheim’s contract manufacturing organization would not be deemed
a “CureVac Competitor,” even if a Boehringer Ingelheim affiliate (including a parent entity) is developing or commercializing
therapeutic products in the field of pNDA and/or mRNA).

 

1.24        “CureVac
Improvement” means any improvement, change, modification, variation, revision, update or enhancement to the CureVac Background
Intellectual Property.

 

1.25        “Development”
shall mean all research, non-clinical, and clinical testing and drug development activities conducted in respect of the Licensed
Products for use in the Field, including those reasonably necessary or useful or required by a Regulatory Authority in support
of obtaining Regulatory Approvals. “Development” shall include generation, validation and optimization, formulation
development, delivery system development, non-clinical testing, mechanism studies, toxicology, pharmacokinetics, clinical studies,
regulatory affairs activities, statistical analysis and report writing, submission of documents, market research, pharmacoeconomic
studies, and epidemiological/real world data studies. “Develop” and "Developed" have a correlative
meaning.

 

1.26        “Development
Program” means the research and development program regarding the identification, optimization and selection of Cas9
mRNA Constructs funded as agreed in this Agreement and to be conducted in accordance with the Work Plan and this Agreement. For
clarity, all activities conducted under the Development Program shall be distinct from the Development of the Licensed Products
and shall not extend to any activities which shall be conducted under the Manufacturing Services Agreement.

 

    4

     

    

 

1.27        “Development
Term” means the period set forth in the Work Plan to perform all of the activities of the Work Plan.

 

1.28        “Dual
Improvement Intellectual Property” shall have the meaning set forth in Section 7.1(d)(iii)(C).

 

1.29        “EMA”
means European Medicines Agency and any successor agency or authority thereto.

 

1.30        “Executive
Officer” means (a) in the case of CureVac, the Chief Corporate Officer, and (b) in the case of CRISPR, the Chief Business
Officer, neither of which may be a member of the JSC. Each Party may change its Executive Officer from time to time by providing
written notice to the other Party in accordance with the terms of this Agreement.

 

1.31        “FDA”
means the United States Food and Drug Administration or its successor.

 

1.32        “Field”
means all human therapeutic applications in the Programs that make use of a CRISPR System.

 

1.33        “First
Commercial Sale” means on a Licensed Product-by-Licensed Product and country-by-country basis, the first arm’s-length
transaction, transfer or disposition for value by or on behalf of CRISPR or any Affiliate or Sublicensee of CRISPR to a Third Party
of such Licensed Product for end use or consumption of such Licensed Product. First Commercial Sale excludes (a) the distribution
of reasonable quantities of promotional samples of Licensed Products, or (b) the transfer of Licensed Product to a Third Party
to use Licensed Product for the sole purpose of performing preclinical or clinical studies or (c) the transfer of Licensed Product
to a Third Party solely for charitable or compassionate use purposes on a named patient basis if the Selling Party transfers Licensed
Product at cost of goods or below.

 

1.34        “First
Exercise Period” has the meaning set forth in Section 7.4.

 

1.35        “Foreground
Intellectual Property” means the Foreground Patent Rights and the Foreground Know-How.

 

1.36        “Foreground
Know-How” means the Know-How first conceived, discovered, developed, reduced to practice or generated by either Party
or jointly by the Parties under this Agreement.

 

1.37        “Foreground
Patent Rights” means all Patent Rights that arise from the Foreground Know-How.

 

1.38        “FTE”
means one employee working full-time for one year, or more than one person working the equivalent of a full-time person,
working directly on performing activities under the Development Program, as applicable, where “full-time” is
considered [*****] hours for one Calendar Year. No additional payment will be made with respect to any individual who works
more than [*****] hours per Calendar Year and any individual who devotes less than [*****] hours per Calendar Year
will be treated as an FTE on a pro rata basis based upon the actuâ] number of hours worked divided by [*****].

 

    5

     

    

 

1.39        “FTE
Costs” means the product of (a) the number of FTEs (proportionately, on a per-FTE basis) used by CureVac or its Affiliates
in directly performing activities assigned to CureVac under and in accordance with the Development Program, and (b) the FTE Rate.

 

1.40        “FTE
Rate” means € [*****].

 

1.41        “Full
Sublicense Rate” has the meaning set forth in Section 5.3.

 

1.42        “GLP”
means the then-current practices and procedures set forth in Title 21, United States Code of Federal Regulations, Part 58 (as amended),
and any other regulations, guidelines or guidance documents relating to good laboratory practices, or any foreign equivalents thereof
in the country in which such studies or clinical trials are conducted or that are otherwise applicable.

 

1.43        “GLP
Toxicology Study” means, with respect to a Licensed Product, a study conducted in a species, in compliance with GLP,
for the purposes of assessing the efficacy, safety or the onset, severity, and duration of toxic effects and their dose dependency
with the goal of establishing a profile sufficient to support the filing of an IND.

 

1.44        “IND”
means any Investigational New Drug application, filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal
Regulations, including any supplements or amendments thereto. References herein to IND will include, to the extent applicable,
any comparable filings outside the United States.

 

1.45        “Infringement
Action” shall have the meaning set forth in Section 8.4(c).

 

1.46        “Joint
Steering Committee” shall have the meaning set forth in Section 3.1(a).

 

1.47        “Jointly-Owned
Foreground Intellectual Property” shall have the meaning set forth in Section 7.1(d)(ii).

 

1.48        “Jointly-Owned
Foreground Know-How” shall have the meaning set forth in Section 7.1(d)(ii).

 

1.49        “Jointly-Owned
Foreground Patent Rights” shall have the meaning set forth in Section 7.1(d)(ii).

 

1.50        “Know-How”
means any and all proprietary data, inventions, methods, information, processes, trade secrets, techniques and technology, whether
patentable or not, including discoveries, formulae, practices, biological sequences, test data, analytical and quality control
data, manufacturing technology and data, registration dossiers and specifications. Know-How includes any such information comprised
or embodied in the Materials, if any.

 

1.51        "Licensed
Intellectual Property" means the CureVac Background Intellectual Property and any Foreground Intellectual Property solely
or jointly owned by CureVac.

 

1.52        "Licensed
Patent Rights" means any Patent Right which is part of the Licensed Intellectual Property.

 

1.53        “Licensed
Product” means any product comprising a Cas9 mRNA Construct, where such Cas9 mRNA Construct (a) the research,
Development, Manufacture, use, sale, offer for sale or importation of which relies on the use of Know-How within the Licensed
Intellectual Property, or (b) the research, Development,
Manufacture, use, sale, offer for sale or importation of which in or into a country is Covered by a Valid Claim of a Patent Right
or by Know-How within the Licensed Intellectual Property. 

 

    6

     

    

 

1.54        “Losses”
shall have the meaning set forth in Section 9.1.

 

1.55        “Manufacture”
means all manufacturing operations for Cas9 mRNA Constructs and Licensed Products, including all activities related to the synthesis,
making, production, processing, purifying, of the Cas9 mRNA Constructs, or any intermediate thereof, including process development,
process qualification and validation, scale-up, pre-clinical, clinical and Commercial production and analytic development, product
characterization, stability testing, quality assurance, and quality control. “Manufacturing” has a correlative
meaning.

 

1.56        “Manufacturing
Services Agreement” means the Manufacturing Services Agreement between the Parties, dated as of the Effective Date for
the pre-clinical and clinical (up to Pivotal Clinical Trials) Manufacture of Cas9 mRNA Constructs.

 

1.57        “Marketing
Authorization Application” or “MAA” means an application for Regulatory Approval in a country, territory
or possession.

 

1.58        “Materials”
means the biological materials set forth on Attachment C hereto, whether by themselves or incorporated into another material,
and any progeny, modifications, mutants, components or derivatives thereof. Attachment C may be amended upon the mutual
written agreement by the Parties.

 

1.59        “NDA”
means a new drug application that is submitted to the FDA for marketing approval for a Licensed Product, pursuant to 21 C.F.R.
 § 314.3, or any foreign equivalent.

 

1.60        “Net
Sales” means with respect to any Licensed Product, the gross amounts received by CRISPR, its Affiliates, distributors
and Sublicensees (each, a “Selling Party”) from Third Party customers for sales of such Licensed Product, less
the following deductions actually incurred, allowed, paid, accrued or specifically allocated in its financial statements in accordance
with such Selling Party’s accounting principles, for:

 

(a)         [*****]

 

(b)         [*****]

 

(c)         [*****] and

 

    7

     

    

 

(d)         [*****]

 

1.61        “Non-Royalty
Sublicense Income” means any payments, including upfront and milestone payments, that CRISPR or its Affiliate receives
in consideration of CRISPR, its Affiliate or Sublicensees granting any sublicense to a Third Party under any Licensed Intellectual
Property to a Sublicensee, other than: [*****].

 

1.62        “Patent
Rights” means patents and patent applications, together with any unlisted patents and patent applications claiming priority
thereto, and any continuations, continuations-in-part, reissues, reexamination certificates, substitutions, divisionals, supplementary
protection certificates, renewals, registrations, extensions including all confirmations, revalidations, patents of addition, PCTs,
and pediatric and other exclusivity periods and all foreign counterparts thereof, and any patents issued or issuing with respect
to any of the foregoing.

 

1.63        “Person”
means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture, governmental
authority, association or other entity.

 

1.64        “Phase
1 Clinical Trial” means a clinical study of a drug candidate in patients with the primary objective of characterizing
its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in
21 C.F.R. 312.21(a), or a comparable clinical study prescribed by the relevant regulatory authority in a country other than the
United States. The drug candidate can be administered to patients as a single agent or in combination with other investigational
or marketed agents.

 

1.65        “Phase
2 Clinical Trial” means a clinical study of a drug candidate in patients with the primary objective of characterizing
its activity in a specific disease state as well as generating more detailed safety, tolerability, and pharmacokinetics information
as described in 21 C.F.R. 312.21(b), or a comparable clinical study prescribed by the relevant regulatory authority in a country
other than the United States including a human clinical trial that is also designed to satisfy the requirements of 21 C.F.R. 312.21(a)
or corresponding foreign regulations and is subsequently optimized or expanded
to satisfy the requirements of 21 C.F.R. 312.21(b) (or corresponding foreign regulations) or otherwise to enable a Phase 3 Clinical
Trial (e.g., a phase 1/2 trial). The relevant drug candidate may be administered to patients as a single agent or in combination
with other investigational or marketed agents.

 

    8

     

    

 

1.66        “Phase
3 Clinical Trial” means a clinical study of a drug candidate in patients that incorporates accepted endpoints for confirmation
of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21
C.F.R. 312.21(c), or a comparable clinical study prescribed by the relevant regulatory authority in a country other than the United
States. The relevant drug candidate may be administered to patients as a single agent or in combination with other investigational
or marketed agents

 

1.67        “Pivotal
Clinical Trial” means a clinical study of a drug candidate in patients, performed after preliminary evidence suggesting
efficacy of such product has been obtained, conducted for inclusion in (a) that portion of the FDA submission and approval process
that provides for the continued trials of such product in sufficient numbers of human patients to confirm with statistical significance
the safety and efficacy of such Licensed Product sufficient to support Regulatory Approval in the proposed indication, as more
fully defined in 21 C.F.R. §312.21(c) or (b) equivalent Regulatory Authority submissions in a country other than the United
States.

 

1.68        “Program”
means applying the CRISPR System and using a Cas9 mRNA Construct for the following programs: (i) the [*****], in accordance
with Section 4.2(a). below, [*****] being set forth on Attachment G, or as substituted in accordance with Section
4.2(b) ("Program 1"); (ii) [*****] or (iii) [*****] or as
substituted in accordance with Section 4.3 (“[*****]”).

 

1.69        “Reduced
Sublicense Rate” has the meaning set forth in Section 5.3.

 

1.70        “Regulatory
Approval” means any and all approvals (including pricing and reimbursement approvals, if any), licenses, registrations
or authorizations of any national or international or local Regulatory Authority, department, bureau or other governmental entity,
necessary for the Manufacture and Commercialization of a Licensed Product in any regulatory jurisdiction. Regulatory Approvals
include approvals by Regulatory Authorities of MAAs.

 

1.71        “Regulatory
Authority” means, with respect to a country or region, any national (e.g., the FDA for the United States, EMA for the
European Union), supra-national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental
authority involved in the granting of any approval required by Applicable Laws to Manufacture and Commercialize a relevant Licensed
Product in such country or region or, to the extent required in such country or region, price approval, for pharmaceutical products
in such country or region.

 

1.72        “Regulatory
Exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with
respect to a Licensed Product.

 

1.73        “Reserved
Program” shall mean any program that is the subject of a signed agreement between CureVac and a Third Party, or the
subject of bona fide ongoing research, development or commercialization activities by CureVac, in each case, that would be breached
if such proposed [*****] under this Agreement at the time CRISPR provides the written notice to CureVac as described in Section
4.3(b).

 

    9

     

    

 

1.74       “Royalty
Term” on a Licensed-Product by Licensed-Product, and country-by-country basis, the period commencing on the First Commercial
Sale of a Licensed Product and ending upon the later of (i) the date on which there is no Valid Claim that would be infringed,
absent a license, by the Development, Manufacture or Commercialization of such Licensed Product in such country,(ii) the date
on which the Regulatory Exclusivity in such country for such Licensed Product expires; or (iii) ten (10) years after the
First Commercial Sale of such Licensed Product in such country.

 

1.75       “Solely-Owned
Foreground Intellectual Property” shall have the meaning set forth in Section 7.1(d)(i).

 

1.76       “Solely-Owned
Foreground Know-How” shall have the meaning set forth in Section 7.1(d)(i).

 

1.77       “Solely-Owned
Foreground Patent Rights” shall have the meaning set forth in Section 7.1(d)(i).

 

1.78       “Sublicensee”
means an Affiliate or any Third Party that is granted a sublicense as permitted under Section 7.2, either directly by CRISPR
or indirectly by any other Sublicensee hereunder.

 

1.79       “Term”
means the period of time beginning on the Effective Date and ending on the expiration of the Royalty Term for all Licensed Products,
unless sooner terminated in accordance with the provision of this Agreement.

 

1.80       “Territory”
means worldwide.

 

1.81       “Third
Party” means any Person other than CRISPR, CureVac and their respective Affiliates.

 

1.82       “Third
Party Agreement” has the meaning set forth in Section 7.4

 

1.83       “Valid
Claim” means (a) a claim of an issued and unexpired patent which has not been revoked or held unenforceable or invalid
by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed
for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, or (b)
a claim of a pending patent application that was filed and has been prosecuted in good faith and has not been (i) cancelled, withdrawn,
abandoned or finally disallowed without the possibility of appeal or refiling of such application, or (ii) pending for more than
[*****] years since such claim was first presented or is the result of amending another claim pending for more than [*****] years
(either in the same application or in another application in the same jurisdiction) so as to add or delete an obvious limitation,
so as to make a trivial or non-substantive change, or so as to change a matter of form.

 

1.84       “Work
Plan” means the plan setting forth (a) the activities to be undertaken as part of the Development Program, (b) the
Party responsible for each such activity, (c) the deliverables, (d) the budget, and (e) timeline for performance, as set
forth in Attachment D hereto, and as may be amended from time to time with written approval of the JSC during the
Development Term. For clarity, on a Program-by-Program basis, the Work Plans shall be limited to the identification,
optimization and selection of Cas9 mRNA Constructs and shall not extend to any activities which shall be conducted under the
Manufacturing Services Agreement.

 

    10

     

    

 

Article 2

CAS9 mRNA DEVELOPMENT PROGRAM

 

2.1       Purpose
and Term. The Parties have agreed to engage in the Development Program on the terms and conditions set forth in this Agreement.
As part of the Development Program, the Parties will work together to identify and optimize Cas9 mRNA Constructs for use in gene
editing therapeutics. The Development Program will be undertaken and performed during the Development Term.

 

2.2       Diligence;
Standards of Conduct with respect to the Work Plan. Each Party agrees to use Commercially Reasonable Efforts to perform the
tasks assigned to such Party under the Work Plan in a timely and effective manner, and each Party further agrees to conduct its
activities under the Work Plan in a good scientific manner and in compliance in all material respects with Applicable Law. In the
event of any inconsistency between the Work Plan and this Agreement, the terms of this Agreement will prevail. Without limiting
the foregoing, in all events, both Parties will provide all resources necessary to support the Development Program, including providing
the appropriate technical resources and personnel with the appropriate skill, training and expertise. All disputes regarding the
level of efforts and resources dedicated by a Party to the performance of the Development Program will be escalated to the JSC.

 

2.3       Amendments
to the Work Plan. During the Development Term, each Party will have the right to propose modifications or amendments to the
Work Plan; provided, however, that any modifications or amendments to the Work Plan that are proposed by either Party will be subject
to review and prior written approval by the JSC pursuant to Section 3.1(b)(ii) and subject to Section 3.2.

 

2.4       Decision
Making. Except as otherwise expressly provided in this Agreement, all matters regarding the Work Plan will be decided by consensus
by the JSC pursuant to Section 3.1(d) and subject to Section 3.2.

 

2.5       Progress.
During the Development Term each Party will keep the other Party reasonably informed regarding the progress and results of performance
of the Development Program. Without limiting the foregoing, following the end of each Calendar Quarter, each Party will prepare
a summary of all work performed to date, such summary to include a discussion of progress against goals set forth in the Work Plan.
The Parties will discuss such summary at the next JSC meeting.

 

2.6       Records.
CureVac will maintain complete and accurate records (in the form of technical notebooks or electronic files where appropriate)
of all work conducted by it under the Work Plan and all Know-How resulting from such work. Such records will fully and properly
reflect all work done and results achieved in the performance of the Work Plan in sufficient detail and in good scientific manner
appropriate for patent and regulatory purposes. CRISPR will have the right to receive copies of such records maintained by CureVac,
including in electronic format if maintained in such format, at reasonable times to the extent reasonably necessary to perform
obligations or exercise rights under this Agreement. Promptly following completion of the Work Plan, CureVac will deliver a final
report to CRISPR summarizing all work performed pursuant to the Work Plan, the results thereof and comparing the results
thereof against any goals set forth in the Work Plan.

 

    11 

     

    

 

2.7       Subcontracts.
Except as outlined in the Work Plan, CureVac may not subcontract any of its obligations under this Agreement absent CRISPR’s
prior written consent.

 

2.8       Manufacture
and Supply. All Cas9 mRNA Constructs required for use by CRISPR, its Affiliates and Sublicensees in accordance with this Agreement
for the non-clinical and Phase 1 Clinical Trial and Phase 2 Clinical Trial Development of the Licensed Products shall comport with
or incorporate CureVac’s most advanced required Manufacturing technology, methods and materials and shall be Manufactured
by or on behalf of CureVac in accordance with Applicable Laws and the terms and conditions of the Manufacturing Services Agreement
attached hereto as Attachment E. The potential supply of Cas9 mRNA Constructs required for use by CRISPR its Affiliates
and Sublicensees for Pivotal Clinical Trials and Commercial supply and a technology transfer in the event CureVac will not supply
such Cas9 mRNA Constructs is set forth in the Manufacturing Services Agreement.

 

2.9       Supply
of Material. CureVac will use Commercially Reasonable Efforts to supply to CRISPR, its Affiliates and Sublicensees the Materials
set forth in Attachment C hereof. CRISPR will use such Materials only in accordance with the Work Plan as set forth in Attachment
D and otherwise in accordance with the terms and conditions of this Agreement and will not reverse engineer or chemically analyze
the Material except as expressly provided for in the Work Plan.

 

2.10       Regulatory
Filings. CureVac hereby grants to CRISPR and its Affiliates, the right of cross-reference in any regulatory filing, Regulatory
Approval, drug master file or other regulatory documentation (including orphan drug applications and designations) Controlled by
CureVac or its Affiliates in any country in the Territory that relate to any Licensed Product to permit CRISPR or its Affiliates
to comply with its regulatory obligations with respect to the Licensed Product in the Field in the Territory, or to exercise CRISPR’s
or its Affiliate’s rights hereunder or under the Manufacturing Services Agreement or the Commercial Supply Agreement. CureVac
shall do and cause to be done such reasonable acts and things, as may be necessary under, or as CRISPR may reasonably request,
to effectuate the rights of cross-reference contemplated in this Section 2.10. The foregoing grant is sublicenseable (through
multiple tiers) by CRISPR and its Affiliates. Notwithstanding anything to the contrary in this Agreement, unless required by any
Applicable Law or Regulatory Authority, CureVac shall not withdraw or inactivate any regulatory filing that CRISPR references or
otherwise uses pursuant to this Section 2.10.

 

Article 3

GOVERNANCE

 

3.1       Joint
Steering Committee.

 

(a)       Formation;
Composition. Within [*****] days following the Effective Date, the Parties will establish a joint steering committee (the
 “Joint Steering Committee” or “JSC”) comprised of two (2) representatives from each
Party (or appointed representatives of an Affiliate of such Party) with sufficient seniority within the applicable Party to
make decisions arising within the scope of the JSC’s responsibilities and each Party will appoint one of its
representatives to the JSC as such Party’s “Work Plan Leader”. The Parties’ initial
representatives to the JSC, and Work Plan Leaders, are set forth on Attachment F hereto. The JSC may change its size
from time to time by mutual consent of its members; provided that the JSC will consist at all times of an equal number
of representatives of each of CureVac and CRISPR. Each Party may replace any or all of its JSC representatives at any time
upon written notice to the other Party. The JSC may invite non-members to participate in the discussions and meetings of the
JSC; provided that such participants (i) will have no voting authority at the JSC and (ii) are bound under written
obligations of confidentiality no less protective of the other Party’s Confidential Information than those set forth in
this Agreement. Each meeting of the JSC will be co-chaired by a representative of each Party. The role of the chairpersons
will be to convene and preside at meetings of the JSC. The chairpersons will have no additional powers or rights beyond those
held by the other JSC representatives. Each Party’s Work Plan Leader will be the primary point of contact for the other
Party on all matters relating to the activities of the Work Plan.

 

    12 

     

    

 

(b)       Specific
Responsibilities. The JSC will:

 

(i)       oversee
the performance of the Work Plan;

 

(ii)       review
the progress of activities under the Work Plan, all reports submitted by the Parties in accordance with Section 2.5, and
review and approve any amendments thereto, including any necessary amendments to the Work Plan budget as a result of any amendment
to the Work Plan, any other amendment to the Work Plan budget and any amendment to the timelines or activities under the Work Plan;

 

(iii)       agree
on amendments of the Work Plan;

 

(iv)       work
to resolve any disagreement between the Parties relating to the Work Plan;

 

(v)       coordinate
Patent Right applications regarding Foreground Intellectual Property; and

 

(vi)       perform
such other functions as appropriate, to further the purposes of this Agreement, in each case as agreed in writing by the Parties.

 

(c)       Meetings.
During the Development Term, the JSC will meet at least quarterly for the first year, and at least twice a year thereafter. Following
the expiration of the Development Term, the Parties may agree to reduce the number of meetings to at least twice a year until
all [*****] Programs have initiated a Phase 1 Clinical Trial, unless otherwise agreed by the Parties. The JSC may meet in person,
by videoconference or by teleconference. Notwithstanding the foregoing, at least [*****] per year will be in person unless
the Parties mutually agree in writing to waive such requirement. In-person JSC meetings will be held at locations alternately
selected by CureVac and by CRISPR. Each Party will bear the expense of its respective JSC members’ participation in JSC
meetings. Meetings of the JSC will be effective only if at least [*****] of each Party is present or participating
in such meeting. Prior to each meeting of the JSC, CureVac and CRISPR will take turns to (i) prepare a written report detailing
the work performed to date under the Work Plan and evaluating such work in relation to the goals of the Work Plan and (ii) provide
such other information as is reasonably requested by the JSC. On a Program-by-Program basis, after each Program has initiated
a Phase 1 Clinical Trial, CRISPR shall provide CureVac with bi-annual reports summarizing all material matters and data relating
to the Programs, the results achieved in performance of the Development and outlining its further Development activities with
respect to such Program. Furthermore, CRISPR will, subject to confidentiality obligations, provide to CureVac copies of Final
Study Reports, once they are available, and will respond to any reasonable request from CureVac to obtain information on the status
of the Programs. Such reporting shall be available on a Program-by-Program basis until the date of the First Commercial Sale of
a Licensed Product for such Program.

 

    13 

     

    

 

(d)       Decision
Making. The representatives from each Party on the JSC will have, collectively, [*****]  on behalf of that Party, and all decision
making will be by consensus. Disputes at the JSC will be handled in accordance with Section 3.2.

 

3.2       Resolution
of JSC Disputes.

 

(a)       Within
the JSC. Subject to the exception specified below in this Section 3.2, all decisions within the JSC will be made by
consensus. If the JSC is unable to reach consensus on any issue for which it is responsible, within [*****] days after a Party
affirmatively states that a decision needs to be made, either Party may elect to submit such issue to the Parties’ Executive
Officers, in accordance with Section 3.2(b).

 

(b)       Referral
to Executive Officers. If a Party makes an election under Section 3.2(a) to refer a matter to the Executive Officers,
the JSC will submit in writing the respective positions of the Parties to the Executive Officers. The Executive Officers will use
good faith efforts in compliance with Section 3.3, which will include at least one in person meeting between such Executive Officers
within [*****] days after the JSC’s submission of such matter to them. If the Executive Officers are unable to reach unanimous
agreement on any such matter, CRISPR will decide such matter, provided that no exercise of such CRISPR’s decisionmaking authority
on any matter may, without CureVac’s prior written consent, not to be unreasonably withheld, conditioned or delayed, (i)
result in a material change to the Work Plan that significantly accelerates or decelerates the planned activities or requires allocation
by CureVac of personnel significantly greater than or less than those provided for in the Work Plan “significantly”to
include anything beyond [*****] percent of the agreed scope, (ii) result in a reduction of CRISPRs diligence obligations under this
Agreement, or (iii) otherwise conflict with this Agreement.

 

3.3       Good
Faith. In conducting themselves on the JSC, and in exercising their rights under Section 3.2, all representatives of
each Party will consider reasonably and in good faith all input received from the other Party. In exercising any decision making
authority granted to it under Section 3.2, each Party will act based on its good faith judgment taking into consideration
the best interests of the Development Program

 

Article 4

DEVELOPMENT AND COMMERCIALIZATION OF
LICENSED PRODUCTS

 

4.1       Development
and Commercialization. CRISPR shall have the sole right and responsibility for Developing and Commercializing Licensed Products
in the Field, including obtaining necessary Regulatory Approvals, at its sole cost and expense.

 

4.2       Back-up
Approach and Substitution for Program 1.

 

(a)       CRISPR
will pursue the primary gene (as set forth in Attachment G) under Program 1. In the event the results of the Development show that
the primary gene should not be further pursued, such results to be discussed within the JSC, and CRISPR may select one of the back-up
genes in Attachment G to replace the primary gene.

 

    14 

     

    

 

(b)       With
respect to Program 1, during the [*****] commencing on the Effective Date, CRISPR shall be permitted once to substitute the treatment
of [*****] upon notice to CureVac, at no additional cost.

 

4.3       Program
Substitution [*****]

 

(a)       Substitution.
With respect to the [*****] Program, during the first [*****] years of this Agreement, CRISPR shall be permitted once to substitute
an alternative program for [*****] using the procedures set forth in Section 4.3(b), provided the intended indication has
an incidence approximately the same or less than the indication [*****]. The substitution is subject to the substitution fee
set forth below, and the milestones set forth in Section 5.4(c) shall not be adjusted for any [*****] Program substitution. For
clarity, even if the [*****] Program had already achieved several milestones, the substitution program would have to pay those
milestones again.

 

(b)       [*****]
Program Substitution Process. CRISPR shall provide CureVac written notice of its request to substitute a target for the [*****]
Program within the [*****] years of the Effective Date. If CureVac provides CRISPR notice that a proposed substitution for the
[*****] Program is a Reserved Program, CureVac shall notify CRISPR within [*****] days after the date on which CureVac receives
notice of the proposed substitution if such proposed substitution is a Reserved Program. CureVac shall, if requested by CRISPR
in writing, provide CRISPR with such evidence to support that such proposed substitution is a Reserved Program. If after providing
such evidence, CRISPR concludes that such a substitution is not a Reserved Program, CRISPR will so notify CureVac, CureVac will
provide such evidence as CureVac believes is reasonably required to establish that such substitution is a Reserved Program to an
independent attorney or other expert with experience that is relevant to the dispute and reasonably acceptable to both Parties.
Such independent expert will review and make a determination in accordance with this Agreement regarding whether such proposed
substitution is a Reserved Program. The independent expert shall promptly notify the Parties of its determination as to whether
a proposed substitution is a Reserved Program, but shall not disclose to CRISPR information provided by CureVac in connection with
such determination. The independent expert’s determination shall be binding on the Parties, absent a manifest error of such
expert’s determination. If the independent expert determines such proposed substitution is a Reserved Program, CRISPR shall
be permitted to select another target for the [*****] Program; if the independent expert determines such proposed substitution
is not a Reserved Program, such proposed substitution shall become the target for the [*****] Program.

 

(c)       Substitution
Fee. In the event CRISPR choses to substitute the [*****] Program a Substitution Fee of [*****] US dollars (US$ [*****]) is
due within [*****] days of confirmation of the new target by CureVac, or once the target is confirmed not to be a Reserved
Program in accordance with Section 4.3(b) above.

 

4.4       Diligence.
Subject to the terms of this Agreement, CRISPR shall use its Commercially Reasonable Efforts to progress the Development and Commercialization
of the Licensed Products in all three Programs in the Field in the Territory. CRISPR shall, inter alia,

 

(a)       conduct
all non-clinical and clinical Development activities in a timely manner, and allocate such Development budgets as are commercially
reasonable and adequate to progress the non-clinical and clinical Development of Licensed Products hereunder;

 

    15 

     

    

 

(b)       when
appropriate based on satisfactory data obtained during the nonclinical and clinical Development, use its Commercially Reasonable
Efforts to secure all required Regulatory Approvals in at least the EU, the US and Japan (with respect to Japan only, after taking
into account, among other things, commercial considerations and disease prevalence of a Program in Japan), following completion
of all appropriate clinical trials; and

 

(c)       use
its Commercially Reasonable Efforts to make the First Commercial Sale of the Licensed Products in each country following the issuance
of the Regulatory Approvals for such country.

 

The diligence obligations set forth in this Section 4.4
may be satisfied by CRISPR, an Affiliate, or its or their Sublicensees.

 

Article 5

PAYMENTS; PAYMENT TERMS

 

5.1       Technology
Access Fee. Within [*****] business days following the Effective Date, CRISPR shall pay to CureVac a one-time payment of three million
US dollars (US$ 3,000,000).

 

5.2       Research
Support Payments. On a quarterly basis, CureVac shall provide an invoice to CRISPR setting forth the total FTE Costs (including
the amount of time actually spent by CureVac’s FTEs on activities under the Work Plan and a brief description of the work
performed by such FTEs), and any reasonable and documented out-of-pocket expenses incurred by CureVac in the performance of the
CureVac activities under the Work Plan until the date of such invoice, and CRISPR shall, within [*****] days after receiving such
invoice, reimburse CureVac for the full amount of such FTE Costs and reasonable out-of-pocket expenses incurred by CureVac; provided
that, CRISPR shall not be responsible for the payment of any costs and expenses (including FTE Costs) that are incurred by CureVac
for any activities that are not set forth in the then-current Work Plan, and such costs and expenses will be borne entirely by
CureVac unless otherwise approved by CRISPR in writing.

 

    16 

     

    

 

5.3       Non-Royalty
Sublicense Income.

 

(a)       On
a Sublicensee-by-Sublicensee basis, CRISPR will, in addition to Development and Commercial Milestones in accordance with Section
5.4 and royalties on Net Sales in accordance with Section 5.5, pay CureVac the percentage set forth below of Non-Royalty
Sublicense Income received by CRISPR or its Affiliates in accordance with the following table:

 

	Stage at which sublicense is granted by	% of Non-Royalty	% of Non-Royalty
	CRISPR	Sublicense Income	Sublicense Income
	 	Payable to CureVac for	from Casebia Payable
	 	Such Sublicense (“Full	to CureVac for Such
	 	Sublicense Rate”)	Sublicense (“Reduced
	 	 	Sublicense Rate”)
	[*****]	[*****]	[*****]
	 	 	 
	 	 	 
	 	 	 
	[*****]	 	 
	 	 	 
	[*****]	[*****]	[*****]
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	[*****]	[*****]	[*****]
	 	 	 
	 	 	 

 

    17 

     

    

 

In the event CRISPR receives the Non-Royalty
Sublicense Income at the Reduced Sublicense Rate from Casebia, CRISPR shall pay the difference to the Non-Royalty Sublicense Income
at the Full Sublicense Rate once and if the Third Party who obtained the sublicense from Casebia grants a sub-sublicense to another
Third Party. For illustration purposes: If Casebia receives an upfront payment from its Sublicensee in the amount of [*****] US
dollars (US$ [*****]), CRISPR shall pay [*****] US dollars (US$ [*****] rather than [*****] US dollars (US$ [*****]) to CureVac.
The difference between the Non-Royalty Sublicense Income calculated at the Full Sublicense Rate and the Non-Royalty Sublicense
Income calculated at the Reduced Sublicense Rate [*****] shall be paid if and once Casebia’s Sublicensee grants a sub-sublicense
to a Third Party and makes a first upfront or milestone payment to Casebia. For clarity, no license or sublicenses between CRISPR
and any of its Affiliates shall give rise to any payments under this Agreement.

 

5.4       Development
 & Commercial Milestones. In consideration of the performance of the Development Program and the licenses granted under
this Agreement, CRISPR will pay to CureVac the amounts set forth below within [*****] calendar days following achievement
of the applicable milestone by a Licensed Product. Milestones listed below shall be paid one time per Program under this Agreement,
and can be satisfied anywhere in the Territory. In the event a milestone event is being skipped, the respective milestone payment
is payable once the next consecutive milestone has been achieved, jointly with the milestone payment for such consecutive milestone.

 

(a)       The
first achievement of any of the following milestones by a Licensed Product Developed by or on behalf of CRISPR, any of its Affiliates
or any Sublicensee in connection with the Program 1:

 

[*****] 

 

    18 

     

    

 

(b)       The
first achievement of any of the following milestones by a Licensed Product Developed by or on behalf of CRISPR, any of its Affiliates
or any Sublicensee in connection with the [*****] Program:

 

[*****]

 

(c)       The
first achievement of any of the following milestones by a Licensed Product Developed by or on behalf of CRISPR, any of its Affiliates
or any Sublicensee in connection with the [*****]:

 

[*****]

 

    19 

     

    

 

5.5       Running
Royalties.

 

(a)       Subject
to the terms and conditions of this Agreement, on a country-by-country and Licensed Product-by-Licensed Product basis, CRISPR
will pay to CureVac a royalty equal to [*****] percent ([*****]%) of Net Sales of Licensed Products sold or transferred by CRISPR, its
Affiliates and its Sublicensees in those countries during the Royalty Term applicable to such Licensed Product.

 

(b)       On
a country-by-country and Licensed Product-by-Licensed Product basis, the royalty rate that CRISPR shall pay CureVac pursuant to
Section 5.5(a) shall be reduced by [*****] percent ([*****]%) if at the time of sale (i) no Valid Claims
exist and (ii) Regulatory Exclusivity has expired. 

 

(c)       No
Multiple Royalties. If the Development, Manufacture, Commercialization or other use of any Licensed Product is (i) Covered
in a given country by more than one Patent Right or by a Patent Right and Know-How within the Licensed Intellectual Property, multiple
royalties with respect to Net Sales of that Licensed Product in that country shall not be due.

 

(d)       Blended
Royalties. With respect to a potential step down in royalty rates to account for the expiry of certain Patent Rights, the
Parties acknowledge and agree that the Licensed Intellectual Property licensed under this Agreement may justify royalty rates
and/or royalty terms of differing amounts for sales of Licensed Products in the Territory, which rates could be applied
separately to Licensed Products involving the exercise of Licensed Patent Rights in the Territory and/or the incorporation of
Know How comprised in the Licensed Intellectual Property, and that if such royalties were calculated separately, royalties
relating to the Licensed Patent Rights in the Territory and royalties relating to the Know How comprised in the Licensed
Intellectual Property would last for different terms. For practicality reasons the Parties have agreed on a blended royalty
rate. For clarity, this Section 5.5(d) solely explains the rationale behind the royalty rates agreed by the Parties
and does not modify any of the other provisions of this Agreement.

 

    20 

     

    

 

(e)       Fully
Paid-Up Licenses. With respect to a Licensed Product in a given country, as of the date on which the Royalty Term applicable
to such Licensed Product ends, the license grants contained in Section 7.1(a) shall become fully paid-up, royalty-free,
perpetual and irrevocable for such Licensed Product in such country.

 

(f)       Timing
of Royalty Payments. CRISPR shall make royalty payments owed to CureVac hereunder in arrears, within [*****] days after the end
of each Calendar Quarter in which such payment accrues. Each royalty payment shall be accompanied by a report for each country
in which sales of Licensed Products occurred in the Calendar Quarter. Such report shall describe the Net Sales of each Licensed
Product sold by or on behalf of CRISPR, its Affiliates or Sublicensees during the applicable Calendar Quarter for each country
in which sales of any Licensed Product occurred, specifying: the gross sales (if available) and Net Sales in each country’s
currency, including an accounting of deductions taken in the calculation of Net Sales; the applicable exchange rate to convert
from each country’s currency to US Dollars; and the royalties payable in US Dollars.

 

5.6       Royalty
Records. CRISPR and its Affiliates and Sublicensees shall keep, for at least [*****] years from the end of the Calendar Year
to which they pertain, complete and accurate records of sales by CRISPR, its Affiliates and Sublicensees, as the case may be, of
each Licensed Product, in sufficient detail to allow the accuracy of the payments hereunder to be confirmed.

 

5.7       Third
Party Payments. To the extent CRISPR enters into a Third Party Agreement pursuant to Section 7.4, CRISPR shall be entitled
to deduct from the then-current sales milestone and royalty payments due to CureVac under this Article 5 the amounts paid
(including milestone payments, royalties or other license fees) by CRISPR to such Third Party under such Third Party Agreement;
provided, however, that in no event shall the amounts due to CureVac from CRISPR in any Calendar Quarter be reduced by more than
[*****]. Any amount that CRISPR is entitled to deduct that is reduced by the foregoing limitation on the deduction, or is otherwise
not deducted in a particular Calendar Quarter (for example, if the amount due to CureVac is less than the amount due to such Third
Party during such Calendar Quarter), such amount that was not deducted shall be carried forward and CRISPR may deduct such amount
from subsequent amounts due to CureVac until the full amount that CRISPR was entitled to deduct is deducted. CureVac agrees to
fully cooperate with CRISPR to acquire such rights.

 

5.8       Review.
Subject to the other terms of this Section 5.8, at the request of CureVac, which shall not be made more frequently
than once per Calendar Year during the Term, upon at least [*****] days’ prior written notice, and at CureVac’s
expense, CRISPR shall permit an independent certified public accountant selected by CureVac and reasonably acceptable to
CRISPR to inspect (during regular business hours) the records required to be maintained by CRISPR relating to royalties
payable pursuant to this Agreement. In every case the accountant must have previously entered into a confidentiality
agreement with all Parties substantially similar to the provisions of Article 6 and limiting the disclosure and use of
such information by such accountant to authorized representatives of the Parties and the purposes germane to this Section
5.8. The Parties shall treat the results of any such accountant’s review of such records under this Section
5.8 as Confidential Information of the applicable Party subject to the terms of Article 6. If any such review
reveals a deficiency in the calculation and/or payment of royalties by CRISPR, then CRISPR shall promptly reimburse CureVac
for such accountant’s fees and pay CureVac the revealed amount remaining to be paid.

 

    21 

     

    

 

5.9       Method
of Payment. All payments under this Agreement will be transferred to the following CureVac account:

 

[*****]

 

5.10       Accounting.
All payments due under this Agreement will be made in United States dollars. Conversion of foreign currency to United States Dollars
shall be made at the average monthly rate of exchange, using Bloomberg foreign exchange rates, using the conversion rates beginning
the second to last business Day of the month preceding the month in which such sales are recorded and ending on the second to last
business day of the month in which the sales are recorded.

 

5.11       Interest.
Payments not paid within [*****] business days after the due date under this Agreement shall bear interest at an annual rate
of [*****] percent ([*****]%) above the three-month-LIBOR rate of the respective currency for the time period in which such
amount is outstanding. If CRISPR disputes the amount of a payment hereunder and does make such payment nonetheless, CRISPR
shall be reimbursed the payment plus statutory interest as of the date of CureVac’s receipt of CRISPR’s notice
disputing such payment, once the Parties agree or it is finally adjudicated that CRISPR was not obligated to make such
payment.

 

5.12       Tax
Withholding; Restrictions on Payment. All payments under or in connection with this Agreement shall be inclusive of any income
taxes and each Party shall be responsible for its own income taxes assessed by a tax or other authority. If laws, regulations or
rules require that taxes be withheld with respect to any payments by CRISPR to CureVac under this Agreement, CRISPR will: (a) deduct
those taxes from the remittable payment as required by law from, (b) pay the taxes to the proper taxing authority, and (c) send
evidence of the obligation together with proof of tax payment to CureVac on a timely basis following that tax payment. Each Party
agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant
agreement or treaty which is in effect, and CRISPR shall forward any refund payments to CureVac without undue delay. The Parties
shall discuss applicable mechanisms for minimizing such taxes to the extent possible in compliance with Applicable Laws, regulations
and rules.

 

5.13       VAT.
All payments due to the terms of this Agreement are expressed to be exclusive of value added tax (VAT) or similar indirect taxes
(e.g., Goods and Service tax). VAT/indirect taxes shall be added to the payments due to the terms if legally applicable.

 

5.13       Refund;
Offset. The payments made under this Article 5 are in no event refundable or creditable.

 

    22 

     

    

 

Article 6

CONFIDENTIALITY

 

6.1       Confidential
Obligations. Each Party agrees that a Party (the “Receiving Party”) receiving Confidential Information of
the other Party (the “Disclosing Party”) (or that has received any such Confidential Information from the other
Party prior to the Effective Date) in connection with this Agreement shall, subject to Section 6.2 and Section 6.3,
(a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain
in confidence its own proprietary industrial information of similar kind and value, but in no circumstances less than a reasonable
standard of care, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing
Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those
expressly permitted by this Agreement, including the exercise of rights and satisfaction of obligations under this Agreement.

 

6.2       Exceptions.
The obligations in Section 6.1 shall not apply with respect to any portion of the Confidential Information that the Receiving
Party can show by competent written proof:

 

(a)       is
publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party by or on behalf of the
Disclosing Party;

 

(b)       was
known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its
use, prior to disclosure by the Disclosing Party;

 

(c)       is
subsequently disclosed to the Receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without
any obligation to keep it confidential or any restriction on its use;

 

(d)       is
published by a Third Party or otherwise becomes publicly available or enters the public domain without violation of this Agreement
by the Receiving Party or any person for whom the Receiving Party is responsible pursuant to Section 6.3(c), either before
or after it is disclosed to the Receiving Party; or

 

(e)       is
independently Developed by or for the Receiving Party or its Affiliates without reference to or reliance upon the Disclosing Party’s
Confidential Information.

 

6.3       Authorized
Disclosure. The Receiving Party may disclose Confidential Information belonging to the Disclosing Party, and Confidential Information
deemed to belong to both Parties under the terms of this Agreement, to the extent (and only to the extent) such disclosure is reasonably
necessary in the following instances:

 

(a)       subject
to Section 6.4, complying with Applicable Laws (including the rules and regulations of the Securities and Exchange Commission
or any national securities exchange) and with judicial or administrative process, if in the reasonable opinion of the Receiving
Party’s counsel, such disclosure is necessary for such compliance, provided that the Disclosing Party is informed,
to the extent practicable, of the obligation of disclosure, so that the Disclosing Party may oppose or limit such disclosure obligation
and provided the Receiving Party limits the disclosure to the strict minimum in order to comply with its obligations;

 

(b)       disclosure
by the Parties of the existence of this Agreement in any annual report to stockholders, filings with the Securities and Exchange
Commission and other Regulatory Authorities and communications with securities analysts and stockholders; and

 

    24 

     

    

 

(c)       disclosure,
solely on a “need to know basis,” to Affiliates, potential or actual research and development collaborators, subcontractors,
investment bankers, investors, lenders, shareholders, or other potential or actual financial or strategic partners, and each of
the Parties’ respective directors, employees, contractors, agents, legal counsel and accountants, each of whom prior to disclosure
must be bound by obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article
6, which for avoidance of doubt, will not permit use of such Confidential Information for any purpose except those permitted
by this Agreement, including the exercise of rights and satisfaction of obligations under this Agreement; provided, however,
that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives
Confidential Information pursuant to this Section 6.3 to treat such Confidential Information as required under this Article
6.

 

If and whenever any Confidential Information
is disclosed in accordance with this Section 6.3, such disclosure shall not cause any such information to cease to be Confidential
Information except to the extent that such disclosure results in a public disclosure of such information (otherwise than by breach
of this Agreement). Where reasonably possible and subject to Section 6.4, the Receiving Party shall notify the Disclosing
Party of the Receiving Party’s intent to make any disclosures pursuant to Section 6.3(a) or 6.3(b) sufficiently
prior to making such disclosure so as to allow the Disclosing Party adequate time to take whatever action it may deem appropriate
to protect the confidentiality of the information, and the Receiving Party will provide reasonable assistance to the Disclosing
Party with respect thereto; provided that, in any event, the Receiving Party will use reasonable measures to ensure confidential
treatment of such information and shall only disclose such Confidential Information of the Disclosing Party as is necessary to
comply with such Applicable Laws or judicial process.

 

6.4       Securities
Filings. If either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state
or other jurisdiction a registration statement or any other disclosure document that describes or refers to the terms and conditions
of this Agreement under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other Applicable
Law, the Party shall notify the other Party of such intention and shall provide such other Party with a copy of relevant portions
of the proposed filing prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior
to the filing thereof), including any exhibits thereto relating to the terms and conditions of this Agreement, and shall use reasonable
and diligent efforts to obtain confidential treatment of the terms and conditions of this Agreement that such other Party requests
be kept confidential, and shall only disclose Confidential Information that is requested by the Securities and Exchange Commission
or legally required to be disclosed. No such notice shall be required under this Section 6.4 if the description of or reference
to this Agreement contained in the proposed filing has been included in the press release or in any previous filing made by the
either Party hereunder or otherwise approved by the other Party.

 

6.5       Publicity.
Except as otherwise provided herein, each Party agrees not to issue any other press release or other public statement disclosing
terms of this Agreement or using the name or trademark of the other Party, its Affiliates or its employees, in either case, without
the prior written consent of such other Party.

 

6.6       Existing
Confidentiality Agreement. The Parties hereby agree that all confidential information disclosed by one Party to the other pursuant
to that certain Confidentiality Agreement, by and between the Parties, dated February 26, 2017, will be governed by the terms of
this Agreement.

 

    25 

     

    

 

6.7       Return
of Confidential Information. Upon expiry or earlier termination of the Agreement, upon written request of a Party (such request,
if made, to be made within three (3) months of such expiry or termination) the other Party will destroy or return (as shall be
specified in such request) to the requesting Party all copies of the Confidential Information of the requesting Party; provided
that the Party may retain: (i) one copy of such Confidential Information for recordkeeping purposes, for the sole purpose of ensuring
compliance with this Agreement; (ii) any copies of such Confidential Information as is required to be retained under Applicable
Law; (iii) any copies of such Confidential Information as is necessary or useful for such Party to exercise a right or fulfill
an obligation towards a Sublicensee, if any, or as set forth in this Agreement; and (iv) any copies of any computer records and
files containing Confidential Information that have been created by such Party’s routine archiving/backup procedures.

 

Article 7

INTELLECTUAL PROPERTY

 

7.1       Ownership;
License Grants.

 

(a)       Exclusive
License. CureVac hereby grants to CRISPR, and CRISPR hereby accepts, an exclusive (even as to CureVac and its Affiliates),
sublicenseable (in accordance with Section 7.2), worldwide, royalty-bearing license under the Licensed Intellectual Property
to Develop, Manufacture, Commercialize and otherwise use, including, but not limited to the right to research, have researched,
develop, have developed, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have
imported, export, otherwise exploit and otherwise have exploited, Licensed Products in the Field in the Territory, in accordance
with the terms and conditions, and subject to the limitations of this Agreement, the Manufacturing Services Agreement and the Commercial
Supply Agreement.

 

(b)       Exclusive
Back License. On a Licensed Product-by-Licensed Product basis, as so long as CureVac is supplying Cas9 mRNA Constructs to CRISPR
for a Licensed Product under the Manufacturing Services Agreement or any Commercial Supply Agreement, and on a Licensed Product-by-Licensed
Product basis, CRISPR hereby grants to CureVac, and CureVac hereby accepts, an exclusive (even as to CRISPR and its Affiliates)
worldwide, cost-free sublicense of the rights granted to CRISPR under Section 7.1(a), to Manufacture and have Manufactured
Licensed Products in the Field in the Territory. For clarity, CureVac has no license to use, sell or otherwise exploit such Licensed
Products and consequently will Manufacture such Licensed Products solely to supply to CRISPR, its Affiliates and their respective
Sublicensees under such agreements.

 

(c)       Background
Intellectual Property. CureVac acknowledges and agrees that with signing this Agreement it does not acquire a license or any
other right to CRISPR Background Intellectual Property except for the limited purpose of carrying out its duties and obligations
under this Agreement and that such limited, non-exclusive, cost-free license will expire upon the completion of such duties and
obligations or the termination or expiration of this Agreement, whichever is the first to occur. CRISPR acknowledges and agrees
that CureVac retains all rights to the CureVac Background Intellectual Property, subject only to the licenses granted hereunder.

 

(d)       Ownership
of Foreground Intellectual Property.

 

(i)       Except
as set forth in subsection (iii) below, each Party will solely own all right, title and interest in and to all Foreground
Intellectual Property that is discovered, created, conceived or reduced to practice solely by or on behalf of such Party
(“Solely-Owned Foreground Know-How”) and all Patent
Rights arising therefrom that Cover such Solely-Owned Foreground Know-How (“Solely-Owned Foreground Patent Rights”),
and together with the Solely-Owned Foreground Know-How, the “Solely-Owned Foreground Intellectual Property”.
All right, title and interest in and to all Solely-Owned Foreground Intellectual Property will automatically vest solely in such
Party.

 

    26 

     

    

 

(ii)       Except
as set forth in subsection (iii) below, the Parties will jointly own all right, title and interest in and to all Foreground Intellectual
Property that is discovered, created, conceived or reduced to practice jointly by or on behalf of the Parties (“Jointly-Owned
Foreground Know-How”) and all Patent Rights arising therefrom that Cover such Jointly-Owned Foreground Know-How (“Jointly-Owned
Foreground Patent Rights”), and together with the Jointly-Owned Foreground Know-How, the “Jointly-Owned Foreground
Intellectual Property”. Each Party will have an undivided one-half interest in and to such Jointly-Owned Foreground Intellectual
Property. CRISPR will have a right to grant non-exclusive licenses (with the right to grant sublicenses through multiple tiers)
to CureVac’s share in such Jointly-Owned Foreground Intellectual Property to the extent such license is required to exercise
or exploit CRISPR Background Intellectual Property; and CureVac will have a right to grant non-exclusive licenses (with the right
to grant sublicenses through multiple tiers) to CRISPR’s share in such Jointly-Owned Foreground Intellectual Property to
the extent such license is required to exercise or exploit CureVac Background Intellectual Property; i.e., neither Party is to
be blocked in the use of its Background Intellectual Property. Subject to the licenses granted herein, any further license to Jointly-Owned
Foreground Intellectual Property requires the prior written consent of the other Party. Each Party, for itself and on behalf of
its and its Affiliates’ employees, subcontractors, consultant and agents, hereby assigns and agrees to assign, without additional
consideration, to the other Party a joint and undivided interest in and to all Jointly-Owned Foreground Intellectual Property to
effect such joint ownership, which assignment such other Party hereby accepts.

 

(iii)       Notwithstanding
subsections (i) and (ii) above,

 

(A)       CRISPR
will solely own any Foreground Intellectual Property that is a CRISPR Improvement and that is not also a CureVac Improvement at
the time such CRISPR Improvement is discovered, created, conceived, developed or reduced to practice, regardless of the Party or
Parties such Foreground Intellectual Property was discovered, created, conceived, developed or reduced to practice by or on behalf
of, and CureVac, for itself and on behalf of its and its Affiliates’ employees, subcontractors, consultants and agents hereby
assigns and agrees to assign, all of its rights, title and interest in such Intellectual Property to CRISPR. CureVac shall execute
and deliver to CRISPR, to the extent necessary, any deed(s) of such assignment, in a mutually agreeable form and will take whatever
actions reasonably necessary, including the appointment of CureVac as its attorney in fact solely to make such assignment, to effect
such assignment.

 

(B)       CureVac
will solely own any Foreground Intellectual Property that is a CureVac Improvement that is not also a CRISPR Improvement at the
time such CureVac Improvement is discovered, created, conceived, developed or reduced to practice, regardless of the Party or Parties
such Foreground Intellectual Property was discovered, created, conceived, developed or reduced to practice by or on behalf of,
and CRISPR, for itself and on behalf of its and its Affiliates’ employees, subcontractors, consultants and agents hereby
assigns and agrees to assign, all of its rights, title and interest in such Intellectual Property to CureVac. CRISPR shall execute
and deliver to CureVac, to the extent necessary, any deed(s) of such assignment, in a mutually agreeable form and will take whatever
actions reasonably necessary, including the appointment of CRISPR as its attorney in fact solely to make such assignment, to effect
such assignment.

 

    27 

     

    

 

(C)       To
the extent a particular item of Foreground Intellectual Property constitutes both a CRISPR Improvement and a CureVac Improvement,
(“Dual Improvement Intellectual Property”), the Parties shall discuss in good faith whether any such Foreground
Intellectual Property can be divided and owned in accordance with subsections (A) and (B) above, made subject to separate patent
filings to be assigned accordingly; and to the extent no such division is possible, such Dual Improvement Intellectual Property
shall be treated as part of the Jointly-Owned Foreground Intellectual Property for all purposes under this Agreement.

 

7.2       Right
to Sublicense. CRISPR shall be entitled to sublicense (through multiple tiers) its rights under Section 7.1(a) to any
Affiliates and to any Third Parties, provided that sublicenses to Third Parties require CureVac’s prior written consent which
CureVac will not unreasonably withhold, condition or delay and that such sublicenses are subject to the Non-Royalty Sublicense
Income in accordance with Section 5.3 above. For any sublicense it must be provided that the respective sublicense agreement
contains terms and conditions that are not inconsistent with those contained in this Agreement, and shall include provisions regarding
confidentiality, indemnification, audit, record-keeping and termination. CRISPR shall remain liable to CureVac for all obligations
under this Agreement. CRISPR shall furnish CureVac with a fully executed copy of any sublicense agreement promptly after its execution,
subject to reasonable redactions to the extent not necessary for CureVac to understand the scope of such sublicense, to calculate
the Non-Royalty Sublicense Income and to determine if CRISPR is in compliance with this Section 7.2, and subject to the
confidentiality provisions therein. The terms of any such sublicense agreement shall be Confidential Information of CRISPR.

 

7.3       Disclosure.
Each Party will promptly disclose to the other Party all Foreground Know-How that is discovered, created, conceived or reduced
to practice by or on behalf of such Party, and will provide documentation regarding the same as the other Party may reasonably
request, including, information obtained by CureVac relating to CureVac’s proprietary mRNA technology platform generally
that would reasonably have an impact on any Cas9 mRNA Constructs or Licensed Products.

 

7.4       Third
Party Licenses. To the extent CRISPR identifies any Patent Rights controlled by a Third Party that are reasonably
necessary for a Party to freely exercise, practice or otherwise use the CureVac Background Patent Rights or the Foreground
Patent Rights solely owned by CureVac, in each case, in connection with a Party’s direct or indirect performance of its
rights or obligations under this Agreement, and with respect to CRISPR’s exploitation of Cas9 mRNA Constructs included
in a Licensed Product in accordance with this Agreement, only if such Cas9 mRNA Constructs are defined by CureVac, CRISPR
will promptly notify CureVac of such Patent Rights, Know-How or other intellectual property and CureVac will have the first
right to negotiate for and enter into a license agreement (“Third Party Agreement”) with respect to such
Patent Rights, Know-How, or other intellectual property, provided that CureVac will notify CRISPR if CureVac wishes to
exercise such right within [*****] days of CRISPR’s notice, and such first right will continue until the earlier of (x)
[*****] days after the date of CureVac’s notice to CRISPR exercising such right or (y) CureVac is no longer actively
negotiating such agreement, in which case CureVac will so notify CRISPR (such period is referred to the “First
Exercise Period”), and CureVac will keep CRISPR reasonably informed as to the status of such negotiations. If
CureVac does not notify CRISPR of its intent to exercise such right or the First Exercise Period expires, CRISPR will have
the right to negotiate for and enter into a Third Party Agreement with respect to such Patent Rights, Know-How or other
intellectual property.

 

    28 

     

    

 

Article 8

PROSECUTION AND ENFORCEMENT

 

8.1       Patent
Prosecution. As between the Parties, each Party will have the sole right, but not the obligation, to file, prosecute and maintain
the Patent Rights owned solely by such Party. During the Term, CureVac will consult with CRISPR as to the preparation, filing,
prosecution, and maintenance of any of its Foreground Patent Rights reasonably prior to any deadline or action with the United
States Patent & Trademark Office or any foreign patent office and will furnish CRISPR with copies of all relevant documents
reasonably in advance of consultation. CureVac will reasonably consider any of CRISPR’s reasonable comments on any documents
to be submitted to such patent offices. In the event CureVac (i) decides not to file a patent application pertaining to any Foreground
Know-How in any given country or countries, or (ii) desires to abandon any patent or patent application within the Foreground Patent
Rights, then, in each case, CureVac shall provide CRISPR with reasonable prior written notice of such intended decision not to
file or such intended decision of abandonment or decline of responsibility. If CRISPR elects to file any such patent application
on behalf of CureVac, or if CRISPR elects to continue such patent or patent application on behalf of CureVac, the Parties shall
promptly consult and CureVac may elect to retain responsibility therefor provided that any such decision shall be made in a sufficiently
prompt time so as not to jeopardize CRISPR’s ability to file such patent application or its ability to pursue or maintain
such patent or patent application. Otherwise, CRISPR shall have the right, but not the obligation, to prepare, file, prosecute
and maintain the relevant Foreground Patent Rights, as applicable, or seek patent protection in the first instance, on behalf of
CureVac and at CRISPR’s expense.

 

8.2       Prosecution
of Jointly-Owned Foreground Patent Rights. CRISPR will have the first right, but not the obligation to file, prosecute and
maintain Jointly-Owned Foreground Patent Rights, and will bear the costs incurred by CRISPR in connection with such efforts. CRISPR
will consult with CureVac as to the preparation, filing, prosecution and maintenance of the Jointly-Owned Foreground Patent Rights
reasonably prior to any deadline or action with any patent office and will furnish CureVac with copies of all relevant documents
reasonably in advance of consultation. CRISPR will reasonably consider any of CureVac’s reasonable comments on any documents
to be submitted to such patent offices. In the event CRISPR (i) decides not to file a patent application pertaining to any Jointly-Owned
Foreground Know-How in any given country or countries, or (ii) desires to abandon any patent or patent application within the Jointly-Owned
Foreground Patent Rights, then, in each case, CRISPR shall provide CureVac with reasonable prior written notice of such intended
decision not to file or such intended decision of abandonment or decline of responsibility. If CureVac elects to file any such
patent application, or if CureVac elects to continue such patent or patent application, the Parties shall promptly consult and
CRISPR may elect to retain responsibility therefor provided that any such decision shall be made in a sufficiently prompt time
so as not to jeopardize CureVac’s ability to file such patent application or its ability to pursue or maintain such patent
or patent application. Otherwise, CureVac shall have the right, but not the obligation, to prepare, file, prosecute and maintain
the relevant Foreground Patent Rights, as applicable, or seek patent protection in the first instance, at CureVac’s expense.

 

8.3       Cooperation.
Each Party will provide the other Party, at the other Party’s request and expense, all reasonable assistance and cooperation
in connection with this Article 8, including providing any necessary powers of attorney and executing any
other required documents or instruments for such filing, prosecution or maintenance, and joining any lawsuit as needed for standing.

 

    29 

     

    

 

8.4       Third
Party Actions.

 

(a)       Patent
Infringement Claims Against a Party. Each Party shall notify the other if it is aware of any claim that the Development, Manufacture,
Commercialization or other use of a Licensed Product in the Field infringes a Patent Right Controlled by a Third Party, setting
forth the facts of such claim in reasonable detail. CRISPR shall have the first right, but not the obligation, at its own expense,
to defend and control the defense of any such claim, by counsel of its own choice. CRISPR shall not enter into a settlement that
imposes a financial obligation upon CureVac or which limits the scope or invalidates any CureVac’s intellectual property
rights without CureVac’s prior written consent and in any settlement CRISPR shall always take into consideration the interest
of CureVac. In case CRISPR elects not to defend and control the defense of any such claim, it shall notify CureVac of such election
within due term to allow CureVac to defend and control the defense of any such claim.

 

(b)       Notice.
If either Party learns of any (i) actual, alleged or threatened infringement or misappropriation of any of the Licensed Patent
Rights in the Field, including based on the Development or Commercialization of a product that competes with a Licensed Product;
(ii) declaratory judgment initiated by a Third Party naming a Party, or a Party’s Affiliate or a Sublicensee as a defendant
and alleging invalidity, unenforceability or non-infringement of any of the Licensed Patent Rights Covering the Development or
Commercialization of a Licensed Product in the Field (“Competitive Infringement”), or (iii) declaratory judgment
initiated by a Third Party naming a Party or a Party’s Affiliate or Sublicensee as a defendant and alleging invalidity, unenforceability
or non-infringement of any Licensed Patent Rights Covering the Manufacture of a Licensed Product in the Field, such Party shall
promptly notify the other Party and shall provide the other Party with available evidence of such infringement or declaratory action.

 

(c)       Enforcement
and Defense. CRISPR shall have the first and exclusive right, but not the obligation, to take any reasonable measures it
deems appropriate with respect to any Competitive Infringement in the Territory of any Licensed Patent Rights. Such measures
may include (a) initiating or prosecuting an infringement, misappropriation or other appropriate suit or action (each an
 “Infringement Action”) in the Territory, or (b) granting adequate rights and licenses to any Third Party
necessary to render continued Competitive Infringement in the Territory non-infringing. Notwithstanding the foregoing, if
CRISPR does not inform CureVac that it intends to either initiate such an Infringement Action or grant adequate rights and
licenses to such Third Party within [*****] after CRISPR’s receipt of a notice of infringement, then CureVac will have
the second right, but not the obligation, to initiate such Infringement Action with respect to such Licensed Patent Rights.
For any infringement other than a Competitive Infringement, and except as set forth below, each Party will have the first
right, but not the obligation to enforce and defend the Licensed Patent Rights owned solely by such Party, and CRISPR will
have the first right, but not the obligation to enforce and defend the Jointly Owned Foreground Patent Rights, with the
exception only of Jointly-Owned Foreground Patent Rights which solely Cover the Manufacture of the Licensed Products, for
which CureVac will have the first right, but not the obligation to enforce and defend. If within [*****] after having been
notified of any alleged Third Party infringement of any Licensed Patent Right or any declaratory action contemplated by Section
8.4(d), in each case, in the Field, the Party enforcing or defending the Patent Right is unsuccessful in persuading the
alleged infringer to desist, or the respective competent Party shall not have brought an infringement action within such
[*****]  period, or if the respective competent Party has not responded to such declaratory action, then, in
any such event the other Party shall have the right, but not the obligation, to prosecute and defend the respective Licensed
Patent Rights in connection with any such matter. The Party taking action to enforce and defend under this Section
8.4(c) shall bear all of its costs related to such enforcement and defense, including any costs incurred by the other
Party providing support to such enforcement and defense at the request of the enforcing and defending Party.

 

    30 

     

    

 

(d)       Standing
to Sue; Collaboration. In any litigation brought by either Party pursuant to this Section 8.4, the enforcing Party shall
notify the non-enforcing Party of the commencement of that litigation and shall have the right and standing to use and sue in the
other Party’s name. Irrespective of which Party brings the infringement action hereunder, (i) the Parties shall collaborate
with respect to such action; (ii) the non-enforcing Party shall have the right, at its own expense, to be represented by independent
counsel in any such litigation; and (iii) the Parties shall consult with each other regarding and agree on strategic decisions
and their implementation in connection with such action. The Party bringing the infringement action hereunder shall bear all the
expenses of any suit brought by it claiming infringement of any Licensed Patent Right.

 

(e)       Recovery.
In the event that either Party exercises the rights conferred in this Article 8 and recovers any damages or other sums in such
action, such damages or other sums recovered shall first be applied to all out-of-pocket costs and expenses incurred by the Parties
in connection therewith (including, without limitation, attorneys’ fees). If such recovery is insufficient to cover all such
costs and expenses of both Parties, the Parties’ costs shall be paid on a pro-rated basis. If after such reimbursement any
funds shall remain from such damages or other sums recovered, such funds shall be [*****] the Parties

 

Article 9

INDEMNIFICATION

 

9.1       Indemnification
by CRISPR. Subject to the terms and conditions hereof, CRISPR shall indemnify CureVac, its Affiliates, and its and their directors,
officers, employees, approved subcontractors and agents (“CureVac Indemnitees”) and defend and hold each of
them harmless, from and against any and all Third Party claims and all losses, damages, liabilities, costs and expenses (including
reasonable attorneys’ fees and expenses) (collectively, “Losses”) that such CureVac Indemnitees may be
required to pay to one or more Third Parties to the extent arising from or occurring as a result of (a) an uncured material breach
of any of CRISPR’s representations, warranties or covenants set forth in this Agreement, (b) the exercise by CRISPR and/or
any of its Affiliates or Sublicensees of the rights granted to CRISPR pursuant to Sections 4.1 and 7.1 (including
the Development, Manufacture, Commercialization or other use of Licensed Products), except to the extent such Losses are in connection
with the CureVac Background Intellectual Property or the Foreground Intellectual Property solely owned by CureVac; or (c) the negligence,
recklessness, or willful misconduct by CRISPR or its Affiliates. Notwithstanding the foregoing, CRISPR will have no obligations
under this Section to the extent Losses arise from or occur as a result of (i) gross negligence or willful misconduct (including
noncompliance with any Applicable Laws, regulations, or rules) on the part of a CureVac Indemnitee, or (ii) a breach by CureVac
of any representations, warranties or covenants set forth in this Agreement.

 

9.2       Indemnification
by CureVac. Subject to the terms and conditions hereof, CureVac shall indemnify CRISPR, its Affiliates, and its and their directors,
officers, employees, subcontractors, and agents (“CRISPR Indemnitees”), and defend and hold each of them harmless,
from and against any Third Party claims and all Losses that such CRISPR Indemnitees may be required to pay one or more Third Parties to the extent
arising from or occurring as a result of (a) an uncured material breach of any of CureVac’s representations, warranties or
covenants set forth in this Agreement, or (b) the negligence, recklessness, or willful misconduct by CureVac or its Affiliates.
Notwithstanding the foregoing, CureVac will have no obligations under this Section to the extent Losses arise from or occur as
a result of (i) gross negligence or willful misconduct (including non-compliance with any Applicable Laws, regulations, or rules)
on the part of a CRISPR Indemnitee, or (ii) a breach by CRISPR of any representations, warranties or covenants set forth in this
Agreement.

 

    31 

     

    

 

9.3       Indemnification
Procedures. Except as set forth in Section 8.4(a), the person claiming indemnity under this Article 9 (the “Indemnified
Party”) shall give written notice to the Party from whom indemnity is being sought (the “Indemnifying Party”)
promptly after learning of any claim, provided, that the failure to provide such notice shall not affect the Indemnifying
Party’s obligations hereunder, except to the extent it is materially prejudiced thereby. The Indemnified Party shall provide
the Indemnifying Party with reasonable assistance, at the Indemnifying Party’s expense, in connection with the defense of
the claim for which indemnity is being sought. The Indemnified Party may participate in and monitor such defense with counsel of
its own choosing at its sole expense; provided, however, the Indemnifying Party shall have the right to assume and conduct
the defense of the claim with counsel of its choice. The Indemnifying Party shall not settle a claim in any manner that would require
payment by the Indemnified Party, or would materially adversely affect the rights granted to the Indemnified Party hereunder, or
would materially conflict with the terms of this Agreement, or adversely affect such Party or its products, without first obtaining
the indemnified Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.
So long as the Indemnifying Party is actively defending the claim in good faith, the Indemnified Party shall not settle or compromise
any such claim without the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, conditioned
or delayed. If the Indemnifying Party does not assume and conduct the defense of the claim as provided above, (a) the Indemnified
Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such claim in any
manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent
from, the Indemnifying Party in connection therewith), and (b) the Indemnifying Party shall remain responsible to indemnify the
Indemnified Party as provided in this Article 9.

 

Article 10

REPRESENTATIONS AND WARRANTIES

 

10.1       CureVac
Representations. Subject to the disclosures in Attachment H hereto, CureVac represents, warrants and covenants to CRISPR,
on the Effective Date, as follows.

 

(a)       CureVac
is a stock corporation, validly existing and in good standing under the laws of Germany, with full power and authority to operate
its properties and to carry on its business as presently conducted.

 

(b)       CureVac
has full power and authority to execute, deliver and perform this Agreement. This Agreement constitutes legally binding and valid
obligations of CureVac, enforceable in accordance with their terms;

 

(c)       The
execution and delivery of this Agreement and the performance of the obligations contemplated hereby have been duly authorized by
all appropriate CureVac corporate action;

 

    32 

     

    

 

(d)       The
execution, delivery and performance by CureVac of this Agreement and the consummation of the transactions contemplated hereby will
not result in any violation of, conflict with, result in a breach of or constitute a default under any contract or agreement to
which CureVac is a party or by which it is bound.

 

(e)       To
the knowledge of CureVac, no consent, approval, order or authorization of, or registration, qualification, designation, declaration
or filing with, any federal, state or local governmental authority on the part of CureVac is required in connection with the execution,
delivery and performance of this Agreement.

 

(f)       There
is no action, suit, proceeding or investigation pending or, to the knowledge of CureVac, currently threatened in writing against
or affecting CureVac that questions the validity of this Agreement or the right of CureVac to enter into this Agreement or perform
CureVac’s obligations hereunder.

 

(g)       There
are no claims, judgments, settlements, litigations, suits, actions, disputes, arbitration, judicial, administrative or legal proceedings
pending or, to the knowledge of CureVac, threatened, against CureVac, including with respect to administrative or other governmental
investigations, which would (a) be reasonably expected to affect or restrict the ability of CureVac to perform its obligations
under this Agreement, or (b) affect in any manner the Licensed Intellectual Property or CureVac’s Control thereof.

 

(h)       To
the knowledge of CureVac, no Third Party is conducting or engaging in any activity that would constitute infringement or misappropriation
of the Licensed Intellectual Property; and to the knowledge of CureVac, the performance of activities contemplated by this Agreement
(including the practice of the Licensed Intellectual property in accordance with the terms and conditions of this Agreement) would
not itself constitute infringement or misappropriation of Third party’s intellectual property rights in existence on the
Effective Date.

 

(i)       To
CureVac’s knowledge, no objection or proceeding is pending or threatened that questions the validity or enforceability of
the CureVac Background Intellectual Property or the issuance of any patent applications included therein.

 

(j)       As
of and following the Effective Date, CureVac has undertaken reasonable efforts to secure and will continue to use reasonable efforts
to secure from all employees, consultants, contractors and other Persons who have contributed or will contribute to the development,
creation, conception or invention of any of the Licensed Intellectual Property a written agreement assigning to CureVac or its
Affiliates all rights to such developments, creations, conceptions or inventions and such Affiliates have assigned such rights
to CureVac, and, to CureVac’s knowledge, neither CureVac nor any of its Affiliates has received any written communication
challenging CureVac’s ownership or right to such Licensed Intellectual Property, unless such an agreement with the inventor
is not required under Applicable Law for ownership in such Licensed Intellectual Property to vest in CureVac.

 

10.2       CRISPR’s
Representations. CRISPR represents and warrants to CureVac, on and as of the Effective Date, that:

 

(a)       CRISPR
is a corporation, duly incorporated, validly existing and in good standing under the laws of Switzerland, with full corporate power
and authority to operate its properties and to carry on its business as presently conducted;

 

    33 

     

    

 

 

(b)       CRISPR
has full power and authority to execute, deliver and perform this Agreement. This Agreement constitutes the legally binding and
valid obligations of CRISPR, enforceable in accordance with their terms;

 

(c)       the
execution, delivery and performance by CRISPR of this Agreement and the consummation of the transactions contemplated thereby will
not result in any violation of, conflict with, result in a breach of or constitute a default under any contract or agreement to
which CRISPR is a party or by which it is bound, its business or assets;

 

(d)       no
consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal,
state or local governmental authority on the part of CRISPR is required in connection with the execution, delivery and performance
of this Agreement; and

 

(e)       there
is no action, suit, proceeding or investigation pending or, to the knowledge of CRISPR, currently threatened against or affecting
CRISPR or that questions the validity of this Agreement, or the right of CRISPR to enter into this Agreement or consummate the
transactions contemplated hereby.

 

10.3       Covenants.
Each Party covenants and agrees that during the Term, neither it, nor its Affiliates, will take any action or cause or permit the
taking of any action that would have the effect of invalidating or breaching any of the representations or warranties contained
in Section 10.1 or 10.2, including, without limitation, any action that would result in any invalidity of any of
the Licensed Patent Rights. Without limiting the foregoing, CureVac covenants and agrees that during the Term, neither it, nor
its Affiliates, will take any action or cause or permit the taking of any action that would materially adversely affect the rights
of CRISPR under this Agreement. For clarity, CureVac cannot and will not grant a license to any Third Party to the extent CRISPR
has obtained exclusive rights under this Agreement.

 

10.4       Disclaimer
of Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY OTHER WARRANTIES CONCERNING
PATENT RIGHTS OR ANY OTHER MATTER WHATSOEVER, INCLUDING, WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS, OR ARISING OUT OF COURSE OF CONDUCT OR TRADE CUSTOM OR
USAGE, AND EACH PARTY DISCLAIMS ALL SUCH EXPRESS OR IMPLIED WARRANTIES.

 

Article 11

INSURANCE; LIMITATION OF LIABILITY

 

11.1       Insurance.
CRISPR shall maintain, at its own cost, a program of insurance and/or self-insurance against liability (including product
liability) and any other risks associated with its activities and obligations under this Agreement, the Commercialization of
any Licensed Products, and its indemnification obligations hereunder, in such amounts, subject to such deductibles and on
such terms as are customary for companies similar to CRISPR for the activities to be conducted by them under this Agreement.
Such insurance coverage shall be kept as long as any Licensed Product is Commercialized. CureVac shall maintain, at its own
cost, a program of insurance and/or self-insurance against liability and any other risks associated with its activities and
obligations under this Agreement, and its indemnification obligations hereunder, in such amounts, subject to such deductibles
and on such terms as are customary for companies similar to CureVac for the activities to be conducted by CureVac under this
Agreement. Such insurance coverage shall be kept as long as any Licensed Product is commercialized.

 

    34 

     

    

 

11.2       Consequential
Damages. EXCEPT WITH RESPECT TO WILLFUL MISCONDUCT, GROSS NEGLIGENCE, ANY BREACH OF ARTICLE 6 (CONFIDENTIALITY), OR
ANY INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 9, TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAWS, IN NO EVENT WILL
EITHER PARTY OR ITS AFFILIATES OR ITS OR THEIR OFFICERS, DIRECTORS, EMPLOYEES OR AGENTS BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES
FOR ANY INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES (INCLUDING LOST PROFITS) ARISING FROM OR RELATED TO THIS AGREEMENT.

 

Article 12

GENERAL COMPLIANCE WITH LAW

 

Each Party will use reasonable commercial
efforts to comply with all Applicable Law relating to the exercise of rights and satisfaction of obligations under this Agreement.

 

Article 13

TERM AND TERMINATION

 

13.1       Term.
The Term will commence as of the Effective Date, and unless earlier terminated in accordance with this Section 13, will
expire on a Licensed Product-by-Licensed Product and country-by-country basis, upon such time as the Royalty Term with respect
to the sale of such Licensed Product in such country expires.

 

13.2       Termination
for Breach.

 

(a)       Material
Breach. Subject to the other terms of this Agreement, this Agreement may be terminated, on a Program-by-Program basis, by either
Party for a material breach by the other Party to this Agreement, provided that the breaching Party has not cured such breach
within [*****] after the date of written notice to the breaching Party, which notice shall describe such breachnn reasonable
detail and shall state the non-breaching Party’s intention to terminate this Agreement pursuant to this Section, provided
further that in no event will the failure of CRISPR to pay a disputed amount under this Agreement, the Manufacturing Services Agreement
or any Commercial Supply Agreement be considered a material breach of this Agreement.

 

(b)       Program
by Program; Development Program. In the event the facts giving rise to termination under Section 13.2(a) relate to one
or more Programs but not all Programs, such termination, if any, will relate only to the affected Program(s) and this Agreement
will otherwise continue with respect to all other Programs in all respects. Further, if CRISPR exercises any of its termination
rights under this Article 13, CRISPR may terminate the Development Program without terminating the remainder of this Agreement.

 

13.3       Voluntary
Termination by CRISPR. CRISPR may terminate this Agreement, in its entirety or on a Program-by-Program basis, at any time upon
[*****] prior written notice to CureVac.

 

    35 

     

    

 

13.4       Termination
for Bankruptcy. If any Party hereto files for protection under bankruptcy laws, makes an assignment for the benefit of creditors,
appoints or suffers appointment of a receiver or trustee over its property, files a petition under any bankruptcy or insolvency
act or has any such petition filed against it which is not discharged within [*****] of the filing thereof, then the respective
other Party may terminate this Agreement effective immediately upon written notice to the insolvent Party.

 

13.5       Change
of Control of CRISPR. In the event of (i) a direct or indirect acquisition of beneficial ownership of fifty percent (50%) or
more of the voting power in CRISPR by a CureVac Competitor; or (ii) the sale or other disposition of all or substantially all of
the assets of CRISPR to a CureVac Competitor; or (iii) the merger, amalgamation or other form of business combination or similar
transaction between CRISPR and a CureVac Competitor (“Change of Control”) the following shall apply:

 

(a)         CRISPR
shall promptly give written notice of such Change of Control to CureVac; and

 

(b)         CureVac
shall have the right to be released of any or all of its ongoing obligations under the Development Program, and of its obligations
of disclosure and information exchange relating solely thereto. In addition, the JSC shall be dissolved upon CureVac’s request.
For clarity, CureVac shall not have the right to be released from any obligations under this Agreement, the Manufacturing Services
Agreement, or the Commercial Supply Agreement relating to the Programs or Licensed Products outside of the Development Program.
For further clarity, CRISPR shall retain all rights hereunder to all Cas9 mRNA Constructs and any other deliverables delivered
to CRISPR under the Development Program prior to such Change of Control, and CRISPR shall have the right to exploit such Cas9 mRNA
Constructs and any other deliverables in accordance with the license grant set forth in Section 7.1.

 

(c)         In
addition to the confidentiality obligations according to Article 6, CRISPR shall take reasonable steps to ensure that any
Confidential Information of CureVac provided under this Agreement is not shared with any others within CRISPR that are not required
to manage, perform and exercise CRISPR’s rights and obligations under this Agreement.

 

13.6       Termination
for Challenge of CureVac Licensed Patent Rights. CureVac may terminate this Agreement by providing [*****]  prior written notice
to CRISPR in the event CRISPR or any of its Affiliates directly or indirectly challenges the validity of the Licensed Patent Rights
in a legal proceeding or supports a Third Party in the challenge of a Licensed Patent Right in a legal proceeding (in each case
before a court of competent jurisdiction). Any such termination shall only become effective if CRISPR or its Affiliate has not
withdrawn such action before the end of the above notice period. In the event a Sublicensee of CRISPR challenges the validity of
a CureVac Licensed Patent Right, CureVac may terminate this Agreement hereunder, if CRISPR does not terminate such sublicense agreement
within the [*****] notice period.

 

13.7       Remedies.
Except as otherwise expressly set forth in this Agreement, the termination provisions of this Article 13 are in addition
to any other relief and remedies available to either Party under this Agreement and at law.

 

13.8       Effects
of Expiration or Termination.

 

    36 

     

    

 

(a)       License
Upon Expiration. Upon expiration, but not upon earlier termination of this Agreement, the licenses granted to CRISPR in Section
7.1 shall automatically covert to the license set forth in Section 5.5(e).

 

(b)       Termination
of Licenses. Upon any termination of this Agreement by a Party prior to expiration, except as otherwise provided in Section
13.5, as of the effective date of such termination, all licenses granted by CureVac to CRISPR under this Agreement shall terminate
automatically, and the Licensed Intellectual Property shall automatically revert back to CureVac.

 

(c)       Notwithstanding
the foregoing, no termination of this Agreement shall be construed as a termination of any sublicense of any Sublicensee hereunder,
and thereafter each such Sublicensee shall be considered a direct licensee of CureVac, provided (i) CureVac has approved such sublicense
in accordance with Section 7.2; (ii) CureVac does not assume undertakings and liabilities towards the Sublicensee beyond
those stipulated herein; and (iii) the Sublicensee is then in full compliance with all terms and conditions of its sublicense.

 

(d)       Post-Termination
Activities. Upon termination of this Agreement CRISPR shall provide CureVac with a written inventory of all Licensed Products
that are in the process of Manufacture, in use or in stock; provided, however, that if CRISPR terminates this Agreement
in part under Section 13.3, such inventory shall only apply to the Licensed Products subject to such partial termination.
All Licensed Products that are not disposed of as provided above shall be delivered to CureVac or otherwise disposed of in CureVac’s
sole discretion and at CRISPR’s sole expense.

 

(e)       Accrued
Payment Claims. Termination of this Agreement for any reason whatsoever shall not relieve CRISPR of its obligations to pay
all royalties, milestones and other amounts payable to CureVac which have accrued prior to, but remain unpaid as of, the date of
expiration or termination hereof.

 

(f)        Reversion.
In the event of termination of this Agreement by CRISPR pursuant to Section 13.3 or by CureVac pursuant to Section 13.2
or 13.4, CureVac shall be entitled to demand from CRISPR the transfer and/or assignment, as applicable, of all right, title
and interest in and to any Cas9 mRNA Constructs, and all data related thereto. Under no circumstance shall CureVac be entitled
to any CRISPR Background Intellectual Property, CRISPR Improvement, CRISPR’s Solely-Owned Foreground Intellectual Property,
CRISPR’s interest in and to any Jointly-Owned Foreground Intellectual Property, or to any CRISPR Drug Product (as defined
in the Manufacturing Services Agreement) or any data related to or generated through the use of or reference to a CRISPR Drug Product.

 

13.9       Surviving
Provisions. Notwithstanding any provision herein to the contrary, the rights and obligations of the Parties set forth in Article
6 (Confidentiality), Article 7 (Intellectual Property) (provided that Sections 7.1(a), 7.1(c), 7.2, and 7.3
shall not survive termination by CRISPR under Section 13.3 (Voluntary Termination by CRISPR) or any termination by CureVac
under Article 13), Article 8 (with respect to Patent Rights Covering Know-How developed prior to Termination), Article
9 (Indemnification), Section 11 (Insurance, Limitation of Liability), Section 13.7 (Remedies), Section 13.8
(Effects of Expiration or Termination), Section 13.9 (Surviving Provisions), Article 14 (Dispute Resolution) and
Article 15 (Miscellaneous, to the extent applicable), as well as any rights or obligations otherwise accrued hereunder (including
any accrued payment obligations), shall survive the expiration or termination of this Agreement. Termination shall not relieve any Party from any liability which
has accrued prior to such termination.

 

    37 

     

    

 

Article 14

DISPUTE RESOLUTION

 

14.1       Mandatory
Procedures. The Parties agree that any dispute arising out of or relating to this Agreement will be resolved solely by means
of the procedures set forth in this Article 14, and that such procedures constitute legally binding obligations that are
an essential provision of this Agreement. If either Party fails to observe the procedures of this Article 14, as may be
modified by their written agreement, the other Party may bring an action for specific performance of these procedures in any court
of competent jurisdiction.

 

14.2       Dispute
Resolution Procedures. In the event of a dispute between the Parties (other than disputes arising out of the JSC), relating
to the validity performance, construction or interpretation of this Agreement, upon the request of either Party by written notice,
the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts shall include at least
one in-person meeting between the Executive Officers of each Party. If the matter is not resolved within [*****] following
the written request for discussions, either Party may then invoke the provisions of Section 14.3.

 

14.3       Any
dispute (other than disputes arising from the JSC) relating to the validity performance, construction or interpretation of this
Agreement, which cannot be resolved amicably between the Parties after following the procedure set forth in Section 14.2,
shall be submitted to arbitration in accordance with the Arbitration Rules of WIPO in effect on the date of the commencement of
the arbitration proceedings. The location of the arbitration proceedings will be London, England. The number of arbitrators will
be three (3). The language of the arbitration proceeding will be English. The decision of the arbitrators shall be final and binding
upon the Parties (absent manifest error on the part of the arbitrator(s)) and enforceable in any court of competent jurisdiction.

 

14.4       Performance
to Continue. Each Party will continue to perform its undisputed obligations under this Agreement pending final resolution of
any dispute arising out of or relating to this Agreement; provided, however, that a Party may suspend performance of its
undisputed obligations during any period in which the other Party fails or refuses to perform its undisputed obligations.

 

14.5       Tolling.
The Parties agree that all applicable statutes of limitation and time-based defenses, as well as all time periods in which a
Party must exercise rights or perform obligation hereunder, will be tolled once the dispute resolution procedures set forth
in this Section 14.5 have been initiated and for so long as they are pending, and the Parties will cooperate in taking
all actions reasonably necessary to achieve such a result. In addition, during the pendency of any dispute under this
Agreement initiated before the end of any applicable cure period, (a) this Agreement will remain in full force and effect,
(b) the provisions of this Agreement relating to termination for material breach with respect to such dispute will not be
effective, (c) the time period for cure as to any termination notice given prior to the initiation of arbitration will be
tolled, (d) any time periods to exercise rights or perform obligations will be tolled; and (e) neither Party will issue a
notice of termination pursuant to this Agreement based on the subject matter of the arbitration, until the arbitral tribunal
has confirmed the material breach and the existence of the facts claimed by a Party to be the basis for the asserted material
breach; provided, that if such breach can be cured by (i) the payment of money, the defaulting Party will have an
additional [*****] within its receipt of the arbitral tribunal’s decision to pay such amount or (ii) the taking of
specific remedial actions, the defaulting Party will have a reasonably necessary period to diligently undertake and complete
such remedial actions within such reasonably necessary period or any specific timeframe established by such arbitral
tribunal’s decision before any such notice of termination can be issued. Further, with respect to any time periods that
have run during the pendency of the dispute, the applicable Party will have a reasonable period of time or any specific
timeframe established by such arbitral tribunal’s decision to exercise any rights or perform any obligations affected
by the running of such time periods.

 

    38 

     

    

 

Article 15

MISCELLANEOUS

 

15.1       Severability.
If any one or more of the provisions of this Agreement is held to be invalid or unenforceable, the provision shall be considered
severed from this Agreement and shall not serve to invalidate any remaining provisions hereof, unless the invalid or unenforceable
provision is of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have
entered into this Agreement without the invalid or unenforceable provision. The Parties shall make a good faith effort to replace
any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when
entering this Agreement may be realized.

 

15.2       Notices.
Any notice required or permitted to be given by this Agreement shall be in writing and shall be (a) delivered by hand or by FedEx,
UPS or any other similar service with tracking capabilities, (b) registered mail, or (c) delivered by facsimile followed by delivery
via any of the methods set forth in this Section 15.2, in each case, addressed as set forth below unless changed by notice
so given:

 

		If to CRISPR:
	 	 	 
	 	 	CRISPR Therapeutics AG
	 	 	Baarerstrasse 14
	 	 	6300 Zug
	 	 	Switzerland
	 	 	Attention: Chief Executive Officer
	 	 	 
	 	 	and
	 	 	 
	 	 	CRISPR Therapeutics Limited
	 	 	85 Tottenham Court Road
	 	 	London W1T 4TQ
	 	 	United Kingdom
	 	 	Attention: Chief Legal Officer
	 	 	 
	 	with copies (which shall not constitute notice) to:
	 	 	 
	 	 	Goodwin Procter LLP
	 	 	100 Northern Avenue
	 	 	Boston, MA 02210
	 	 	Attention:	[*****]
	 	 	Facsimile:	[*****]
	 	 	Telephone:	[*****]
	 	 	 
	 	 	and
	 	 	 
	 	 	 	[*****]
	 	 	 

    39 

     

    

 

		If to CureVac:
	 	 	 
	 	 	CureVac AG
	 	 	Paul-Ehrlich-Str. 15
	 	 	72076 Tübingen
	 	 	Germany
	 	 	Attention: CEO and General Counsel

 

Any such notice shall be deemed given on
the date received. A Party may add, delete, or change the person or address to which notices should be sent at any time upon written
notice delivered to the Party’s notices in accordance with this Section 15.2.

 

15.3       Assignment.
Neither Party may, without the consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed,
assign or transfer any of its rights and obligations hereunder; provided that no such consent is required for an assignment
or transfer (in whole or in part) by either Party (a) to an Affiliate or (b) to a successor-in-interest by reason of merger or
consolidation or sale of all or substantially all of the respective Party’s assets to which this Agreement relates; provided
further that, with respect to an assignment or transfer by a Party in accordance with the prior provisions, (i) with respect
to an assignment to a successor-in-interest, such assignment includes all relevant rights and obligations under this Agreement,
and (ii) any assignee or transferee shall have agreed as of such assignment or transfer to be bound by the terms of this Agreement
in a writing provided to the other Party. Subject to the foregoing, this Agreement shall inure to the benefit of and be binding
on the Parties’ successors and permitted assigns. Any assignment or transfer in violation of the foregoing shall be null
and void and wholly invalid, the assignee or transferee in any such assignment or transfer shall acquire no rights whatsoever,
and the non-assigning, non-transferring Party shall not recognize, nor shall it be required to recognize, such assignment or transfer.
Upon request by CRISPR, the Parties shall cooperate to enter into a separate agreement or agreements with respect to one or more
Programs covered under this Agreement (i.e. severing such Program(s) from this Agreement and covering them instead in a separate
agreement having the same terms as this one but being limited to such Program or Programs), which separate agreement(s) may be
assigned in accordance with the foregoing provisions of this Section 15.3.

 

15.4       Waivers
and Modifications. The failure of any Party to insist on the performance of any obligation hereunder shall not be deemed to
be a waiver of such obligation. Waiver of any breach of any provision hereof shall not be deemed to be a waiver of any other breach
of such provision or any other provision on such occasion or any succeeding occasion. No, modification, release, or amendment of
any obligation under or provision of this Agreement shall be valid or effective unless in writing and signed by both Parties.

 

15.5       Governing
Law. This Agreement shall be governed by and construed and interpreted in accordance with the laws of Switzerland; irrespective
of the choice of laws principles of the laws of Switzerland, as to all matters, including matters of validity, construction, effect,
enforceability, performance and remedies, provided, that questions affecting the construction and effect of any Patent Rights shall
be determined by the law of the country in which the Patent Rights have been filed, granted or issued.

 

    40 

     

    

 

15.6       Relationship
of the Parties. Each Party is an independent contractor under this Agreement. Nothing contained herein is intended or is to
be construed so as to constitute CureVac and CRISPR as partners, agents, or joint venturers. Neither Party shall have any express
or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the
other Party to any contract, agreement, or undertaking with any Third Party. There are no express or implied third party beneficiaries
hereunder.

 

15.7       Entire
Agreement. This Agreement and the attached attachments constitutes the entire agreement between the Parties as to the subject
matter of this Agreement and, as of the Effective Date, supersedes and merges all prior and contemporaneous negotiations, representations,
agreements, and understandings regarding the same. The Material Transfer Agreement between the Parties dated June 13, 2016, as
amended from time to time, and the Confidentiality Agreement between the Parties dated February 26, 2016 are being replaced as
of the Effective Date, provided that the ownership rights with respect to any Intellectual Property (as defined in the Material
Transfer Agreement) discovered, created, conceived or reduced to practice under the Material Transfer Agreement prior to the Effective
Date will remain to be governed by the Material Transfer Agreement. This Agreement, and its attachments, may not be amended except
in a writing signed by duly authorized representatives of the Parties expressly stating that it is amending this Agreement and
identifying each provision being amended.

 

15.8       Counterparts.
This Agreement may be executed in counterparts (whether delivered by facsimile or otherwise) with the same effect as if both Parties
had signed the same document. All such counterparts shall be deemed an original, shall be construed together and shall constitute
one and the same instrument.

 

15.9       Interpretation.

 

(a)       Each
of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and negotiated by and between them,
that in such negotiations each of them has been represented by competent counsel, and that the final agreement contained herein,
including the language whereby it has been expressed, represents the joint efforts of the Parties and their counsel. Accordingly,
in interpreting this Agreement or any provision hereof, no presumption shall apply against any Party as being responsible for the
wording or drafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed
against any Party, irrespective of which Party may be deemed to have authored the ambiguous provision.

 

(b)       The
definitions of the terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context
may require, any pronoun shall include the corresponding masculine, feminine, and neuter forms. The word “will” shall
be construed to have the same meaning and effect as the word “shall.” The word “any” shall mean “any
and all” unless otherwise clearly indicated by context. The word “including” will be construed as “including
without limitation.” The word “or” will be interpreted in the inclusive sense commonly associated with the term
 “and/or”.

 

    41 

     

    

 

(c)       Unless
the context requires otherwise, (a) any definition of or reference to any agreement, instrument, or other document herein
shall be construed as referring to such agreement, instrument, or other document as from time to time amended, supplemented,
or otherwise modified (subject to any restrictions on such amendments, supplements, or modifications set forth herein or
therein), (b) any reference to any Applicable Laws herein shall be construed as referring to such Applicable Laws as from
time to time enacted, repealed, or amended, (c) any reference herein to any Person shall be construed to include the
Person’s successors and assigns, (d) all references herein to Articles, Sections, or Attachments, unless otherwise
specifically provided, shall be construed to refer to Articles, Sections, and Attachments of this Agreement, and references
to this Agreement includes all Articles, Sections, and Attachments hereof, (e) the words “herein”,
 “hereof” and “hereunder”, and words of similar import, will be construed to refer to this Agreement
in each of their entirety, as the context requires, and not to any particular provision hereof, (f) the word
 “notice” means notice in writing (whether or not specifically stated) and will include notices, consents,
approvals and other written communications contemplated under this Agreement, and (g) provisions that require that a Party,
the Parties or any committee hereunder “agree,” “consent” or “approve” or the like will
require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved
minutes or otherwise (but excluding e-mail and instant messaging).

 

(d)       Headings
and captions are for convenience only and are not be used in the interpretation of this Agreement.

 

15.10  Section
365(n).

 

(a)       All
licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of
right to “intellectual property” as defined in Section 101 of such Code. Each Party, as licensee, may fully exercise
all of its rights and elections under the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction
over a Party or its assets. The Parties further agree that, if a Party elects to retain its rights as a licensee under such Code,
such Party shall be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology.
Such embodiments of the technology shall be delivered to the licensee Party not later than:

 

(i)       the
commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations
under the Agreement, or

 

(ii)      if
not delivered under Section 15.10(a)(i), upon the rejection of this Agreement by or on behalf of the licensor, upon written
request.

 

(b)       Any
agreements supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section
365(n) of the Bankruptcy Code.

 

[Signature page follows.]

 

    42 

     

    

 

CONFIDENTIAL

 

IN WITNESS WHEREOF, the Parties hereto have
executed this Agreement effective as of the Effective Date.

 

	CureVac AG 	CRISPR Therapeutics AG
	By:	/s/ Dr. Ingmar Hoerr	By:	 
	Name:	Dr. Ingmar Hoerr	Name:	 
	Title:	Chief Executive Officer	Title:	 

 

    43 

     

    

 

CONFIDENTIAL

 

IN WITNESS WHEREOF, the Parties hereto have
executed this Agreement effective as of the Effective Date.

 

	CureVac AG	CRISPR Therapeutics AG
	By:	 	By:	/s/ Rodger Novak
	Name:	 	Name:	Rodger
    Novak
	Title:	 	Title:	Chief Executive Officer

 

    44 

     

    

 

EXECUTION COPY

 

CONFIDENTIAL

 

ATTACHMENT A

 

CRISPR Background Intellectual Property

 

A.            [*****]

 

     

     

    

 

ATTACHMENT B

 

CureVac Background Intellectual Property

 

[*****]

 

     

     

    

 

ATTACHMENT C

 

Materials

 

Cas9 mRNA Constructs developed under this Agreement

 

     

     

    

 

ATTACHMENT D 

Work Plan

 

[*****]

 

     

     

    

 

ATTACHMENT E

 

Manufacturing
Services Agreement

 

[*****]

 

     

     

    

 

ATTACHMENT F

 

JSC Participants

 

[*****]

 

     

     

    

 

ATTACHMENT G

 

Alternative Program 1 Target List

 

[*****]

 

     

     

    

 

ATTACHMENT H

 

Disclosure Letter

 

[*****]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]